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ABSTRACT 
The initial discovery in experimental research showed osteocalcin (OC), a bone protein, might 
regulate glucose homeostasis. However, the investigations in humans have found conflicting 
evidence. Therefore, we conducted a systematic review with meta-analyses to investigate the 
association of type 2 diabetes (T2DM) with the total osteocalcin (TOC) and undercarboxylated 
osteocalcin (ucOC). 
 
Three major databases were searched. We included 43,366 unique participants from 104 
studies:15,027 T2DM and 23,680 controls. The main ethnicities were Asian and Caucasian. About 
48% female and 52% male aged 36-84 were identified. The risk of bias was 30% for selection, 29% 
for comparability, 36% for exposure/outcomes. We found a lower mean levels ofOC in T2DM 
patients compared with non-diabetic controls (TOC: -3.35ng/ml [95% CI: -4.22, -2.48]; ucOC -
0.67ng/ml [95% CI: -1.10, -0.24]). Furthermore, TOC and fasting plasma glucose (FPG) was 
inversely correlated (-0.23 [95%CI: -0.30, -0.18]). Results also showed that with per SD increase in 
TOC, the incidence of T2DM decreased (OR: 0.76 [0.63,0.92]). However, the relationship did not 
exist in the analysis of ucOC (OR: 0.79 [0.56,1.11]). 
The sources of heterogeneity for the mean difference in TOC between T2DM patients and controls 
was partially explained by the assays of TOC (R2= 32%). Interestingly, the correlation between TOC 
and FPG for controls was the weakest (−0.16 [95% CI: −0.26, −0.06]) while the correlation for T2DM 
was stronger (−0.23 [95% CI: −0.28, −0.18]). 
 
In conclusion, we found a low OC level in patients with impaired glucose metabolism; TOC was 
correlated with glucose metabolic indices in T2DM. Hence, patients with T2DM might be in a low 
bone status. It is still unclear whether OC could be a suitable marker measuring bone status for 
T2DM; whether TOC/ ucOC could predict the risk of T2DM. Further study is called for investigating 
the causality of the lower OC status in T2DM patients. 
Words: 300 
Characters with space: 1957 
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CHAPTER ONE: LITERATURE REVIEW 
1.1.Type II diabetes and metabolic phenotypes  
An overview of T2DM is summarised in Figure 1. In this section, the definition of T2DM, the burden 
of the disease, possible complications, changed clinical variables and metabolic phenotypes of T2DM 
are discussed. The International Statistical Classification of Disease and Related Health Problems 
(ICD) code for T2DM is E11.  
Figure 1. An overview of T2DM.  
 
 
* VD: vitamin D or 25-hydroxyvitamin D or 25(OH)D, FINS: fasting plasma insulins, FPG: fasting plasma glucose, 
HOMA-IR:homeostasis assessment model insulin resistance, HbA1c: haemoglobin A1c. 
 
1.1.1 Definitions 
It is known that T2DM is a chronic disease that is associated with both genetic and lifestyle factors. 
Those risk factors may lead to insulin resistance and insulin secretion dysfunction, contributing to the 
progression of T2DM. When the body cannot correctly respond to pancreas secreted insulins, blood 
sugar will increase, leading to progressively higher average blood glucose levels (1,2). Accordingly, 
patients exhibit insulin resistance and are diagnosed with T2DM when blood glucose exceeds normal 
levels (3). Long-term progression is one of the characters of T2DM, and it may take several years to 
diagnose it after its onset. In the beginning, the pancreas produces more insulin to reduce the high 
blood glucose levels caused by the inadequate response to insulin (1,2). However, in the long term the 
excessive use of the pancreas results in insufficient insulin being produced (1,2). It is noted that 
T2DM is related to genetic factors: for instance, the risk of developing this condition increases when 
parents or siblings share the disease (4,5). It is commonly agreed that several variables could be used 
in a model to predict T2DM, as these variables are different in T2DM compared with healthy 
controls. These include age, adiposity, body mass index (BMI), waist circumference (WC), and 
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family history of T2DM (6). Other variables include those related to inappropriate lifestyles and other 
health conditions, such as malnutrition, diet, inactivity, smoking and high blood pressure (3–5,7,8).  
 
1.1.2 Magnitude 
T2DM is becoming a pandemic disease worldwide, with an increasing incidence, growing mortality 
rate and a rising economic burden of treatment. T2DM is the most prevalent type of diabetes and 
comprises about 90% of the whole (9). An increase in T2DM of over three-fold from 1980 to 2014 
has been reported (10). The incidence of T2DM has continuously increased, reaching 8.5% in 2014 
(10). T2DMThere is also a rapid growth of T2DM in low-income and middle-income countries 
(11,12). The WHO demonstrated that people in Southeast Asia and the Western Pacific Region have 
the highest rates of diabetes, which make up 50% of the incidence globally (3). In 2012, there was 
about 1.5 million deaths results from having diabetes, and 2.2 million people died due to having 
hyperglycaemia (3). Furthermore, the World Health Organisation (WHO) reported that there were 
around 1.6 million deaths due to diabetes in 2015 and estimated that it will become the seventh 
highest risk factor for death in 2030 (3). In Australia, it was estimated that 1 in 20 people has diabetes, 
with about 86% of patients have T2DM (13). There were about 1 million adult Australian identified 
with T2DM in 2014- 2015. The number of death due to T2DM reached up to 9,020 in 2015 (13). 
 
Additionally, the cost of direct and indirect medication of diabetes has become a substantial economic 
burden (3,12). It is predicted that about $1.7 trillion will be spent globally on diabetes medication 
between 2011 and 2030, with $900 billion and $800 billion in high- and low-/middle- income 
countries, respectively (14). As projected by the WHO, low/middle-inco(13)me countries will spend 
more on healthcare than high-income countries in the future, and there will be increasing expenditure 
on diabetes health globally (3). 
 
1.1.3 Complications 
It has been well established that patients with T2DM may develop concomitant adverse health 
conditions over time. These diseases, such as heart attack, stroke, diabetic retinopathy and renal 
dysfunction, are mainly caused by elevated blood glucose and abnormal metabolism, accordingly 
decreasing the lifespan and life quality of patients (15). In addition, nerve damage in diabetes 
patients’ feet can result in significant complications, namely Charcot foot and even limb amputation 
(16,17). 
 
Compared with traditional complications of diabetes, the increased risk of fractures has become a new 
threat to the quality of life of patients with T2DM. A growing number of studies have reported that 
patients with T2DM had become more frequently suffered from osteoporosis or hip fractures than 
healthy people (18–21). Although several studies have shown that patients with T2DM have a higher 
bone mineral density (BMD), which acts against the development of osteoporosis, a growing number 
of investigations support the hypothesis that patients with T2DM have an increased likelihood of bone 
fragility due to other pathological mechanisms (22–24). A number of epidemiological studies have 
indicated that the risk of osteoporosis might closely correlate with anti-diabetic medications, which 
indirectly complicates the management of blood glucose in T2DM (25,26). In particular, hip fracture 
and vertebral fractures are more prevalent in T2DM, which are life-threatening health conditions in 
older adults (21,27).  
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1.1.4 Clinical profiles 
In general, obesity, family history of diabetes, and high blood glucose levels are associated with the 
onset of T2DM. Some other risk factors are aging, increased body mass index or waist circumference, 
and ethnicity (28). Besides, studies reported that smoking, systolic blood pressure, hypertension and 
triglycerides are associated with complications or cardiovascular disease in patients with T2DM 
(8,29).   
 
However, those common risk factors associated with T2DM may not be sufficient to predict T2DM 
because those factors might be changed during the progression of this disease. There is the increasing 
number of studies indicate that more novel variables need to be investigated in addition to these 
standard factors in the context of biomarkers (30–34). In humans, it has been proposed that adipose 
tissue signaling, inflammation, and endothelial dysfunction should be assessed in patients suspected 
of having T2DM (6). Additionally, adiponectin, inflammation markers (including C-reactive protein 
(CRP), ferritin, and interleukin-2 receptor A (IL2RA)) have been assessed and provide more evidence 
in distinguishing T2DM from healthy controls in suggested predicting models (31,32). Furthermore, a 
novel study reported that novel biomarkers, which involved with the glucose dysfunction via other 
organs or hormonal access other than insulin resistance or beta cell dysfunction, may contribute to the 
predicting model of T2DM as there were discriminate results when adding those factors to the 
original model (34). They suggested the accumulated lipolysis of fat cells, deficiency in incretin or 
abnormal glucose reabsorption in the kidney might increase the risk of progression or complications 
of T2DM (34).  
 
1.1.5 Metabolic phenotype indices 
To assess T2DM, according to the WHO, fasting plasma glucose (FPG) and glycated haemoglobin 
A1c (HbA1c) are frequently applied in diagnosis. FPG is a measurement of the concentration of 
glucose in plasma after the patient has not eaten for at least eight hours (35). Different from the test of 
HbA1c, it is a single point glucose concentration measurement . The normal level of FPG is 3.9–5.4 
mmol/l (70–99 mg/dl); prediabetes or impaired glucose tolerance is diagnosed when it is 5.5–6.9 
mmol/l (100–125 mg/dl); and diabetes is defined when it exceeds 7 mmol/l (126 mg/dl) (2). HbA1c is 
generated when haemoglobin joins with glucose in blood circulation, and represents the average 
plasma glucose level (36). It is used for measuring the overall blood glucose levels in the body within 
a period, which is a more stable way to measure the glucose concentrations (35). As the survival time 
of red blood cells in the human body is about eight to twelve weeks, the HbA1c result shows the long-
term trend in sugar levels (35,37). The risk of developing T2DM or its complications increases when 
HbA1c goes up. The normal level of HbA1c should be below 42 mmol/mol (6%). A level of 42–47 
mmol/mol (6.0–6.4%) signals the development of prediabetes. A level exceeding 48 mmol/mol 
(>6.5%) indicates diabetes (36). 
 
The other parameters, fasting insulin (FINS) and homeostatic model assessment of insulin resistance 
(HOMA-IR), are frequently used biomarkers when investigating T2DM. The normal range of FINS is 
2–25 uIU/Ml (12– 125 pmol/L) (38). Higher levels of FINS are a signal of insulin resistance or 
prediabetes (39). Furthermore, hyperinsulinemia, characterised by excess levels of insulin, is often a 
symptom of the early stage of T2DM (39). It is reported that FINS can predict the likelihood of 
T2DM independently of other insulin resistance measurements (40). Besides, patients with T2DM can 
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have normal to high levels of FINS (41). HOMA-IR is a measurement of insulin resistance from basal 
fasting glucose levels and insulin concentrations (41). It reflects the level of insulin sensitivity by 
looking at the association between insulin and glucose. The calculation formula is [FINS (microU/L) 
× FPG (nmol/L)/22.5] or [FINS (microU/L) × FPG (mg/dL)/405] (42). A higher value of HOMA-IR 
indicates a greater likelihood of insulin resistance. The threshold values of HOMA-IR are 1, 1.9 and 
2.9 (42). A HOMA-IR below 1 indicates optimal insulin sensitivity; a value exceeding 1.9 indicates 
early insulin resistance; and a value greater than 2.9 indicates significant insulin resistance (42).  
 
1.2.Osteopenia and osteoporosis 
1.2.1 Definitions 
Osteopenia is a disordered metabolic condition with lower bone mass than the normal bone (43). It is 
confirmed when the bone mineral density T-score is of standard deviation between -1.0 and -2.5 (43). 
This health condition also has been regarded as the precursor to osteoporosis (43).  
 
Osteoporosis is a disordered skeletal disease characterized by low bone density, microarchitectural 
deterioration of bone tissue and increased risk of fracture. This bone disease develops when there is 
disordered bone remodelling: the excessive consumption of bone, the inadequate production of new 
bone or both of the situations (44). Also, the depletion of calcium and bone proteins contributes to the 
decrease in bone density (44). Consequently, the bone becomes weak. Compared with healthy bone, 
whose shape is similar to the honeycomb, the osteoporotic bone is known as “porous bone” (44,45). 
Within this context, the osteoporotic bone has substantial large holes and spaces than the healthy bone 
(45). As a result, there are less bone mass and abnormal tissue structure observed in patients under 
conditions of osteoporosis. When bone is continuously losing its density, it is at higher risk of being 
broken (44,45). The definition of osteoporosis statistically is the bone mineral density lies at or below 
the standard deviation of 2.5 for the average value of young adults (44,46).  
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1.2.2 Magnitude 
There are an increasing number of populations diagnosed with osteopenia or osteoporosis globally. 
WHO had reported that about 75 million population have osteoporosis in Europe, USA and Japan in 
1994 (47). There was nearly 200 million worldwide population diagnosed with osteoporosis, and 
about 9 million people suffer from osteoporosis-associated fractures (46). According to the study with 
self-reported data, about 1 in 10 Australians (aged ≥ 50) had osteoporosis or osteopenia in 2014- 
2015. Furthermore, the morbidity and mortality of osteopenia and osteoporosis mainly from the 
incidences of related fractures. Patients with osteopenia are less likely to suffer from associated 
fractures than patients with osteoporosis but have a higher likelihood of experiencing fractures than 
people with normal bone density (47). The osteoporotic fractures are commonly characterised in those 
fractures, such as hip fractures, vertebral fractures and forearm fractures (47).  
 
Osteopenia and osteoporosis have become one of the public health economic burdens because of the 
substantial costs of those diseases in healthcare management internationally. Although it is 
complicated to impute the direct and indirect cost of the management of osteoporosis, there is a 
substantial amount of expenditure in the management of osteoporosis induced hip fractures (47). 
Patients with hip fractures require medical treatments at hospitals, at homes or nursing homes (47). In 
Australia, the total cost of osteoporosis was $2.7 billion in 2012 (48). A total direct cost relating to hip 
fractures was $695 million, and the direct costs of vertebral fractures were $165 million in 2012 (48). 
Furthermore, the cost of preventing osteoporosis was around $10.3 million in 2012 (48). In 2013, the 
total cost of all types of fractures, including direct and indirect costs, was about $1.3 billion, and the 
costs will be raised to nearly $2.6 billion in 2022 (48).t 
 
1.2.3 Risk factors and pathophysiology of disease 
Female sex, postmenopausal status in women and aging are the common factors leading to the 
increased risk of osteoporosis (46). While there is similar prevalence of osteopenia in male and female 
population, women compromise an increasing proportion of people with osteoporosis than men. 
Globally, over one in three women and one in five men after 50 years old will experience fractures 
resulted from fragile bone (49). According to the report of US, there are about 28% - 47% population 
experienced osteopenia, and about 30% - 50% population had osteoporosis (50). Regarding the 
osteoporosis, approximately 80% of female patients have osteoporosis in the US population (50). 
Compared with males, women had three times increased risk of suffering from osteoporotic fractures 
than men (50). Women after 50 years old and with menopause are at the highest risk of having 
osteoporosis (49). Postmenopausal women have a lower peak bone mass partially resulted from the 
reduction of estrogen hormones (46,47). The increased prevalence of osteoporosis also occurs 
frequently in the elderly (47). Additionally, reduction of body mass index and the deficiency of 
vitamin D and calcium ion also increase the risk of developing osteoporosis (46).  
1.3.Bone, an endocrine organ, may participant in the whole-body energy metabolism 
Bone is a dynamic organ, offering support and protection of organs of the body. The cortical bone 
(hard bone), the trabecular bone (spongy bone), bone marrow and bone cells mainly compose the 
structure of bone (51). Bones have a variety of mechanical functions, such as synthesis blood 
production, mineral storage and remodelling itself. The red marrow and yellow marrow generate 
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blood cells and store fat respectively (52). Bone tissue also stores calcium and phosphorus to nourish 
the body (51).  
 
Bone remodelling, also called bone metabolism, is defined as “absorption of bone tissue and 
simultaneous deposition of new bone; in normal bone, the two processes are in dynamic 
equilibrium.”(53) This process is a lifelong activity where the mature bone tissue is rigidly absorbed 
while the new bone tissue is produced. Besides, the bone resorption and bone formation are always 
coupling activities. Bone cells play a role in the bone remodelling by synthesising and secreting bone 
proteins. 
 
Apart from bone’s role in balancing calcium and phosphorus metabolism and skeleton construction, 
bone plays a role in whole-body metabolism. Regarding the possible metabolic network, a growing 
number of novel studies support the hypothesis that bone could act as an endocrine organ 
communicating with the pancreas and adipose tissues (54,55). It has been reported that the two 
hormones secreted by bone cells, fibroblast growth factor 23 (FGF23) and osteocalcin (OC), could 
affect energy metabolism (55). FGF23 is found to regulate serum phosphate and 1,25-dihydroxy 
vitamin D (VD) (55). Specifically, FGF23 works on the kidney to inhibit the activity of VD (55). On 
the other hand, OC could communicate with pancreatic beta cells, adipocytes, and muscle (56). With 
its action on these targets, the production, secretion, and sensitivity of insulin are enhanced, and the 
secretion of adiponectin is increased (55–57).  
 
1.4.Bone cells that produce OC, and its role in bone 
A brief overview of OC is shown in Figure 2 witha summary of OC functions. OC influences Ca2+ 
homeostasis, bone mineralisation, insulin secretion and sensitivity, male fertility and exercise 
capacity.  
 
 8 
Figure 2. An overview of osteocalcin (OC). 
 
 
 
1.4.1 Definitions and forms of OC 
Bone is a rigid but dynamic organ that can adapt its structure over time. The remodelling of bone 
involves two activities: bone formation and bone resorption (52). There are many bone cells in bone 
tissue, such as osteoblasts involved in bone formation and mineralisation and osteoclasts involved in 
bone tissue resorption (52). OC, also known as bone Gla protein (BGP), is a gamma-carboxyglutamic 
acid protein secreted by osteoblasts. It is a 49-amino-acid peptide that is abundant in bone and dentin, 
comprising about 15% of the non-collagenous protein in the skeleton extracellular matrix (58). The 
normal range of OC is between 9- 42 ng/ml for adults while there is no established reference range of 
OC for people below the age of 18 (59–61). In the human protein, there are three glutamate residues 
per molecule of OC (located in positions 17, 21, and 24) that can be post-translationally modified by 
vitamin K (VK)-dependent carboxylation to form -carboxyglutamate (Gla) residues, which 
contribute to bone mineralisation by binding calcium irons in hydroxyapatite (62). Thus, there are two 
forms of OC – carboxylated osteocalcin (cOc) and undercarboxylated osteocalcin (ucOC) – and VK 
regulates cOC and ucOC by gamma carboxylation (63). The cOC mainly contributes to the building 
of bone matrix because its negative charge binds the positively charged calcium ions at the surface of 
bone mineral. In contrast, as ucOC has a lower affinity for calcium ions, it stays in the serum. 
Although ucOC does not contribute to bone mineralisation, it is a hormonal form of OC and might 
play a role in the regulation of glucose homeostasis. When bone resorption initiated, OC is relased 
into the circulating from matrix (64). The circulating OC are cleared mainly by the kidney and partly 
by the liver and it can survive in the circulation about 5 minutes of its half-life (62).  
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1.4.2 OC as a bone turnover marker (BTM) may contribute to assessment of bone health 
BTMs are markers of bone resorption or bone formation. The concept of monitoring of bone 
metabolism via measuring enzymes and proteins which were produced and secreted during bone 
formation or degraded during bone resorption was pointed out in the last decade (65). Bone resorption 
markers include C-terminal telopeptide of type 1 collagen (CTX/CrossLaps), N-terminal telopeptide 
of type 1 collagen (NTX) and pyridinium crosslinks (deoxypyridinoline (DPD), pyridnoline (PYD)) 
(66). Alkaline phosphatase (ALP), procollagen type 1 N propeptide (P1NP) and osteocalcin (OC) are 
the bone formation markers (66). In some cases, the levels of BTMs were not discriminated between 
osteoporotic patients and healthy controls which limited the utility of BTMs in the diagnosis of 
osteoporosis (67). However, the BTMs could reflect the rate of bone metabolism in a specific and 
sensitive scale despite of its limitation in diagnosing osteoporosis (68). The test for BTMs can be 
conducted regardless of the results of bone mineral density (BMD) when measurement of BMD could 
not provide sufficient information for the risk of bone, e.g. check for fracture risk (68). Generally, 
patients with higher levels of BTMs have a low bone density (66). They reflect the process of bone 
remodelling and are a non-invasive way to assess skeleton metabolism status. 
 In term of clinical applications, OC could be mainly used to monitor the response after taking 
antiresorptive medications (66).  A study reported that BTMs presented a quicker response to the 
antiresorptive therapy than the dual-energy X-ray absorptiometry (DXA) scans (69). The response 
effect was measured by comparing treatment values to reference intervals for that group of patients, 
e.g. premenopausal women (69). Another study indicated that urinary OC was useful in monitoring 
the effect of alendronate therapy in postmenopausal women (70). Furthermore, the degree and phase 
of carboxylation of OC, usually shown as %ucOC, may indicate the skeleton strength (71). One study 
showed that ucOC is associated with hip fractures in 195 elderly institutionalized women (72). In 
return, the proportion of circulating ucOC relative to the total appears to indicate the status of VK 
(73). However, there are still limitations to be addressed before it is used clinically. The reference 
intervals for OC may vary with different sources, such as age, gender and ethnicity. Children have 
presented higher biochemical markers than adults, specifically during puberty. Before 50 years old, 
the levels of OC is decreased with age both in men and women. Besides, OC levels are higher in 
young men than young women. By contrast, postmenopausal women have higher OC levels than 
older men. At the age of 50 for women, the serum OC levels are increased significantly. A study 
conducted in 4,248 healthy Australian elderly male population reported that the reference intervals for 
TOC and ucOC were 10.2– 41.0 ng/mL and 5.2– 21.9 ng/mL, respectively (60). Another study from 
Pomerania reported that the median serum OC concentrations were 15.4 ng/mL, 14.4 ng/mL and 18.6 
ng/mL in men and postmenopausal women, respectively (74). Furthermore, people with various 
health conditions, for example, chronic metabolic disease, have effective levels of BTMs that are 
different from those of healthy people. In a recent study, Shou et al. developed reference intervals for 
OC in a group of elderly but healthy male subjects, with a range of 9–28 ng/ml (75).  
 
1.4.3 OC plays a role in glucose homeostasis in experimental studies 
There are several interesting studies on the discovery of OC. Around 1975, the BGP was purified 
from chicken bone and bovine bone and named ‘osteocalcin’ (76,77). Price et al. implied that OC may 
play a role in bone mineralisation regulation in calcified tissues and that higher levels of circulating 
osteocalcin may indicate mineral loss of surrounding tissues (78). Apart from its role as a diagnostic 
parameter of skeleton pathology, OC has attracted a number of investigations due to its possibly 
unique role as a hormone in whole-body energy metabolism.  
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Since these novel findings, extensive studies based on mouse experiments and in vivo experiments 
have reported on the physiological functions of OC as a hormone in energy metabolism (79,80). As 
underscored by Karsenty et al., several significant experiments led to the hypothesis of the endocrine 
function of skeleton and bone through the activity of OC (54). In particular, in 2007, Lee et al. 
showed that OC plays a role in energy metabolism (79). They observed that mice lacking osteocalcin 
exhibited reduced beta-cell proliferation, glucose intolerance, and insulin resistance (79). In later 
years, Ferron et al. added detail in this context, showing that OC could stimulate beta cell 
proliferation in the pancreas and promote the expression of adiponectin (adiponectin is the hormone 
that improves insulin sensitivity) produced by adipocytes in a wild-type (WT) mouse model (80). 
Their results showed that WT mice implanted with osteocalcin had a reduced risk of developing 
obesity and diabetes in an eight-week controlled experiment (80). Following these findings that OC 
can exert an effect on glucose metabolism and insulin secretion, it was demonstrated by Ferron et al. 
that insulin may also have the ability to activate the secretion of ucOC by signaling in osteoblasts 
(81). Together with previous studies, this finding indirectly provided evidence for a possible feed-
forward loop in which improving/elimating insulin signalling in osteoblasts could promote/limit 
glucose metabolism by increasing/decreasing circulating levels of OC. In line with the investigation 
of insulin in osteoblasts, high-fat diet (HFD) experiments indicated that bone could be one of the sites 
that become insulin resistant, resulting in the inactivity of osteoblasts and hampered activation of OC 
(82). 
 
The findings in the experimental study led to the proposal that a measurement of OC activity could be 
used to assess glucose intolerance in humans. However, Aoki et al. disagree with this idea, as they 
observed elevated serum levels of TOC in T2DM and PD, and suggest that it is too early to conclude 
that OC is an effective indicator of glucose metabolism in humans (83).  
 
1.5.Evidence in human research that OC is associated with glucose homeostasis  
1.5.1 Observational studies report lower levels of OC in patients with glucose intolerance 
It is well known that patients with metabolic syndrome and T2DM have a glucose metabolism 
disorder and become glucose intolerant. Epidemiological studies in patients with those diseases have 
found lower levels of OC in persons with T2DM compared with controls with normal glucose 
tolerance (84,85). To explore the endocrine function of OC in humans, a large number of 
observational studies have investigated this role using different measurements across diverse 
populations (86–89). Consistently, studies reported that patients with diabetes had lower baseline 
serum OC than healthy controls, with cohorts sourced from the middle-aged male population, 
postmenopausal women, and both men and women aged between 18 and 65 years old (90–92). In 
addition, patients with metabolic syndrome (MetS), which have glucose intolerance and a higher risk 
of developing T2DM, also presented lower baseline serum OC compared with controls (93–96). 
Furthermore, in a cross-sectional study with a population-based cohort, findings showed that for every 
7.04 nm/ml increase in serum OC there was a 1.75-fold reduced risk of developing T2DM (Odds ratio 
(OR): 0.57; 95% CI: [0.46,0.70] for T2DM) (97). However, in a retrospective cohort study with 1,229 
middle-aged non-diabetic male participants, it was reported that the circulating level of OC was not 
associated with T2DM (OR: 1.10; 95% CI: [0.67,1.81]) after follow-up at 8.4 years (98).  
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1.5.2 Clinical trials show OC levels increased after glycaemic control improvement 
Some interventional studies showed increased serum levels of OC after glycaemic control (99–101). 
Yuqian et al. showed that serum TOC could be increased by improvement of glycaemic control in 59 
T2DM patients after eight weeks of medication with antidiabetic drugs (99). At baseline, they also 
observed positive associations between TOC and parameters for assessing beta-cell function (99). 
Itamar-Levinger et al. conducted a post-exercise intervention in 28 obese men and reported that there 
were significant increases both in TOC and ucOC after aerobic exercise (100). Moreover, in the 
subgroup analyses of T2DM patients, a positive association between changes in ucOC and changes in 
glucose after exercise intervention was observed (100). Another study also reported that 
hyperglycaemic conditions affected bone metabolism by inhibiting osteoblast differentiation and 
negatively affecting bone formation (101). As a result, a reduction of OC was observed in cells (101).  
 
1.5.3 Published systematic reviews/meta-analyses suggest consistent results of OC  
Three published systematic reviews/meta-analyses that aimed to address the issue of inconclusive 
results in patients with T2DM concluded that patients with T2DM have lower serum OC levels (102–
104). It has been consistently proved by these reports that patients with T2DM present lower levels of 
serum OC compared with standard glucose tolerance controls (NGC) (102–104). The newest study by 
Hygum et al. investigated a series of BTMs and concluded that patients with diabetes (including 
T1DM and T2DM) have significantly decreased BTMs compared with healthy controls (102). 
Furthermore, the authors concluded that the abnormal bone conditions in diabetes may lead to future 
bone fragility in these patients (102). Similarly, another two studies conducted in 2015 by Kunutsor et 
al. and Liu C et al. showed that the bone formation marker OC is lower in patients with T2DM than in 
healthy controls: Mean difference (MD): −3.31 ng/ml [−4.04, −2.57]; standard mean difference 
(SMD): −2.87 ng/ml [−3.76, −1.98] for Kunutsor et al. and Liu C et al.’s studies, respectively 
(103,104).  
 
The reviews showed the protective role of OC in the development of T2DM (103,104). Both 
Kunutsor et al. and Liu C et al.’s studies reported that increased OC levels are significantly correlated 
with a reduced incidence of T2DM (103,104). Kunutsor et al. conducted a subgroup analysis in terms 
of study types and demonstrated that only cross-sectional studies showed that OC played an 
independent and significant role in the prevention of developing T2DM, which is in contrast with the 
findings from cohort studies (OR:0.23 [0.12,0.46]; OR: 0.89 [0.78,1.01] for cross-sectional studies 
and cohort studies, respectively) (103). Consistent with Kunutsor et al.’s conclusion, Liu C et al. 
provided an overall risk estimate (OR:0.70[0.56,0.88]) for the same group of studies included in 
Kunutsor et al.'s analyses, with the exclusion of one study from Movahed et al. 2012 (103–105).  
 
1.6.The reason for investigating the association between OC and T2DM in humans 
 
1.6.1 Patients with T2DM are suspected of impaired bone health to which the assessment of
 BTMs (including OC) may be a better approach than BMD 
Usually, bone strength is determined by mineralisation and predicted by measuring bone mineral 
density (BMD), although studies point out that other valuable bone properties also contribute (106). It 
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is generally accepted that reduced bone mass and altered bone architecture have tremendous effects 
on bone quality. To assess bone quality, several methods on the macro scale, including DXA and 
radiography, have been widely used to acquire information on BMD, and accordingly to determine 
the likelihood of osteoporosis (106). However, observing bone from a micro perspective could bring 
greater power to bone assessment. Increasingly, evidence shows that bone remodelling, by bone 
resorption and bone formation, predicts bone quality (68,107). Three principal bone cells, namely, 
osteoblasts, osteoclasts, and osteocytes, cooperatively regulate bone remodelling (22). Consequently, 
BTMs secreted by these cells can reflect bone cell activity and be used to predict bone quality on a 
micro scale. Although BTMs are not used for clinical diagnosis of osteoporosis, they may become a 
useful parameter when BMD is not reliable in certain medical conditions, for example, patients with 
T2DM.  
 
Patients with T2DM have altered elevated BMD compared with healthy controls, and, paradoxically, 
have a higher prevalence of osteopenia, osteoporosis, bone fragility and bone fractures. Interestingly, 
T2DM patients have higher BMD compared to patients with T1DM and controls, which cannot 
explain the increased prevalence of bone diseases in patients with T2DM (108,109). It is well known 
that patients with lower BMD have a higher risk of developing osteoporosis or bone fragility. 
However, extensive studies have reported that the incidence of bone fragility and fractures is 
increasingly elevated in T2DM (21,110,111). Several lines of research have shown that patients with 
T2DM have significantly decreased levels of certain BTMs, indirectly proving slower bone 
remodelling (84,102,112). Hypotheses on whether patients have ‘good bone condition' vary among 
studies. A few studies have indicated that insulin resistance (IR) might have a protective function for 
bone as accumulated BMD may delay bone loss, particularly in postmenopausal women (113). 
However, this hypothesis is in doubt because of the growing numbers of bone issues observed in 
T2DM. People with diabetes always exhibit abnormal Ca2+ metabolism, which is a significant risk 
factor for developing osteopenia over time with decreasing Ca2+ from bone (113). Furthermore, it is 
well known that disordered bone remodelling increases the risk of osteoporosis; in particular, that 
impaired osteoclast function can result in cases of osteoporosis. Evidence from several reviews shows 
that diabetes patients have decreased bone turnover markers for both bone resorption and bone 
remodelling (102,103). A newly published study by Hygum et al. suggests that increased sclerostin 
levels and osteoprotegerin in diabetes may contribute to bone fragility, reflected by decreased levels 
of BTMs CTX and OC (102).  
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1.6.2 Glycaemic control in T2DM may affect bone remodeling and associate with OC  
BTMs are altered in cases of disordered glucose homeostasis, especially in patients with T2DM. 
There are changes in both bone formation markers and bone resorption markers in T2DM compared 
with healthy controls. Hygum et al. conducted a systematic review/meta-analysis of BTMs in diabetes 
(102). From their analysis of 66 relevant studies in humans, they found that patients with diabetes 
have low BTMs, including decreased levels of OC and procollagen type 1 amino-terminal propeptide 
(P1NP), involved in bone formation, and C-terminal cross-linked telopeptide (CTX), involved in bone 
resorption (102). Their findings are consistent with those of the previously published systematic 
reviews/meta-analyses by Kunutsor et al. and Liu C et al. in 2015, while Takizawa suggested that 
bone resorption markers (for instance, CTX) were increased in T2DM instead (102–104,114). 
Remarkably, one study observed that OC levels increased at the stage of prediabetes (IFG/IGT), 
which is in contrast to the observation of decreased OC in T2DM (83). These findings may suggest 
that OC levels could change over time according to different glycaemic status in humans.  
 
Although histology of bone and skeleton in patients with T2DM and their function in regulating 
glucose metabolism are still uncertain, it is increasingly clear that good glycaemic control can 
contribute both to reduced bone resorption and bone formation markers except for OC. In humans, it 
is well known that the bone formation and bone resorption processes are always coupled. However, 
their relationship is less clear in T2DM (115). Regardless of this unclear relationship, it has been 
proved that both bone resorption and formation markers will decrease with glycaemic control 
improvement in poorly controlled T2DM (116–119). Also, an increasing number of studies have 
reported that BTMs (for example, OC) are inversely correlated with the levels of HbA1c, which 
works as an indicator for glycaemic control among diabetes patients (99) but may not be a reliable 
marker to reflect bone formation in poorly controlled T2DM (116). In addition, Okazaki et al. 
suggested that an improvement in glycaemic control is correlated with a decrease in bone loss that 
would in turn exert a protective effect on bone in T2DM (116). This hypothesis was based on an 
observed reduction in bone turnover markers associated with improvement of glycaemic control, such 
as deoxypyridinoline (Dpd), type I collagen carboxy-terminal telopeptide (CTx) and bone type 
alkaline phosphatase (BALP), in their study (116).  
 
Compared with the findings in rats regarding the positive effect of insulin on bone, whereby insulin 
stimulates the activities of osteoblasts, the evidence in diabetic humans is inconclusive. Rosato et al. 
pointed out that when considering the insulin-like growth factor 1 (IGF-I) as a potential confounder 
(which is known for promoting osteoblast differentiation, maturation and function), direct 
relationships between BTMs and insulin became complicated (120). Furthermore, the changes in IGF-
I could be an indirect effect of insulinopenia (120). Sayinalp et al. also supported the conclusion that 
the glycaemic control associated with an improvement in insulinopenia promoted osteoblast function 
(118). 
 
On the other hand, in 1994, Gregorio et al. observed reduced levels of bone mineral content (BMC) in 
patients with DM (121). Accordingly, they assumed that the impaired insulin activity was linked to 
lower levels of OC (121), and therefore that osteoblast insulin resistance could result in a reduction in 
BMC and OC. Furthermore, the OC levels were lower in well-controlled DM than in poorly 
controlled DM in their report (121). As OC levels in poorly-controlled T2DM were similar to controls 
and higher than in well-controlled T2DM, the researcher suggested that the decreased parathyroid 
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hyperactivity in well-controlled T2DM might  account for the inactivity of osteoblasts and the 
reduced the levels of OC (121). According to their study, patients with poorly-controlled T2DM had 
higher serum parathyroid hormone concentrations (PTH) than well-controlled T2DM patients. 
Furthermore, It was elucidated in other studies that daily injection in PTH had a positive effect on the 
bone formation rate and bone strength (122,123). The stimulating effect of PTH increased the number 
of osteoblasts, its activation frequency, and the levels of OC (122,123).  
 
1.6.3 It is not clear whether OC associates with the risk indices for T2DM 
Research investigating the relationships between OC and glucose metabolism in T2DM in humans 
has increasingly involved epidemiological studies and interventional studies (91,124–126). As for 
observational studies, a large number of studies have compared OC levels in T2DM with those in 
healthy controls and concluded that there are reduced levels of OC in patients with T2DM (84,127–
129). Furthermore, associations between OC and other biomarkers have been widely reported across 
human research (130,131). It should be noted that from 2007 to the present, Kanazawa et al. have 
been continuously reporting on the relationships between OC and insulin resistance, adipose tissue 
and glucose metabolism in patients with T2DM (132–135). Their research shows that there are not 
only significant inverse relationships between OC and glucose metabolism parameters, such as FPG 
and HbA1c, but also positive associations between OC and insulin sensitivity and insulin secretion, 
determined by assessing beta cell functions (85,133,136). Within a similar time period, a large 
number of research groups, regardless of the different cohorts of participants, showed an inverse 
correlation coefficients between osteocalcin and glucose metabolism measured by insulin resistance 
parameters, for example of  HOMA-IR (131,137,138).  
 
In contrast to the findings of correlations between OC and glucose metabolism, several research 
groups have concluded that there is no association between OC and the incidence of T2DM. Hwang et 
al. stated that OC could not predict the risk of developing T2DM in a group of middle-aged male 
participants (139). A cohort of 1229 men hospitalised and without T2DM at the baseline were 
included in the retrospective cohort study and were followed up for around eight years; the hazard 
ratio of the increase in OC per standard deviation for the incidence of T2DM is around the null value 
of 1 after adjustment of possible confounders, which indicated that OC had a non-significant 
association with developing T2DM (139). Another research group supported similar conclusions to 
those of Hwang et al. from a study of a group of people of both sexes with and without T2DM (140). 
The ten-year prospective cohort study suggested that neither TOC nor ucOC are associated with the 
incidence of T2DM (OR:0.97, [0.92,1.02] for TOC; OR:0.96, [0.87,1.06] for ucOC) (140).  
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1.7.The unaddressed issues in the current literature  
1.7.1 Published systematic reviews/meta-analyses have sizeable unexplained heterogeneity 
The enormous heterogeneity in study findings has not been explained in the pooled analyses 
(103,104). In the subgroup analysis of Kunutsor et al., concerning risk estimates, the result from the 
cohort studies has an I2 value of 0% while the result from cross-sectional studies has an I2 of 84%, 
indicating a considerable heterogeneity among cross-sectional studies (103). However, it should be 
noted that only three cohort studies were eligible for analysis, which might partly bias the I2 
heterogeneity analysis (92,103,124,139). In addition to the conflicting research findings, there are 
fewer prospective or retrospective studies than cross-sectional studies, from which no causal 
relationships between OC and T2DM can be explained. Hence, the discrepancies in the findings of the 
studies indicate possible gaps in the literature. 
 
1.7.2 Insufficient results from observational studies of ucOC need evaluation 
On the one hand, experimental studies have proved that ucOC rather than cOC acts in the glucose 
metabolism in circulation. Instead, cOC contributes to bone mineralisation and bone structure. On the 
other hand, in contrast to mice studies, it is still not known which form of OC plays a role in glucose 
metabolism in humans (104,141). A considerable number of the observational studies reported that 
baseline TOC could predict an adverse outcome of metabolism without reporting ucOC (142–144). 
However, there are still several studies that investigated ucOC and presented contrasting results 
(96,140,145–147). Hence, it is necessary to include the analyses both of TOC and ucOC. In the two 
published reviews, ucOC was not included in the meta-analysis of risk estimates of the incidence of 
T2DM because few observational studies were identified(103,104). Although Liu C et al. showed that 
there were lower levels of ucOC in T2DM than in non-diabetic controls (MD: −1.29 ng/ml; 95% CI 
[−3.05, 0.46]), this conclusion lacks statistical power because only three observational studies 
contributed to the meta-analysis results (20,92,104,148).  
 
1.7.3 Prediabetes (PD), the intermediate state before T2DM, has not been analysed in the 
published reviews 
PD is a condition in which blood glucose levels exceed the normal range but the patient is not 
diagnosed with T2DM. Patients with PD have impaired glucose tolerance and become insulin 
resistant (149). Usually, there are two types of PD: impaired fasting glucose (IFG) or impaired insulin 
tolerance (IGT) (149). The ICD for PD is R73.0. 
 
Some observational studies have reported conflicting results regarding the associations between OC 
and glucose metabolism in patients with PD. Im et al. reported lower baseline levels of TOC in 
patients with IFG than in healthy controls in a cross-sectional study of postmenopausal women (150). 
Liang et al. also showed that Chinese males aged between 17 and 88 years with IFG had lower levels 
of baseline serum TOC compared with controls with healthy glucose metabolism (151). On the other 
hand, Aoki et al. claimed that patients in the early stage of diabetes had increased circulating OC 
levels (83). They observed higher levels of TOC in patients with PD than in standard glucose 
tolerance controls (83). Also, it is well known that patients with PD have an increased risk of T2DM 
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and cardiovascular disease, which provides the evidence on the degree of alternations of levels of OC 
with the circumstance that glucose intolerance becomes increasingly severe.   
 
However, neither of the reviews by Kunutsor et al. or Liu C et al. addressed the conflicting results 
from patients with PD (103,104). Another published review/meta-analysis reported on the correlation 
between TOC and ucOC and glucose metabolism parameters (FPG and HbA1c) in the general 
population, while serum levels of OC were not compared between different groups based on T2DM or 
PD status (141). Therefore, there is a gap in the literature that must be filled to explain the 
contradictory results of OC in patients with PD. 
 
1.8.The importance of the present work and its objectives 
The present research aims to fill the gaps reported by previous published reviews/meta-analyses and 
the current literature. We conducted an aggregational systematic review/meta-analysis that 
investigates the relationships between OC and T2DM in humans. Compared with the findings from 
mice models, these relationships are less understood in humans, with conflicting results from 
observational studies.  
 
As discussed in the pevious section, to date, there have been two published meta-analyses and 
systematic reviews, both published in 2015, assessing the pooled mean difference of TOC in patients 
with T2DM and non-diabetic controls, as well as the risk estimates of OC for the development of 
T2DM (103,104). Both reviews suggested that TOC levels were significantly lower in T2DM 
(103,104). However, significant unexplored between-study heterogeneity remained for the main 
findings of both meta-analyses, and few published prospective studies could be found before 2015 in 
their search results.  
 
Thus, the primary aims of the present review are to comprehensively explore the relationships by 
applying a variety of outcomes (mean difference, correlation coefficient, and odds ratios), including 
more cohort variables to identify sources of between-study heterogeneity, and identifying more 
current observational studies in the literature. By investigating OC levels in T2DM compared with 
non-diabetic controls, we can determine whether T2DM has affected bone turnover markers because 
OC is used as the bone formation marker.It might explain why T2DM patients have increased BMD 
yet have a higher risk of skeleton disease, as they have negative alterations in bone remodelling. The 
investigation of associations between serum OC and metabolic phenotype parameters (such as FINS, 
HOMA-IR, FPG, and HbA1c) may provide evidence as to whether OC levels and the condition of 
hyperglycaemia are correlated, and on the power of this association. As published studies have 
mentioned that increased OC levels might regulate glucose homeostasis to resist the progress of 
T2DM, retrieving the odds ratio of OC for the risk of developing T2DM could indicate whether OC is 
a powerful predictor for the incidence of T2DM.  
 
Furthermore, by assessing ucOC, the active form of OC, in patients with T2DM, the present study 
may help in translating the understanding of the hormonal function of OC in glucose metabolism from 
mouse models to human research. In addition, with the analysis of patients with PD, this thesis may 
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provide comparisons of serum levels of OC in different glycaemic conditions to see whether OC 
changes are consistent with the increased glucose in the blood.   
 
This study aims to investigate the following: 1) serum mean differences of TOC/ucOC between 
T2DM and non-diabetic controls, between PD and non-diabetic controls, and between T2DM and PD; 
2) correlation coefficients between OC and metabolic phenotype parameters (such as FINS, HOMA-
IR, HbA1c and FPG); 3) the odds ratio of a 1-standard deviation increase in OC in the development of 
T2DM; and 4) useful factors to explain the sources of heterogeneity at the study level. 
 
There following are the research questions concerning participants, interventions, comparisons, 
outcomes and study design (PICOS):  
1) Is there any difference in OC levels between patients with T2DM/PD and healthy controls 
with normal glucose metabolism? TOC or ucOC, which one provide the more useful 
information? 
2) How does OC associated with glucose metabolism parameters in humans (regarding 
T2DM/PD/healthy controls), such as FINS, HOMA-IR, FPG and HbA1c? TOC or ucOC, 
which one provide the more useful information?  
3) Which factors that are clinically significant and plausible may interfere with the associations 
between OC and glucose metabolism or insulin sensitivity in T2DM? 
4) What are the outcome measures that could be used to assess the relationships between OC 
and T2DM?  
5) What are the analysis measures that could explain the interesting heterogeneity of effect size? 
Furthermore, what are the variables that could significantly affect the outcomes of effect size 
in the meta-analysis? 
 
Chapter 1 has disclosed the background, rationale and an overview of the present systematic 
review/meta-analysis. It has explored and summarised the current literature and stated the research 
questions. Chapter 2 describes the study methodology of the systematic review/meta-analysis, in line 
with the guidelines from PRISMA and MOOSE. Chapter 3 presents the results of the thesis: it reports 
the mean differences (MD) of OC in T2DM, PD, and non-diabetic controls; identifies the 
relationships between TOC/ucOC and fasting plasma insulins (FINS), homeostatic model assessment 
insulin resistance (HOMA-IR), haemoglobin a1c (HbA1c) and fasting plasma glucose (FPG); presents 
heterogeneity tests for the meta-analyses; and publication bias assessments shown with funnel plots. 
Chapter 4 discusses and interprets the findings of the review, and Chapter 5 concludes the work.  
 
CHAPTER TWO: METHODS 
2.1 Procedure and time frame 
According to the guidelines of PRISMA and MOOSE, this study followed four initial steps: study 
identification; title and abstract screening; full-text assessment of eligible studies, including eligible 
studies for quantitative meta-analyses; and data extraction (152,153). This research was initiated in 
Feb 2017 and completed by June 2018. We submitted a systematic review/meta-analysis protocol 
designed with PRISMA-P checklist to British Medical Journal Open Access (BMJ-OA). This protocol 
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was also registered in PROSPERO. Furthermore, the protocol works as the primary reference for this 
review. 
 
2.2 Eligibility Criteria 
2.2.1 Inclusion and exclusion criteria for patients 
In general, we included patients with T2DM/PD at baseline and those that developed T2DM/PD 
afterward. As a comparison, subjects with normal glucose levels were included. Eligible participants 
were free from illness/medications that affect bone metabolism. However, we did not exclude patients 
with anti-diabetic treatments. Patients were adults (over 18 years old) and both men and women were 
included.  
 
The exclusion criteria and justification, are listed as follows: 
1) Children or adolescents (age younger than 18 years old) were excluded, as bone and 
remodelling varies significantly between children and adults . Accordingly, the level of bone 
turnover markers (including OC levels) differs so that they are not clinically comparable 
(154). Besides, there is no consistent standard reference for levels of OC in subjects younger 
than 18 years old (61). 
2) Pregnant or lactating women were not eligible because of the possibility of significant 
alterations in sex hormones and glucose metabolism. Due to the status of pregnancy or 
lactation favour their changed glucose homeostasis and hormonal regulation, it is not valuable 
to make comparisons in those subjects with these groups (155). 
3) Patients with T1DM or gestational diabetes mellitus (GDM) were excluded. The mechanisms 
by which T1DM and GDM develop are different from that of T2DM (156–158). Patients with 
T1DM have an auto-immune condition, and are not able to produce insulin because of the 
destroyed cells in the pancreas (157). The development of GDM also follows another 
mechanism, and it occurs during pregnancy (155,158). On the other hand, the development of 
T2DM is progressive; the patients have problems using insulin efficiently and gradually 
become unable to produce enough insulin for normal glucose homeostasis (156). Therefore, 
these three diabetic diseases are not comparable in this study. 
4) Patients with a disease that affects either bone metabolism or glucose metabolism were 
excluded because they could be a significant confounder in the investigation of the 
relationships of OC in T2DM. 
Examples of such diseases include the following:  
• Cushing’s disease or Cushing's syndrome, which is characterised by elevated secretion of 
the adrenocorticotropic hormone (159). 
• Paget’s disease, which is a chronic bone disorder disease. Patients have an abnormal bone 
remodelling process, suggesting changed patterns of bone turnover markers (160).  
• Patients with growth hormone deficiency were excluded as they usually have disordered 
whole body metabolism. In particular, adult patients with this illness have decreased lean 
body mass, muscle mass, and accordingly, there are abnormal protein levels in their body 
(161). Hence, if this group of patients were not excluded, it could interfere with 
assessment of the associations between OC and T2DM. 
• Patients with hyperparathyroidism or hypoparathyroidism were excluded. These patients 
have increased or reduced parathyroid hormone (PTH) in the blood as a result of the 
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abnormal function of parathyroid glands (162). As patients with this disease have altered 
biomarkers in their blood, the disease was eliminated from the inclusion criteria.  
5) Patients with liver dysfunction (alanine transaminase > 3 times the upper limit of normal) 
were excluded from the study. In these patients the liver loses its ability to regulate normal 
metabolism (163). For this reason, the levels of biomarkers could be significantly altered, 
which would become an interfering factor in this study.  
6) Patients with impaired kidney function were excluded:  
• Chronic renal disease, when the glomerular filtration rate of impaired renal function 
patients is below 30 ml/min/1.73 m2 at stage four or five (164). 
• Chronic renal illness, when serum creatinine is over 2.07 mg/dL, or renal osteodystrophy, 
or kidney transplant, as 21% to 50% of kidney transplant recipients may develop 
secondary hyperparathyroidism after kidney transplantation or treatment with dialysis or 
haemodialysis (164).  
The assays of OC could be negatively affected if the renal functions of patients are severely 
damaged.  
7) Patients with any cancer or tumor were not eligible as there is a physiologically abnormal 
metabolism in the body.  
8) Patients diagnosed with human immunodeficiency virus (HIV) were not eligible as this illness 
can progressively damage the human body's immune system and affect whole-body 
biomarkers. 
9) Patients with the following medications were not eligible due to the effect of the medication 
on bone metabolism: 
• Antiresorptive therapy for osteoporosis and selective estrogen receptor modulators (such 
as bisphosphonates, alendronate, etidronate, and raloxifene) 
• Estrogen replacement therapy 
• Glucocorticoids and thiazide diuretics. 
Note: We included any interventional study that reported baseline data of OC and T2DM. We 
eliminated observational studies with more than 20% of the cohort taking therapy that influences bone 
metabolism. 
 
2.2.2 Inclusion and exclusion criteria for study types  
 In brief, the present study included observational studies, and did not consider randomised controlled 
trials (RCTs). Observational studies are also known as epidemiological studies, where the researcher 
only observes the nature of relationships between exposure factors and outcome factors, rather than 
interfering with the relationship between exposure and outcome by testing some intervention. The 
following list introduces the types of observational studies: the ecological study, retrospective and 
prospective cohort study, case-control study, case-crossover study, and cross-sectional study (165–
167).  
 
• An ecological study, also called correlational study, measures the correlations between one or 
more variables and the health outcomes at population level. Hence, the data collected are 
aggregational (167). 
• A retrospective and prospective cohort study studies the exposure of healthy participants to 
observe whether they develop the disease outcomes over time. Usually, a cross-sectional 
study is conducted at the baseline of a cohort study to divide comparison groups based on 
their exposure status and to exclude participants that already have the outcome disease. 
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Afterwards, the outcomes of subjects that were without disease at baseline are measured 
within the designed period. The cohort study can provide information about the outcome 
incidence and risk estimates (165,167). 
• A case-control study is based on the study outcomes, and study participants are selected 
according to their outcome status. The exposure is measured back to a period. This study is 
usually a retrospective study, and it is likely to involve recall bias (165,167).  
• A case-crossover study involves the same cohort of participants. Investigators measure the 
exposure status of subjects when they become a case. Their exposure status at the time that 
they become a case will be compared with their exposure status before they developed the 
outcome. Generally, this study type is known as a retrospective study (165,167). 
• A cross-sectional study, the prevalence study, is conducted at the level of a single time point. 
Researchers select participants based on their exposure and measure the study outcomes of 
the participants after recruitment. According to the characteristics of this study type, selection 
bias should be considered (165,167).  
 
RCTs were not included in this review. However, if the baseline data of any trial could be used, we 
regarded it as a cross-sectional study and included it. A RCT is one of the frequently used types of 
interventional studies. In RCT studies, subjects are randomly assigned to two study groups, and they 
are expected to share the same characteristics (165). In other words, the intervention factor is the only 
differentiating factor between the two comparable groups.  
 
We excluded reviews, commentaries, short surveys, case reports and letters because they are not an 
appropriate study designed to provide information for our study review and meta-analysis, and 
relevant data cannot be extracted from them. We included all published studies with no time 
restriction. There was no limitation to language in the requirements. If there was no English version of 
a study, we tried to translate it. However, if it could not be translated properly, we excluded it. 
Unpublished studies were not considered, but conference reports or abstracts in conference 
proceedings were included if necessary.  
 
2.3 Information sources and search strategy 
The search was conducted in three central databases: MEDLINE, EMBASE, and SCOPUS. The first 
search date was Mar 2017 and the last update was in May 2018. We contacted authors in the 
individual study if it was necessary to acquire information about a risk estimate used in the meta-
analysis or about missing data that needed to be completed.  
 
We produced a comprehensive search strategy by hand with the help of an university librarian. In 
addition, a reference list was generated including all the additional articles not originally from our 
search results but from the citations of individual paper during full-text assessment. With 
consideration of duplication of the studies retrieved, we chose the most relevant and up-to-date paper 
if they could provide more complete data. The terms of the search strategy involved language, article 
type, the published year, characteristics of populations, exposures, and outcomes. A summary of the 
search strategy is shown in Table 1, and detailed, comprehensive search terms are shown in Table 2.  
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Table 1. Summary of search strategy in databases: Medline, Embase, and Scopus. 
 
Keyword 
 
Medline 
 
Embase 
 
Scopus 
Population = 
adults 
N/A N/A N/A 
 
Exposure(s) = 
osteocalcin 
Osteocalcin, bone gla 
protein, vitamin k 
dependent bone protein 
Osteocalcin, bone gla 
protein, vitamin k 
dependent bone protein 
Osteocalcin, bone gla 
protein 
Methodology 
= 
observational 
studies 
N/A 
 
N/A N/A 
Comparator = 
none 
 
N/A N/A N/A 
Outcome(s) = 
T2DM 
T2DM/hyperglycemia/ 
HbA1c 
T2DM/hyperglycemia/ 
HbA1c 
 
T2DM/ 
hyperglycaemia/ HbA1c 
 
Additional 
specific filters 
Human Human, exclude Medline 
Journals 
Human 
 
*N/A : Not Applicable
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Table 2 Terms applied in databases: Medline, Embase, and Scopus 
 
 
Medline (Ovid SP) Embase (Ovid 
SP) 
Scopus 
1. exp osteocalcin 
2. osteocalcin.mp 
3. bone gla protein.mp 
4. 1 or 2 or 3 or 4 
5. exp diabetes 
mellitus, Type 2 
6.diabetes mellitus type 
2.mp 
7. (T2D* or NIDDM or 
“type 2” or “type 
II”).tw 
8. (non 
insulin$ depend$ or 
nonsinulin$depend$ or 
non insulin?depend$ or 
noninsulin?depend$).t
w 
9.exp Hyperglycemia 
10. hyperglycemia.mp 
11. hypergly?emi*.tw 
12. exp Hemoglobin A/ 
or exp Hemoglobin 
A，Glycosylated 
13. HbA1c.mp 
14. (“HbA(1c)” or 
HbA1c or “HbA 1c” or 
((glycosylated or 
glycated) adj 
h?emoglobin)).tw 
15. 6 or 7 or 8 or 9 or 
10 or 11 or 12 or 13 or 
14 or 15 
16. 5 and 16 
17. limit 17 to humans 
1. exp osteocalcin 
2. osteocalcin.mp 
3.bone gla 
protein.mp 
4.vitamin 
k?dependent bone 
protein*.mp 
5. 1 and 2 and 3 
and 4 
6. exp noninsulin 
dependent 
diabetes mellitus 
7. exp diabetes 
mellitus 2/II 
8. (T2D* or 
NIDDM or “type 
2” or “type II”).tw 
9. (prediabet* or 
pre diabet*).tw 
10. 
hyperglyc?emi*.t
w 
11. 6 or 7 or 8 or 9 
or 10 
12. 5 and 11 
13. limit 12 to 
(human and 
exclude medline 
journals) 
( KEY ( 'osteocalcin' )   
OR  KEY ( 'bone  AND gla  AND protein' )   
OR  KEY ( 'bone  AND turnover  AND markers' ) ) 
  
AND  ( KEY ( 'diabetes  AND mellitus' )   
OR  KEY ( 'hemoglobin  AND a1c' )   
OR  KEY ( 'fasting  AND plasma  AND glucose' ) )
   
AND  KEY ( 'human' )  AND  ( LIMIT-
TO ( DOCTYPE ,  "ar" ) )  
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2.4 Study selection 
2.4.1 Screening and full-text assessment 
The study selection was based on two primary processes: the screening and the full-text assessment. 
1) Screening: one author ran the search strategy and documented the search results in Endnote 
software (168). The duplications of retrieved studies were identified and excluded by the same author. 
Two investigators completed the screening process by reading titles and abstracts of identified 
articles. Studies that reported any aim to assess the association between OC and T2DM were 
included. Alternatively, they could provide data with baseline levels of OC in T2DM, PD, and healthy 
controls. The selection process of screening was saved in a single Excel file with ‘include,' ‘exclude' 
or ‘not sure' markers. Where the eligibility of a paper was uncertain, a third reviewer took part in 
making a final decision after discussion with the other two reviewers. Any discrepancy was addressed 
by face-to-face meeting to collect the relevant authors’ points of view. A third person made the final 
decision based on the discrepancies between the other two reviewers. The screening was conducted 
according to the study protocol for this review/meta-analysis. 
 
 2) Full-text assessment: one author acquired the full-text version for all eligible studies included in 
the screening, and two authors independently read and assess the full text of the articles. If there was 
any statistic reported in line with the following information, the paper was eligible for later meta-
analysis. The information of interest included levels of OC in T2DM, PD, or HC; or any risk estimate 
(correlation coefficient or odds ratio) between OC and T2DM measurements. Studies that did not 
include relevant statistics were only used for descriptive purposes in this review. Exposures and 
outcomes are defined below for screening and full-text assessment. 
 
2.4.2 Concepts of exposures and outcomes  
The study exposure was OC, including levels of both TOC and ucOC. The assays for OC were 
usually performed by one or more of five methods: enzyme-linked immunoassay (ELISA), solid-
phase enzyme immunoassay (EIA), electro-chemiluminescence immunoassay (ECLIA), 
immunoradiometric assay (IRMA), radioimmunoassay (RIA), and hydroxylapatite binding assay 
(HAP) (65,169). The standard unit of OC concentration is ng/ml, and other forms (e.g., nmol/l) were 
transformed to ng/ml (65).  
 
The diabetic status of patients was classified as T2DM, PD, or healthy controls. The primary study 
outcome was T2DM, also known as NIDDM. The secondary outcome was PD, also recognised as 
impaired glucose tolerance (IGT) or impaired fasting glucose (IFG). When diagnosing the status of 
diabetes, measurements of HbA1c and fasting plasma glucose (FPG) were commonly applied. 
Specifically, the ranges for HbA1c of >6.5%, 5.7–6.5% and <5.7% indicated an outcome of T2DM, 
PD, and HC, respectively. Levels of FPG in the range of >126 mg/dl, 100–126 mg/dl and <100ml/dl 
indicated an outcome of T2DM, PD, and HC, respectively.  
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2.5 Data collection process & data items 
Two reviewers independently collected the data of characteristics of the individual study and the 
characteristics of the population from all eligible studies retrieved from full-text assessment, and one 
of them compared and combined the collected data in the Excel spreadsheet if there was no significant 
discrepancy. If disagreement occurred, the problem was addressed by discussing with the other 
reviewer and a final decision was made. One single reviewer collected the statistical data used for 
meta-analysis, and collected data were rechecked in the process of meta-analysis. All extracted data 
were documented in Microsoft Excel spreadsheets (Version 16.9:180116). The extracted items 
included are listed in the initiated protocol (Appendix 1). Specifically, the extracted data are listed in 
the following sections.  
 
2.5.1 The characteristics of the individual study 
• ‘Author and year' distinguished individual studies from each other. The first name of the first 
author was recorded, and the year represented the publication year of the study. 
• ‘Study type’ was the study design of each paper, which belongs to one of the categories of 
observational study: ecological study, cohort study, case-control study, cross-over case study 
and cross-sectional study.  
• ‘Study exposure’, ‘primary study outcome’ and ‘secondary study outcome’ were recorded in 
line with each study’s research questions. The study exposures were either TOC or ucOC, and 
T2DM measurements were either the primary or secondary outcome.  
• With consideration of ecological factors, the data on the country and ethnicity of the 
population from each paper were extracted. By a secondary aggregation, the continent of each 
study is summarised.  
• The places that the population was recruited from are listed as one or more of the following 
items: ‘medicine department/outpatient clinic’, ‘hospital’, ‘communities/multiple nursing 
homes’, ‘hospital and clinic’, ‘general population', and ‘volunteer.' To summarise, we 
classified them into three main groups for marking each study. Group ‘A’ included people 
from the outpatient clinic or medical department of a hospital, university or centre. Group ‘B’ 
comprised inpatient/hospitalised patients, or inpatients and outpatients if they were grouped 
together in the study. Group ‘C’ comprised people from communities/multiple nursing 
homes, or from population-based studies, or from the database of a trial/study/registry.  
• The data on OC assays were collected. The names of the specific OC assays were recorded 
with abbreviations: ELISA/EIA, ECLIA, IRMA, RIA, and HAP. Detailed information about 
the specific assay kits, as well as the intra-assay and inter-assay variabilities, was 
documented. 
• The characteristics of the baseline of the population in each study were recorded: whether 
they only recruited patients with T2DM or controls with normal glucose levels or PD; or they 
recruited people from more than one group.  
 
2.5.2 The characteristics of the population 
• ‘Sample size’ is the total number of the cohort of population recruited in the individual study 
after assessment of inclusion and exclusion criteria at baseline.  
• ‘Numbers of T2DM’ ‘Numbers of PD' and ‘Numbers of HC' count the numbers of patients 
with T2DM, PD, and healthy glucose levels, respectively. 
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• Three forms collected the age of the population in each study. ‘Mean age & SD’ is the mean 
age with standard deviation of the whole population. ‘Mean age of T2DM & SD’ is the mean 
age of people with T2DM with standard deviation. Similarly, the ‘mean age of PD & SD’ and 
‘mean age of HC & SD’ is the mean with standard deviation for people with PD and HC, 
respectively.  
• Information about the sex of the cohort was recorded. There were three categories 
documented in Excel: male, female and both. Accordingly, the numbers in each category 
were calculated. Notably, the postmenopausal status of women was also considered with an 
item ‘proportion of postmenopausal.' 
• The health of the participants was recorded, including whether they were suspected of 
impaired renal function, or the use of any anti-diabetic drug or medication that could affect 
bone metabolism.  
 
As it is necessary to record data in a consistent manner, for measures of continuous data, for instance 
of age, only mean and standard deviation were used. Any other forms, for example, median and range 
or interquartile range (IQR), were transformed to mean and standard deviation. The methods of Hozo 
et al. and Xiang et al. were used to convert median and range and median and IQR to mean and 
standard deviation, respectively (170,171).  
 
2.6 Assessment of risk of bias in individual studies  
The Newcastle-Ottawa Scale (NOS) was applied in the quality assessment of each individual study in 
the present work. Cohort and case-control studies can be assessed by three main parts of the NOS: 
selection, comparability and outcome/exposure (172). The maximum score is nine points (172). A 
higher score indicates a better methodological quality of the individual study (172). Cross-sectional 
studies can be assessed by modified NOS (173). The maximum score is ten points for the modified 
NOS, representing the highest quality (173). It should be noted that some cross-sectional studies did 
not control the confounders. The scale was updated with a zero score for the ‘comparability’ part. 
Also, in the section “ascertainment of the exposure (risk factor)” of scale guide for the cross-sectional 
study, the original selection “a) Independent blind assessment” was replaced by a new selection 
according to our study design “a) Blood sample test”. This selection still weights two scores out of ten 
scores in total. The quality assessment template can be found in supplementary materials. 
 
2.7 Summary measures and synthesis of results 
In the meta-analyses, overall mean differences (MD), risk estimates for T2DM and Pearson 
correlation coefficients were retrieved. 1) MD of TOC and unOC levels were compared between 
patients with T2DM and healthy controls. The null hypothesis was that there is no difference between 
cases and controls regarding TOC or ucOC levels; in other words, the MD equals zero. 2) Odds ratios 
(ORs) per standard deviation increase in TOC and ucOC with the incidence of T2DM were estimated. 
The null hypothesis for OR was that there is no association between the levels of TOC or ucOC and 
the risk of developing T2DM: statistically, OR has a value of one. In the case that OR is greater than 
one, it indicates that increasing levels of OC contribute to the risk of the disease. In contrast, when 
OR is less than one, it means that OC is a protective factor for developing T2DM. Any other forms of 
OR were transformed to the OR of a 1-SD increase in study factor if the logistic regression analysis 
was available in that study. 3) To investigate the association between two continuous variables, a 
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crude Pearson correlation coefficient was applied when the data was normally distributed. Overall 
estimates of crude Pearson correlations in the relationships between TOC or ucOC and fasting plasma 
insulin (FINS), HOMA-IR and HbA1c and FPG were produced. A negative value indicates an inverse 
relationship between OC and the parameter of interest, and vice versa. The produced value is within 
the range of −1 to 1. The degrees of the correlation coefficient can be classified as no correlation (0); 
low degree (-0.29,0 or 0,0.29); moderate degree (-0.50, -0.29 or 0.29,0.50); high degree (-1, -0.50 or 
0.50, 1) and perfect (±1). (174,175).  
 
In the present research, R computer language was the platform used to conduct all meta-analyses 
(176). The Metafor package in Rstudio was applied to produce the pooled estimates with forest plot 
trees and heterogeneity examinations with meta-regression analyses and subgroup analyses (177). The 
developed codes of R for this present project was attached in Appendix 7. 1) The graphical view of 
the pooled estimate was presented by forest plot, from which the overall effect size was summarised 
at the bottom of the plot with 95% CI. The size of the square represents the sample size of the 
individual study, and the square expands when the sample size increases. The single line across each 
square reflects the 95% CI of every study. The vertical line in the middle represents the null value for 
the effect measurements. 2) The consistency of results was shown by I2, and a large quantity of I2 
indicates a heterogeneity issue across studies. Statistically, the thresholds of 0–40%, 30–60%, 50–
90% and 75–100% indicate possibilities of low, moderate, substantial and considerable heterogeneity, 
respectively (178). Meta-regression and subgroup analyses were used to explain the sources of 
significant heterogeneity. Meta-regression analysis measures the association between study-level 
moderators and the effect size. Continuous and categorical covariates are assessed by methods with 
meta-regression and subgroup analysis, respectively. Furthermore, we explored the potential 
moderators within each subgroup. As a result, the pooled effect estimate, 95% CI, proportion of 
variation explained, and the evidence on whether the pooled estimate changed with the moderator, are 
summarised. 
 
2.8 Assessment of risk of bias across studies  
Publication bias assessment examines the risk of bias across studies with a graphical observation of 
funnel plots. As Egger et al. reported, the asymmetry of the funnel plots implies inconsistency in the 
results (179). The overall detection of heterogeneity was presented by the measure of a linear 
regression analysis, and the standard normal deviate (SND) was regressed against the estimate’s 
precision. The definitions of SND and precision are the risk estimate divided by its standard error and 
the inverse of the standard error, respectively (179). Accordingly, due to the natural characteristics of 
studies with a small size or a large size, small studies situate close to the origin in the plot while large 
studies have larger values and lie away from the origin (179). Ideally, all the scatter plots formulate a 
line which crosses the origin and has a pooled slope. This slope is consistent with the size and the 
direction of the effect size. However, if there was an asymmetry of the funnel plots when the effect of 
small studies was systematically different from large studies, the regression line will not cross the 
origin (179). Furthermore, the degree of the asymmetry is increased as the intercept moves away from 
zero. Smaller studies with significant protective effect could lead to significant bias as they drive the 
intercept to negative values (179,180). In this context, smaller studies tend to pool to give a more 
apparent positive result than larger studies. The test of a funnel plot can provide an adequate 
resolution to this problem. In Egger’s test, when a P value is below 0.1, the funnel plot is 
asymmetrical (179). Apart from detecting publication bias, the asymmetry of funnel plots can also 
result from other sources, such as location bias, true heterogeneity, data irregularities, artefacts and 
chance (167).  
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Trim- and fill- method was applied to find and correct the asymmetry of the funnel plot. This method 
involved with two steps: trimming the asymmetry part of the funnel plot, and filling the modified 
funnel plot with imputed values by measuring the true center of the plot (181). Regarding the trim- 
and fill- funnel plot, solid points represented the original studies included in the meta-analysis, and 
circle points are the imputed values (181). If there were no missing studies estimated, the original 
funnel plot was symmetrical (182,183). The main disadvantage of applying this method was that trim- 
and fill- method could not guarantee whether the adjusted effect was consistent with the effect that 
would be observed without publication (184). Besides, this method could not evaluate the sources that 
caused the asymmetry of the funnel plot if publication bias was not the reason (184).  
 
Contour-enhanced funnel plot aimed to distinguish publication bias from other factors which 
contribute to the asymmetry of the funnel plot. The statistical significance area could be found on the 
contour-enhanced funnel plot (such as p < 0.01, p <0.05, or p <0.1) (185). If the imputed missing 
study points situated in the non-significant area, it was more likely that the funnel plot asymmetry was 
from publication bias (185). On the other hand, if the imputed missing studies were on the statistical 
non-significant area (p >0.1), it indicated the funnel plot asymmetry might from other sources other 
than publication bias (185).  
 
2.9 Meta-regression and subgroup analysis 
We performed the meta-regression analysis for the continuous variables and subgroup analysis for 
categorical variables to explore sources of heterogeneity. Items used in meta-regression were the 
proportion of T2DM, the proportion of females, proportion of postmenopausal women, and mean age 
of the population. Categorical variables were transformed to dummy variables for the purpose of 
standardising and pool the results with a meta-regression analysis. Transformed items included sex, 
ethnicity, continent, study type, study base, renal function, use of anti-diabetic drugs and medications 
affecting bone metabolism functions.  
 
Our meta-regression analyses were all based on the random effect model. There were two different 
methods to compute the weighted mean of all the included studies for a meta-analysis: the fixed effect 
model and random effect model (186). These two methods were distinguished from each other by 
different definitions and different ways assigning weights (186). By definition, fixed effect model 
assumed that all the included studies share one true effect size and the imputed weighted mean of 
effect size approached to the common effect size (187). Accordingly, large studies would receive 
substantial weights, and small studies were likely to be ignored by weights (186,187). However, the 
random effect model was used to estimate the mean of the distribution of true effect size (186–188). 
In other words, the random effect model allowed the true effect sizes vary randomly among studies. 
Furthermore, the precision of studies dominated the assignment of the weights in the random effect 
model, in which large studies were less likely to impact the estimation of effect size on a large scale 
(187). As we could not assume that all the included studies share the same true effect size in this 
present systematic review/ meta-analysis, random effect model was applied in all meta-analyses.  
 
To our concern of the heterogeneity in the current review, we used subgroup analyses to aid the 
investigation of the sources of heterogeneity. Subgroup analyses were performed according to the 
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study type of the individual study (e.g., cross-sectional study, case-control study and cohort study), 
sex of the population (e.g., male, female and mixed sex), continents, ethnicities, renal function.  
 
CHAPTER THREE: RESULTS 
3.1 Study identification 
3.1.1 Screening 
From the given search strategy, 759 studies were identified from three databases: Medline (Ovid SP), 
Embase (Ovid SP), and Scopus, and additional six studies were acquired from reference lists. After 
duplication assessment, 505 remained for screening. With the screening of abstracts and titles, 217 
articles were identified as eligible for full-text evaluation by two investigators (Figure 3). Besides, the 
PRISMA checklist was attached in Appendix 5. To summarise the reasons for exclusion, items were 
divided into seven groups and given a number from 1 to 7, respectively. The ordered items are as 
follows: 1) non-eligible study type (including review, letter or comment, short survey, editorial, note, 
and case report); 2) non-epidemiological or non-observational epidemiological study (including mice 
experiments, cell studies, genetic studies, chemical polymer studies, and non-eligible RCTs); 3) 
children or adolescents; 4) diabetes different from T2DM (including T1DM/NIDDM and GD); 5) 
other non-eligible disease or health condition (including haemodialysis, kidney failure/transplant, 
heart/liver failure/transplant, growth deficiency, hyperparathyroidism, Cushing’s disease, cancer, and 
HIV); 6) non-eligible medications/ therapies (including growth hormone therapy, sex hormone 
therapy, glucocorticoid therapy, and alendronate therapy); and 7) duplicate studies. The detailed 
information with numbers of study that were excluded during screening is summarized in Table 3.  
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Table 3 The detailed reasons for exclusion of studies during screening 
Reasons for excluded 
studies 
(total numbers) 
Detailed reasons and numbers of excluded studies 
 
Non-eligible study 
type (173) 
142 
reviews 
12 
comments 
9 
editorial 
reports 
5 
notes 
3 
short 
surveys 
2 
case 
reports 
Non-epidemiological 
or non-observational 
epidemiological 
studies (39) 
21 
cell studies 
7 
mice 
experiments 
 
7 
non-eligible 
RCTs 
3 
genetic 
studies 
 
1 
other 
study 
 
Non-eligible 
participants (12) 
12 
Children or 
adolescents 
     
Diabetes different 
from T2DM (26) 
22 
type I 
diabetes 
4 
gastational 
diabetes 
    
Other non-eligible 
diseases or health 
conditions (22) 
6 
haemodialysis 
5 
kidney 
transplant/ 
failure 
4 
hyperparathy-
roidism 
2 
heart/ 
liver 
failure/ 
transplant 
1 
growth 
deficiency 
syndrome, 
1 
polycystic 
ovary 
syndrome,  
1 
Cushing’s 
disease, 1 
prostate 
cancer,  
1 
The 
human 
immuno-
deficiency 
virus 
 
Non-eligible 
therapies/medications 
(6) 
5 
hormone 
therapy 
2 
glucocorticoid 
therapy 
1 
alendronate 
therapy 
   
Duplicate studies (2) 2  
duplicate 
population 
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Additional records identified 
from reference lists 
(n = 6) 
Records after duplicates removed 
(n = 505) 
 
Records screened 
(n = 505) 
Records excluded 
(n = 288) 
1. Non-eligible 
article types. 
(n=173) 
2. Non-
epidemiological/n
on-eligible 
observational 
studies (n=39) 
3. Children or 
adolescents (n=32) 
4. T1DM or GD 
(n=12) 
5. Other non-eligible 
diseases or health 
conditions. (n=22) 
6. Non-eligible 
therapies. (n=8) 
7. Duplicated 
population. (n=2) 
Full-text articles  
assessed for eligibility 
(n=217) 
 
Full-text articles excluded 
(n=113) 
 
Not fitting study outcomes 
(n=35). 
Not measuring OC levels 
(n=16). 
Not providing relevant 
statistics/associations 
(n=51). 
Non-English language 
cannot be translated (n=3). 
Duplicate population (n=4). 
Full-text article not 
available (n=4). 
 
Studies included in quantitative 
synthesis (meta-analysis) 
(n = 104) 
 
Figure 3 The PRISMA flowchart for the systematic review/meta-analysis 
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3.1.2 Full-text assessments 
In the process of full-text assessment, the two reviewers agreed that 196 of the 217 articles were to be 
either included or excluded for quantitative analyses; on the other hand, there was a discrepancy on 21 
articles (10%). A list of the disputed papers and comments from another reviewer is attached in 
Appendix Table 6. After discussion with a third and fourth reviewer, 104 studies were included and 
pooled for the meta-analysis while 113 studies were not eligible for quantitative analyses. Among the 
113 excluded studies, 35 were excluded for not fitting the study outcomes, 16 were excluded for not 
measuring OC levels, 51 were excluded for not providing relevant statistics/associations, 3 were 
excluded for being in a non-English language that could not be translated, 4 were excluded for having 
a duplicate population, and 4 were excluded as the full-text articles could not be accessed. As a result, 
there were 104 unique articles eligible for quantitative analysis and the reference list for those articles 
could be found in Appendix 4.  
 
3.2 Study characteristics 
The characteristics of the studies and populations were extracted and summarised from the 104 
articles that were eligible for quantitative analysis.  
 
3.2.1 Individual studies 
Regarding the study design of the 104 different studies, 74 were cross-sectional designed studies, 19 
were case-control studies, 7 were cohort studies, and 4 were baselines of interventional studies.  Most 
included studies were from Asia and Europe. Specifically, China, Japan, Spain and U.S. reported 
more studies contributing to the present systematic review/ meta-analysis. Regarding ethnicities, 
Asian and Caucasian were the main studied population in this present work, composing about 97% in 
the entire cohort of participants. Other detailed information regarding the geographical location, 
countries and ethnicities were showed in Table 4. 
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Table 4 The characteristics of included studies 
Categorization in 
study 
Detailed information 
Geographical 
location with 
numbers of study 
49 Asia 39 Europe 12 North 
America 
3 Australia 1 Africa 
Countries with 
numbers of study 
16 China, 
16 Japan, 
4 Korea, 
4 Saudi 
Arabia, 
3 India, 
3 Iran 
2 Thailand 
1 Malaysia 
 
9 Spain, 
5 Turkey 
3 Italy 
3 Brazil 
2 Austria 
2 Denmark 
2 Hungary 
2 Sweden， 
2 Romania 
1 Belguim, 
1 Czech 
Republic, 
1 Finland, 
1 Germany， 
1 Greece, 
1 Kuwait 
1 Netherlands, 
1 Poland 
1 Russia 
8 U.S. 
3 Mexico 
1 Canada 
3 Australia 1 Morroco 
Ethnicithies with 
numbers of 
participants 
23,441 Asian 18,111 
Caucasian 
630 Hispanic 
Latinos, 
531 Latino 
653 Mixed 
with ethnicities 
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As not every study could provide the data we were investigating, the following partial datasets were 
summarised using the accessible data. Out of 104 studies, only 94 studies reported assays of TOC. 
The majority of the studies used the methods of ELISA and ECLIA to measure TOC (31 studies used 
ELISA and 32 studies used ECLIA); 10 and 17 studies used assays of IRMA and RIA respectively for 
the measurements of TOC; while four studies applied the assays of HAP, IHC or EIA, which are less 
accurate compared with the former assays. 22 studies assayed ucOC: 10 with ECLIA, 8 with ELISA, 
two with EIA and two with HAP. When considering the sources of population in each study, 86 
articles provided the information while 18 studies did not. As the sources of population varied to 
some extent, we divided them into three main streams. Of 86 studies, the majority of studies (60) 
recruited the participants from outpatients. The second stream of 23 studies included patients from 
communities, multiple nursing homes, or databases from other studies. Only three studies recruited 
people that were hospitalised patients. Detailed information on the characteristics of individual 
participants is shown in Table 7 (in Appendix), along with the baseline population and the matched 
variables between cases and controls. 
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3.2.2 The population 
From the 104 individual studies, we acquired data on 43,366 unique participants. Among the subjects, 
there were 15,027 (34.7%) patients with T2DM, 23,680 (54.6%) controls with normal glucose levels, 
2,712 (6.3%) patients with prediabetes, and another 1,947 (4.4%) patients with another disease 
(metabolic syndrome (ICD: E88.81), obesity, or unclassified diabetes). There were 19 studies that 
only recruited people with T2DM, while 7 studies only recruited participants with normal glucose 
tolerance. The other 77 articles reported data for both T2DM and controls. With the exception of three 
studies not providing information on sex, of the base of 42,800 (98.7%) unique participants, there 
were 20,457 females (47.7%) and 22,343 males (52.3%) included in the review.  
 
Table 8 (in Appendix) summarises information on the participants from each of the studies reviewed, 
which was also used in subgroup analysis: the mean age of the population (including subgroups based 
on their glycaemic status), the proportion of females in each study and the postmenopausal status of 
women, and medical conditions. The proportion of T2DM patients ranged from 0–100%. The mean 
age of the population in each study ranged from 36 to 84 years old, except for three studies which did 
not provide information on the mean age. The age ranges for T2DM and NGC were similar (36–83 
years old from 86 studies, and 37–84 years old from 67 studies, respectively), while the age range for 
PD was slightly younger (44–66 years old from 6 studies). 
 
Regarding the renal function of the populations, 47 studies reported the relevant information while 57 
studies did not. Of the 47 available studies with 12,900 (30%) subjects, four articles with some 1,370 
(10.6%) subjects were suspected of having renal problems while 43 studies with 11,530 (89.4%) 
subjects had normal kidney function. T2DM patients with slightly impaired renal function were not 
excluded in the screening. Therefore, we recorded their renal function descriptively for further 
analysis. 
 
 Additionally, 62 papers with 30,061 (69.3%) subjects reported information about intake of anti-
diabetic drugs. About 5,621 (18.7%) subjects from 10 studies were free from anti-diabetic drugs while 
24,440 (81.3%) subjects from 52 studies used anti-diabetic drugs. Excluding 12 studies that did not 
provide information about medications that influence bone metabolism, most of the participants – 
some 36,611 from 89 studies – were free from medications that influence bone metabolism, while 
only 2,151 participants from three studies reported medication issues. 
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3.3 Baseline serum levels of osteocalcin in patients with T2DM, NGC, or PD 
3.3.1 The mean difference in OC between T2DM and NGC 
The pooled result of a random-effects meta-analysis of TOC for mean difference in T2DM versus 
NGC across 64 studies was −3.35 ng/ml ([95% CI: −4.22, −2.48]; p<0.0001; I2 = 99.48%). An 
original forest plot across 64 studies is shown in Figure 4. In the meta-regression analysis of 61 
studies providing information on TOC assays, the factor assays for TOC explained around 16% of the 
heterogeneity (R2 = 16%), and it was positively correlated with the effect size of MD (p=0.016). In 
the meta-regression analysis of 64 studies providing information about the mean age of the overall 
population, the explanatory factor age explained around 6% of the heterogeneity (R2 = 6%), and age 
was weakly inversely correlated with the effect size of MD (−0.1 [−0.21,0]; p=0.05). Similarly, in the 
meta-regression analysis of 33 studies providing information about matched variables between cases 
and controls, the factor-matched variables explained about 6% of the heterogeneity (R2 = 6%). In the 
mixed-effect analysis of assays for the above three variables (TOC, mean age and matched variables) 
across 30 studies, the variables explained about 32% of the heterogeneity (R2 = 32%). However, after 
the backward analysis, only assays for TOC remained in the final model (p= <0.0001). 
 
The forest plot based on the subgroup of four main assays for TOC (ECLIA, ELISA, IRMA, and 
RIA) is shown in Figure 5. This random-effect forest plot across 57 studies gave an overall MD in 
TOC between T2DM and NGC of −3.53 ng/ml ([95% CI: −4.39, −2.66]; p <0.0001; I2 = 99%). The 
estimates of MD shared the same direction in each group but varied to a great extent regarding the 
absolute values. With the RIA assays, T2DM had a lower TOC of 0.79 ng/ml compared with NGC 
(−0.79 [95% CI: −1.60,0.01]); while with the IRMA and ELISA assays, T2DM had around 3 ng/ml 
lower levels of TOC than NGC (−2.98 [95% CI: −4.29, −1.68] and −3.20 [95% CI: −4.44, −1.96] for 
IRMA and ELISA assays, respectively). The biggest difference was found in the ECLIA group with 
around 5 ng/ml lower levels of TOC in T2DM than NGC (−5.31 [95% CI: −7.05, −3.57]). Although 
stratified by assays of TOC, studies in each subgroup were still different with statistical I2 more than 
90% individually. 
 
Additionally, the pooled result of the random-effects meta-analysis of ucOC for mean difference in 
T2DM versus NGC across nine studies was −0.67 ng/ml ([95% CI: −1.10, −0.24]; p<0.0001; I2 = 
87%). The forest plot with detailed information is shown in Figure 23 (Appendix 2).  
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Figure 5 The forest plot of subgroup analysis based on assays for TOC of the mean difference between 
T2DM and NGC across 57 studies 
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3.3.2 The mean difference in OC comparing T2DM, PD and NGC 
The pooled result of the random-effect meta-analysis of TOC for MD in T2DM versus PD across 
seven studies was −1.18 ng/ml ([95% CI: −2.54, 0.17]; p=0.09; I2 = 88%) Figure 24 (Appendix 2). On 
the other hand, the pooled result for MD in PD versus NGC across nine studies was −1.63 ng/ml 
([95% CI: −3.10, −0.16]; p=0.03; I2 = 99%) Figure 25 (Appendix 2). Table 5 shows a comparison of 
MD in TOC between T2DM, PD and NGC. 
 
Table 5. The results of meta-analyses of MD of TOC (ng/ml) comparing T2DM, PD, and NGC. 
Results T2DM vs. NGC T2DM vs. PD PD vs. NGC 
Estimate −3.35 −1.18 −1.63 
95% CI [−4.22, −2.48] [−2.54, 0.17] [−3.10, −0.16] 
 
3.4 The associations between osteocalcin and insulin/glucose metabolism parameters. 
We investigated the associations between total osteocalcin (TOC) and insulin/ glucose metabolism 
parameters by synthesising the results based on the Pearson correlation coefficients across studies.  
 
3.4.1 TOC and fasting insulins (FINS)  
The pooled meta-analysis across 14 studies of the correlation coefficient between TOC and FINS 
produced an estimate of −0.11 ([95% CI: −0.19, −0.04]; p =0.004; I2= 87%). The forest plot of these 
synthesised results is shown in Figure 26 (Appendix 2). After examining the sources of heterogeneity 
by measuring their R2 individually, six variables were selected as they could explain the heterogeneity 
to some extent. The postmenopausal%, sex, assays of TOC, study type, T2DM%, and mean age 
overall could explain about 38%, 24%, 18%, 15%, 13% and 8% of the heterogeneity, respectively. 
After putting these variables into the mixed-effect model and further selecting them with the 
backward stepwise method, sex and T2DM% were significant at p<0.05 and remained in the final 
model. They explained around 41% of the heterogeneity in the final mixed-effect model.  
 
The subgroup analysis based on sex (men and women) with a forest plot (Figure 6) indicated that 
TOC is significantly correlated with FINS in the female group (−0.18 [95% CI: −0.25, −0.12]; p < 
0.0001; I2 = 46%) while no association was observed in the male group (−0.04 [95% CI: −0.16, 0.08]; 
p=0.5; I2 = 91%). The forest plot with heterogeneity test of I2 is shown in Figure 6.  
 
Furthermore, we also generated a subgroup analysis based on T2DM status to investigate the 
association between TOC and FINS in the T2DM group and the general population. Interestingly, the 
analysis showed that this correlation only existed in the general population (−0.12 [95% CI: −0.17, 
−0.08]) and did not appear in the T2DM group (−0.09 [95% CI: −0.20,0.02]) (Figure 7). In addition, 
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in the subgroup of general population, the include studies were homogenous in study-level (p=0.19, I2 
= 45%). In contrast, there was heterogeneity in the group with T2DM (p<0.0001; I2 = 86%). 
 
Figure 6. The sex-stratified forest plot of the correlation coefficient between TOC and FINS across 12 
studies. 
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Figure 7. The T2DM status-stratified forest plot of the correlation coefficient between TOC and FINS 
across 15 studies. 
 
 
3.4.2 TOC and HOMA-IR 
The pooled meta-analysis across 19 studies of the correlation coefficient between TOC and HOMA-
IR produced an estimate of −0.16 ([95% CI: −0.22, −0.09]; p < 0.0001; I2= 87%). The forest plot of 
these synthesised results is shown in Figure 27 (Appendix 2). After examining the sources of 
heterogeneity by measuring their R2 individually, four variables were selected as they could explain 
the heterogeneity to some extent. The variables of study type, sex, assays of TOC, and use of an 
antidiabetic drug could explain about 20%, 28%, 16%, and 8% of the heterogeneity, respectively. 
After putting these variables into the mixed-effect model and further selecting them with the 
backward stepwise method, only assays of TOC was significant (p=0.05) and remained in the final 
model.  
 
The subgroup analyses based on the assays of TOC (IRMA, ECLIA, and ELISA) are shown in Figure 
8. In the IRMA group, TOC was significantly inversely associated with HOMA-IR (−0.16 [95% CI: 
−0.23, −0.09]; p < 0.0001; I2 = 52%) while it was not associated with HOMA-IR in the ECLIA group 
(−0.10 [95% CI: −0.21, 0.02]; p =0.10; I2 = 89%). The strongest association between TOC and 
HOMA-IR was in the ELISA group (−0.21 [95% CI: −0.35, −0.08]; p =0.002; I2 = 86%). We then 
divided the meta-analysis into three groups: T2DM, healthy population and the general population. 
The healthy population were healthy controls compared to T2DM. General population were 
participants were not specified to any groups in terms of their health status. It can be seen in Figure 9 
that the links between TOC and HOMA-IR were statistically similar in the T2DM group and the 
general population group (−0.16 [95% CI: −0.25, −0.06] and −0.16 [95% CI: −0.22, −0.10], 
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respectively). It is notable that the association became weak in the group of healthy subjects (−0.08 
[95% CI: −0.12, −0.03]).  
 
Figure 8. The TOC-assay-stratified forest plot of the correlation coefficient between TOC and HOMA-IR 
across 19 studies. 
 
 
 42 
Figure 9. The T2DM-status-stratified forest plot of the correlation coefficient between TOC and HOMA-
IR across 20 studies. 
 
3.4.3 TOC and HbA1c 
The pooled meta-analysis across 30 studies of the correlation coefficient between TOC and HbA1c 
produced an estimate of −0.25 ([95% CI: −0.30, −0.20]; p < 0.0001; I2= 79.1%). The forest plot of 
these synthesised results are shown in Figure 29 (Appendix 2). After examining the sources of 
heterogeneity by measuring their R2 individually, four variables were selected as they could explain 
the heterogeneity to some extent. The variables of study population, proportion of women, and study 
type could explain about 13%, 12%, and 11% of the heterogeneity, respectively. By putting these 
variables into the mixed-effect model and further selecting them with the backward stepwise method, 
the study population and study type variables were significant (p=0.03 and p=0.02 respectively) and 
remained in the final model. Furthermore, they explained the heterogeneity of about 34% (R2 =34%) 
in the final mixed-effect model.  
 
Subgroup analysis based on where the study population came from was conducted for two groups 
across 27 studies: (1) the group made up of population-based studies, community-based studies or 
databases from trials; and (2) the outpatient clinics group (from the medicine department of hospitals, 
medical department at university, or diabetes centres). Figure 10 shows the results. In both groups, 
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TOC was significantly inversely associated with HbA1c: −0.17 [95% CI: −0.21, −0.13] and −0.25 
[95% CI: −0.31, −0.19] for groups 1 and 2, respectively. Studies were homogeneous in the former 
group (I2 = 18%, p=0.33) while studies were still varied at the study level in the latter group (I2 = 
76%, p<0.0001). Subgroup analysis based on the study type of an individual study is shown in Figure 
11, with two groups (cross-sectional study group and case-control study group) across 28 studies. 
Results showed that TOC was significantly inversely related to HbA1c in the cross-sectional group 
(−0.27 [95% CI: −0.32, −0.22]; p<0.0001) while there was no evidence of association in the case-
control group (p=0.45). There were still heterogeneity concerns in these two groups (I2=69%; 
p<0.0001 and I2=92%; p<0.0001 for the cross-sectional study group and case-control study group, 
respectively). The third subgroup analysis was conducted based on the T2DM status of subjects 
(Figure 12). The association of TOC and HbA1c was inverse and showed similar statistical values in 
the T2DM group and the general population group (−0.25 [95% CI: −0.30, −0.19] and −0.29 [95% CI: 
−0.30, −0.19], respectively). In contrast, the relationship was not observed in the non-diabetic group 
across three studies with 1266 subjects (0.06 [95% CI: −0.23, 0.35], p =0.69). 
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Figure 10. The study-population-stratified forest plot of the correlation coefficient between TOC and 
HbA1c across 27 studies. 
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Figure 11. The study-type-stratified forest plot of the correlation coefficient between TOC and HbA1c 
across 28 studies. 
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Figure 12. The T2DM-status-stratified forest plot of the correlation coefficient between TOC and HbA1c 
across 34 studies. 
 
3.4.4 TOC and FPG 
The pooled meta-analysis across 29 studies of the correlation coefficient between TOC and FPG 
produced an estimate of −0.23 ([95% CI: −0.30, −0.18]; p < 0.0001; I2= 82%). The forest plot of these 
synthesised results is shown in Figure 29 (Appendix 2). After examining the sources of heterogeneity 
by measuring their R2 individually, three variables were selected as they could explain the 
heterogeneity to some extent. The variable ‘proportion of postmenopausal women’ could explain 
about 80% of the heterogeneity within ten studies that provided relevant data on the postmenopausal 
status of women (R2=78%, I2 =61%, p=0.01). In 28 studies that had relevant data on the study 
population and the location of the study, these variables could explain about 29% and 13% of the 
heterogeneity, respectively. By adding the two variables to the mixed-effect model of 28 studies and 
further selecting them with the backward stepwise method, the study population variable was 
significant (p<0.0001) and remained in the final model, while the location of the study was a non-
significant variable (p=0.4) and was eliminated from the final model. 
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Figure 13 shows the results of a subgroup analysis based on the study population base from which the 
subjects were recruited. Two groups were generated and named group 1 and group 2: studies that 
were based on population/community/databases from trials, and studies based on outpatient clinics, 
respectively. TOC was significantly and inversely correlated with FPG in the two groups, with 
correlation coefficients of −0.19 [95% CI: −0.24, −0.15] and −0.23 [95% CI: −0.29, −0.16], 
respectively. The former group had a smaller statistical I2 than the latter group (I2 = 56% and I2 = 
77%, respectively), but studies in both groups still had heterogeneity issues. Furthermore, in the 
subgroup analysis based on T2DM status, the correlations between TOC and FPG remained inverse 
and significant in the three groups (Figure 14). The correlation coefficients for the T2DM group and 
the general population group were similar (−0.23 [95% CI: −0.28, −0.18] and −0.24 [95% CI: −0.37, 
−0.11], respectively). The weakest association was found in the non-diabetic group (−0.16 [95% CI: 
−0.26, −0.06]). 
Figure 13. The study-population-base-stratified forest plot of the correlation coefficient between TOC and 
FPG across 27 studies. 
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Figure 14. The T2DM-status-stratified forest plot of the correlation coefficient between TOC and FPG 
across 34 studies. 
 
 
3.4.5 UcOC and HOMA-IR and HbA1c 
We generated two forest plots analysing the associations between ucOC and HOMA-IR and HbA1c 
across five studies. UcOC was inversely and significantly correlated with both of these variables 
(−0.11 [95% CI: −0.18, −0.05]; p<0.001 and −0.18 [95% CI: −0.25, −0.10], p <0.0001 for HOMA-IR 
and HbA1c, respectively). Studies were homogeneous in each of the two groups (I2 = 18%; p= 0.44 
and I2 = 33%; p= 0.30 for HOMA-IR and HbA1c, respectively). Figure 15 and Figure 16 show the 
forest plots of the associations between ucOC and HOMA-IR and ucOC and HbA1c, respectively.  
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Figure 15. The forest plot of the correlation coefficient between ucOC and HOMA-IR across five studies. 
 
Figure 16. The forest plot of the correlation coefficient between ucOC and HbA1c across five studies. 
 
3.5 The odds ratio of OC for developing T2DM 
The meta-analysis of per-SD increase in TOC for developing T2DM was conducted across seven 
studies, shown in Figure 17. The results showed that with one standard deviation increase in TOC, the 
incidence of T2DM decreased (OR: 0.76 [0.63,0.92]; p=0.003; I2 = 92%). Interestingly, the weight in 
the meta-analysis for the individual study was similar to each other despite their varied sample size. 
The estimated weight in each study depended on the inverse-variance. Accordingly, the weights for 
small studies and large studies became more uniform when the heterogeneity increases (189). 
However, small studies were assigned with comparatively large weights in the random effect model, 
which might bias the result (189–191).  
In contrast, there was no observed association between one standard deviation increase in ucOC and 
the incidence of developing T2DM in the meta-analysis across three studies (OR: 0.79 [0.56,1.11]; 
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p=0.17; I2 = 96%). The forest plot is shown in Figure 18. As only three studies included in the meta-
analysis for ucOC, this result might be underpowered and present a false negative result (192). 
Reports mentioned that the number of studies matters in random effects meta-analysis to trigger 
reliable conclusions. Furthermore, if a meta-analysis shows non-significant results with a large 
heterogeneity, it may present false negative results (193). 
Figure 17. The forest plot of 1-SD increase in TOC for developing T2DM across seven studies. 
 
 
Figure 18. The forest plot of 1-SD increase in ucOC for developing T2DM across three studies. 
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3.6 Publication bias 
3.6.1 The assessment of the MD of OC in T2DM, NGC, and PD 
The symmetry of the funnel plot of the MD in TOC in T2DM vs. NGC, shown in Figure 19, was used 
to assess publication bias. The Egger’s regression test was highly significant with p=0.01, indicating 
the asymmetry of the funnel plot. Furthermore, the contour-enhanced funnel plot showed that two out 
of 14 missing studies lay in the non-significant effect area (the area where p>0.1), suggesting that the 
asymmetry may be due to publication bias. After adding the 14 missing studies into the analysis by 
the trim fill method, the new estimated effect size of the MD was −2.11 ng/ml ([95% CI: −3.12, 
−1.10]. Compared with the original estimates of −3.35 ng/ml ([95% CI: −4.22, −2.48], the difference 
was moderate, adding additional credence to the influence of publication bias. However, the majority 
of the added missing studies (the white scatter in Figure 19) were situated in the more statistically 
significant areas, implying that the asymmetry of the funnel plot is more likely to be caused by factors 
other than publication bias. Similarly, publication bias appears to exist in the MD in ucOC in T2DM 
vs. NGC, but with little influence (Figure 20). The Egger’s regression test showed a weak statistical 
p-value of 0.07, indicating that the asymmetry of the funnel plot was marginal. Only one added 
missing study (by the trim fill method) appeared in the non-significant effect size field, and the 
difference in the estimation of effect size was small before and after adding the missing studies, 
changing from −0.67 [95% CI: −1.10, −0.24] to −0.45 [95% CI: −0.95, 0.05], respectively. Therefore, 
Figure 20 indicates that publication bias exists, but on a small scale. In other words, the asymmetry 
may result from other factors, and publication bias only partially explains the sources of 
heterogeneity.  
 
Figure 19. The trim-filled contour-enhanced funnel plot of the MD in TOC in T2DM vs. NGC across 64 
studies. 
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Figure 20. The trim-filled contour-enhanced funnel plot of the MD in ucOC in T2DM vs. NGC across nine 
studies. 
 
There was no publication bias identified in the analyses of MD between PD and NGC, and between 
T2DM and NGC, across ten studies and seven studies, respectively (Figure 30, Figure 31). The 
statistical Egger’s regression tests were both insignificant (p= 0.2 for PD vs. NGC; p= 0.4 for T2DM 
vs. PD), and their funnel plots were free from asymmetry suspicion (Appendix 2 -Figure 30 and 
Figure 31).  
 
3.6.2 The assessment of the correlation coefficients between OC and glucose/insulin metabolism
 parameters 
Publication bias was not observed in the associations between TOC and FINS, TOC and HbA1c, or 
TOC and FPG. In the meta-analysis of the correlation coefficient between TOC and FINS across 17 
studies, the funnel plot was symmetrical, and no publication bias was observed. Studies with sizeable 
standard errors were around the lower level of the funnel plot (indicating that the heterogeneity was 
not from publication bias), and the two estimated missing studies retrieved by the trim fill method 
were also situated in the statistically significant effect size area (Appendix 2 Figure 32). In addition, 
the Egger’s regression test was non-significant (p=0.19). Similarly, no publication bias was observed 
in the association between TOC and HbA1c, as the funnel plot was obviously symmetrical with a 
statistically non-significant Egger’s test (p=0.3) (Appendix 2 Figure 33). The funnel plot of the 
estimated association between TOC and FPG was also symmetrical with a statistically non-significant 
Egger’s regression test (p=0.3) (Appendix 2 Figure 34). 
Publication bias was detected in the association between TOC and HOMA-IR across 19 studies, 
although to a small degree. The Egger’s regression test was significant (p=0.1; z= −1.62), indicating a 
slight asymmetry of the funnel plot. Furthermore, three studies out of the five estimated missing 
 53 
studies by the trim fill method were in the statistically insignificant effect size area (Appendix 2- 
Figure 35). The results suggest there is a somewhat enhanced probability that studies with negative 
results had not been published. However, the estimated effect size did not change to a great extent 
before and after adding the missing studies (from −0.16 ([95% CI: −0.22, −0.10] to −0.10 [95% CI: 
−0.17, −0.04]), indicating that the influence of publication bias may not be critical and that the result 
is still stable.  
 
3.6.3 The assessment of the odds ratio of TOC in T2DM 
The funnel plot shown in Figure 21, produced from the analysis of the odds ratio of a 1-SD increase in 
TOC on the incidence of T2DM, was asymmetrical, but not due to publication bias. The Egger’s 
regression test was strongly statistically significant (p<0.001), confirming the apparent asymmetry of 
the funnel plots. However, the contour-enhanced funnel plot suggests that the source of the plot 
asymmetry is not publication bias but rather other unknown factors, as no small studies spread into 
the non-significant area.  
 
Figure 21 The contour-enhanced funnel plot of the OR of a 1-SD increase inof TOC of OR to developing 
T2DM. 
 
 
3.7 Risk of bias assessment (quality assessment) in individual studies 
The results of quality assessment based on the NOS of 104 individual studies are shown in Figure 22. 
Overall, there is a low to medium risk of bias in these studies because only around 30% of the studies 
were identified as poor (having a high risk of bias). Specifically, around 42% and 56% studies were 
regarded as good studies in the selection bias analysis domain and the comparability bias analysis 
domain, respectively, indicating that the risk of selection bias and comparability bias is low. On the 
other hand, exposure ascertainment bias/outcome ascertainment bias may influence the results of the 
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present meta-analysis because only 5 studies out of 104 were identified as having good design in term 
of exposure/outcome ascertainment. However, as 61% satisfactorily met the requirement of 
exposure/outcome ascertainment, the risk of bias in the individual studies is relatively low. Detailed 
information on NOS scores for each item, and for cross-sectional studies, cohort studies and case-
control studies individually, is shown in Appendix 3, Figures 36-38.  
Among the included 104 studies, one study was written in Chinease other than English (194). 
However, there is little impact of language bias in the quality assessment of individual study. 
 
Figure 22 The risk of bias assessment (quality assessment) based on the Newcastle-Ottawa-Scale of 104 
studies. 
 
 
CHAPTER FOUR: DISCUSSION 
4.1 Summary of evidence  
The present systematic review and meta-analysis compared the levels of serum OC in patients with 
T2DM and non-diabetic controls and assessed the association between levels of OC and the risk of 
having T2DM. In addition, it summarised the associations between serum OC and glucose/insulin 
metabolism parameters (such as FINS, HOMA-IR, HbA1c, and FPG). We identified and included a 
substantially larger number of studies than previous meta-analyses on the topic (n= 104 unique 
studies). Our meta-analyses were synthesised data from many observational studies, with the majority 
being cross-sectional studies. The findings consistently demonstrated that patients with glucose 
intolerance have lower levels of OC: there are lower levels of OC in T2DM vs. NGC and slightly 
lower levels of OC in PD vs. NGC. From the primary results, we can infer that OC changes with the 
development of T2DM. Patients with T2DM had a lower OC level (both in TOC and ucOC) 
compared with normal glucose tolerance controls (MD: -3.35 ng/ml, [95% CI: −4.22, −2.48]; 
p<0.0001). Also, patients with PD had decreased OC levels compared to controls (MD: −1.63 ng/ml, 
[95% CI: −3.10, −0.16]; p=0.03). We also found that the TOC levels were lower in T2DM than in PD 
(MD: −1.18 ng/ml, [95% CI: −2.54, 0.17]; p=0.09). Our meta-analysis results across 14 studies 
showed that OC was inversely correlated with fasting insulin levels. It has been postulated that higher 
fasting insulin levels may indicate the status of insulin resistance and be a sign of prediabetes, 
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metabolic syndrome or even T2DM. Other inverse correlation coefficients between OC and metabolic 
parameters were found for HOMA-IR, HbA1c and FPG. It is notable that TOC was correlated more 
closely with the glucose metabolism parameters than insulin resistance parameters in both T2DM and 
the general population. No significant relationships were discovered in the non-diabetic healthy 
groups in terms of the correlation coefficient between TOC and HbA1c.  
The sources of heterogeneity in the meta-analysis mean difference in OC between patients with 
T2DM and non-diabetic controls was partially explained by the assays of TOC (R2= 32%). Sex of 
female or postmenopausal status partly explained the heterogeneity in the correlation coefficient 
between TOC and FINS (R2 = 24%, R2 = 38% respectively). Interestingly, it was found that in the 
subgroup analysis in male subjects, TOC was not correlated with FINS (r= -0.04 [95%CI: 0.16, 
0.08]). On the contrary, TOC and FINS was associated in the postmenopausal women (r= -0.18 
[95%CI: -0.25, -0.12]). Besides, it was found that the relationship remained in the general population 
while became invalid in the subjects only with T2DM (r= -0.12 [95%CI: -0.17, -0.08] and r= -0.09 [-
0.20, 0.02] respectively). Regarding the correlation coefficient between TOC and HOMA-IR, the 
TOC assays stratified results showed that there was no association in the subgroup analysis of 
assaying TOC by ECLIA (r= -0.10 [95% CI: -0.21, 0.02]) while the association existed in the 
subgroups analysis of ELISA and IRMA (r= -0.21 [95% CI: -0.35, -0.08] and r = -0.16 [95%CI: -
0.23, -0.09] respectively). More interestingly, in the study type stratified analysis, we found that TOC 
and HbA1c was correlated only in the cross-sectional studies and was not associated in the case-
control studies (r= -0.27 [95%CI: -0.32, -0.22] and r= -0.12 [-0.42, 0.19] respectively). Furthermore, 
this relationship only existed in the subgroup analysis of subjects with T2DM and not shown in the 
subgroup analysis in healthy controls (r= -0.25 [95%CI: -0.30, -0.19] and r= 0.06 [95%CI: -0.23, 
0.35] respectively).  
 
4.2 Interpretation of evidence 
4.2.1 Significantly lower levels of OC present in T2DM 
Our finding that T2DM patients have lower levels of OC compared with healthy controls is consistent 
and extends upon conclusions from experimental studies, observational studies, and several 
systematic reviews that have reported decreasing levels of OC in the condition of adverse metabolic 
outcomes (79,80,84,103,104). Furthermore, the results suggest that poorer glucose tolerance status 
might associate with lower levels of OC because patients with T2DM have lower levels of OC than 
PD. This is consistent with Cutrim et al. and Gregorio et al.’s conclusions to some extent, as they 
found that T2DM patients with poorly controlled glucose levels exhibited lower levels of OC 
compared to those with controlled glucose levels (119,195). Interestingly, in the subgroup analysis of 
assays for TOC in the mean difference (MD) of TOC between T2DM and NGC, the absolute values 
of MD in each subgroup varied considerably. The group with ECLIA assays displayed the largest MD 
of −5 ng/ml, followed by the IRMA and ELISA groups with a MD around −3 ng/ml, and lastly groups 
with RIA only showed a MD of TOC of −0.8 ng/ml. The results of this subgroup analysis could be 
explained by the sensitivity and precision of the assays themselves, as it is known that the sensitivity 
of the assays decreases in the following order: ECLIA, IRMA/ELISA, RIA, HPLC (65,169). 
Although the differences in sensitivity might not be relevant when the majority of studies are within 
the assay range, it is still significant to subgroup studies based on their assay types. A report also 
indicated that absolute OC  concentration could not be compared directly between different 
laboratories as the differences in assay type, standardisation and specificity (196). The Accordingly, 
this enhances the evidence that OC levels are significantly different between T2DM and NGC. 
Compared with the meta-regression of MD of TOC in T2DM vs. NGC, the result for ucOC was not as 
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distinct. The result showed a MD of only −0.67 ng/ml in ucOC between T2DM and controls, but this 
might be explained by the fact that the methods for identifying ucOC are more complicated than for 
TOC (197). 
 
In contrast to our findings, several studies have shown the opposite results, with elevated levels of OC 
in T2DM or no change in the levels of serum OC in T2DM compared to healthy controls. Aoki et al. 
assessed the serum levels of TOC in groups of people with early-stage T2DM and PD along with 
healthy controls (83). They discovered elevated levels of TOC in T2DM/PD compared to controls, 
which was in contrast to the findings of most published reports (83). They suggested that while the 
reason for their results being different from other published studies was not known, it may be that 
serum levels of OC are elevated in the early stage of diabetes and then start to decline with the 
progressive development of the disease (83). Another five studies reported no difference in the levels 
of serum OC between T2DM and NGC (198–202). Reyes-Garcia et al. found decreased serum levels 
of bone resorption markers, while no difference was found between the serum levels of bone 
formation markers (including OC) in T2DM and NGC (199). It was postulated that these results may 
be due to ethnic variations of BTMs and the effect of glycaemic control on BTMs (199). Interestingly, 
the assays of TOC in their study was RIA which has the lower sensitivity compared with other assays 
(199). This finding supported our previous assumption that the assays of TOC may explain the 
heterogeneity of the meta-analysis in the mean difference in TOC between T2DM and controls. In the 
three-year prospective study by Liatis et al., it was suggested that OC was not associated with glucose 
metabolism in humans, and that it could not predict the risk of the incidence of T2DM; this was also 
supported by the studies by Hwang in 2012 (98,198). Liatis et al. also provided possible reasons for 
the contradictory results with other studies: that they might be due to differences in the characteristics 
of the subjects, such as age, gender, menopausal status, physical activity, and smoking (198). 
However, our meta-analysis, which examined whether those factors (such as ethnicity, age, sex) 
influenced the effect size, did not identify any distinct variable that could explain the heterogeneity on 
a large scale between studies.  
 
Interestingly, although Witzke et al. reported no significant difference between T2DM and controls in 
the serum levels of TOC, it was found that people with T2DM with Charcot neuroarthropathy had 
significantly reduced serum levels of TOC compared to controls (203). This led to another hypothesis: 
that patients with T2DM and with diabetes complications might have altered bone metabolism. This 
hypothesis may explain the discrepancies between the studies, and is a subject for future studies to 
investigate.   
 
A significant finding of the present study is that OC is lower in T2DM compared with NGC, which 
suggests that there is a low bone turnover state in T2DM that may lead to lower bone quality and the 
risk of future bone fragility in those patients. This is consistent with Hygum et al.’s findings that both 
bone formation markers and bone resorption markers are decreased in patients with diabetes (102). 
They proposed that the decreased level of markers for bone metabolism may be a result of elevated 
sclerostin which could inhibit the activity of osteoblasts and osteoclasts; accordingly, OC levels 
would decrease because of the reduced bone formation and bone resorption. Several studies have 
reported that elevated levels of sclerostin and decreased levels of OC are associated with the increased 
risk of having fractures and osteoporosis (91,204).  
 
4.2.2 Weak inverse associations between OC and metabolic phenotypes 
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Regarding the meta-analysis of the correlation coefficient between OC and FINS, we generated a sex-
stratified subgroup analysis. The sex-stratified subgroups comprised 7 and 6 studies in the male and 
female groups, respectively. In the main analysis of 13 unstratified studies, OC was found to be 
inverse associated with FINS. However, there were conflicting results within the male group: four 
studies reported an inverse correlation coefficients, while the other three studies showed positive 
correlation coefficients. Therefore, the data on the association is still inconclusive in males. The meta-
analysis of the male group found an insignificant inverse relationship between TOC and FINS (−0.04 
[95% CI: −0.16, 0.08]). In contrast, the correlation was more evident in the postmenopausal women 
group. Each of the included individual studies reported inverse correlation coefficient between TOC 
and FINS, and the meta-regression analysis showed an inverse association between TOC and FINS 
(0.18 [95% CI: −0.25, −0.12]). This difference between males and females is consistent with a study 
by Buday et al. (205), in which the authors suggested that the mechanisms of the association between 
OC and glucose metabolism are different between men and women (205). Their study found that the 
association between OC and improved glycaemic states was partially influenced by the secretion of 
adiponectin in the female group (205). However, in the male group, testosterone had an influence on 
the association between OC and better glycaemic control (205). More specifically, our results in 
postmenopausal women with T2DM are consistent with previously published studies. A large number 
of observational studies have revealed that postmenopausal women with T2DM have reduced levels 
of OC (128,206).(103,149). 
 
The present results of an inverse association between TOC and FINS in humans are indirectly 
consistent with the outcomes from the crucial mice studies which suggested that OC has a regulatory 
role in glucose metabolism. On the other hand, it is suggested, in principle, that OC as a hormone 
could be controlled by insulin and leptin (207,208). There is a feed-forward loop where the secretion 
of the active form of OC is promoted by insulin signaling in osteoblasts (209). In return, this action 
also promotes insulin production and beta-cell function (209). The present inverse relationship 
between TOC and FINS in our analysis is not consistent with this hypothesis but might be explained 
by the fact that the assayed TOC contains both active and inactive forms of OC (the carboxylated and 
undercarboxylated OC) and therefore cannot represent the association between ucOC and FINS. Our 
results showed that the associations between TOC and FINS and HOMA-IR were stronger in the non-
diabetic controls, which was consistent with Hwang et al.’s 8.4-year prospective cohort study (139). 
They suggested that serum OC was more strongly associated with insulin resistance before the onset 
of T2DM and more strongly associated with glucose tolerance after the onset of the disease (139). 
 
As HbA1c reflects glycaemic control in diabetes, it is interesting that our meta-analysis showed an 
inverse correlation coefficient between TOC and glycaemic control measured by HbA1c. This trend is 
in line with the findings of extensive studies reporting links between serum OC and HbA1c 
(205,210,211). Also, the association is in agreement with the findings in mice that impaired insulin 
functions suppressed osteoblast activity and thereby reduced the secretion of osteocalcin (79). Our 
consistent findings of inverse correlation coefficients between OC and FINS, HOMA-IR, HbA1c, and 
FPG might indicate that the serum OC levels are indirectly associated with the incidence of T2DM, as 
it is correlated with the multiple variables of T2DM. However, the design of the included studies may 
influence the results of the present studies. As most included studies in this review are of cross-
sectional nature, we cannot conclude the temporal nature of the observed relationship. Furthermore, 
the pooled associations were weak (correlation coefficients between OC and FINS, HOMA-IR, 
HbA1c and FPG were all around 0.2).  
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Regarding the associations between TOC and other metabolic phenotypes (FINS, HOMA-IR, HbA1c, 
and FPG) in different study groups based on T2DM status, the correlations were weak in the non-
diabetic healthy group, while the associations remained significant and inversely correlated in the 
T2DM and all subject groups. In the study group of non-diabetic healthy subjects, extremely weak 
associations existed with HOMA-IR; weak associations were observed with FPG, and there was no 
significant correlation between TOC and HbA1c. This is consistent with the finding from a previous 
report on a cohort of non-diabetic female subjects, that OC was not correlated or only weakly 
correlated with glucose metabolism in the study population (212). In contrast, in the study groups of 
T2DM and all subjects, TOC was inversely associated with FINS and HOMA-IR, which showed the 
insulin resistance while it had a stronger inverse correlation coefficients with the glucose metabolism 
parameters (such as associations between TOC and HbA1c or FPG). This may suggest differences 
between the T2DM and healthy subjects. (155). \  
 
Regarding the associations between ucOC and glucose metabolism or insulin resistance, small 
numbers of studies were found and included. Despite of this, at baseline, ucOC also had inverse 
correlation coefficients with HOMA-IR or HbA1c which are consistent with the results of those in 
TOC. Few studies have reported on the associations between ucOC and FPG or FINS. Ngarmukos et 
al. showed serum ucOC was not associated with FPG at baseline (92).  
 
4.2.3  OC and the incidence of T2DM  
The present meta-analysis across six studies demonstrated that higher OC was associated with lower 
risk of developing T2DM (OR: 0.76[95% CI: 0.63, 0.92]) however there was large unexplained 
heterogeneity. This result is in agreement with other published studies that reported that lower levels 
of OC at baseline are associated with an increased risk of T2DM. Movahed et al. generated a binary 
logistic model for the association between lower levels of OC and T2DM and found that patients with 
below median levels of OC were around four times more likely to develop T2DM than those whose 
levels were above the median in the unadjusted model (OR: 3.71[95% CI: 2.26,6.1]) (105). However, 
we cannot conclude that serum levels of OC predict the incidence of T2DM. Firstly, the meta-analysis 
based on only six studies with considerable heterogeneity. The recruited population varied across the 
six studies in terms of their ages, sex and T2DM status. Secondly, an 8.4-year-follow up cohort study 
with 1229 participants found that circulating OC is not associated with the occurrence of T2DM in the 
middle-aged male population (213). Compared with other studies, this investigation is more potent 
with a longer cohort duration and a large sample size (213). Thus, the hypothesis that OC is 
associated with the incidence of T2DM remains unproven despite the statistical results. The potential 
for OC as an intervention for T2DM in humans is still unclear, despite the subcutaneous infusion of 
recombinant OC in mouse models demonstrating a positive effect by improving glucose tolerance and 
insulin resistance. 
 
It is notable that in an experimental study, only ucOC exhibited the ability to stimulate insulin 
secretion and sensitivity. Our results on ucOC showed inconsistent and heterogenous results in 
humans (OR: 0.79 [0.56,1.11]). However, as this was based on only three studies these findings 
remain inconclusive. 
 
4.2.4 Possible mechanisms back to the relationships between OC and metabolic factors 
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The authors of several studies have tried to explain the mechanisms of the low bone turnover in 
T2DM. Manavalan et al. hypothesised that the delay of osteoblast development exerts an effect on the 
bone formation, and tested this hypothesis by characterising the circulating osteogenic precursor cells 
(COP) in T2DM (214). They suggested that both the number of COP and the functions were altered in 
T2DM (214). Furthermore, the biochemical markers of bone turnover, such as OC and P1NP, were 
reduced, indicating an impaired bone formation process (214). Garcia-Martin et al. proposed that the 
Wnt signaling pathways might be impaired in T2DM when they found increased levels of sclerostin 
in T2DM which was also associated with bone turnover markers (215). To some extent, sclerostin 
might account for the higher risk of bone fragility in T2DM (91,215,216). Reyes-Garcia et al. 
postulated that the impaired levels of PTH in diabetes may induce decreased levels of BTMs, with the 
evidence that i-PTH and bone resorption markers were positively linked in their study (217). As part 
of their results, this low bone turnover with a higher likelihood of bone fractures or fragility (217). 
4.3 Strengths and limitations 
The strengths of the present systematic review/meta-analysis are as follows: the large numbers of 
studies identified and included in the meta-analysis, including data on both forms of OC (TOC and 
ucOC), the comprehensive assessment of heterogeneity tests in the investigated relationships of OC, 
the thorough analyses and discussion of publication bias with contour-enhanced funnel plots, and the 
replicable statistical analysis methods and process coded in R. Firstly, there were 104 unique studies 
with 43,366 participants identified and included in our review. The characteristics of a large number 
of included subjects were documented, including a large number of T2DM patients and PD patients. It 
is notable that the present study is the first to compare the OC levels of PD with T2DM and NGC 
using the mean difference across studies. This meta-analysis was robust because it was based on large 
population and variety measurement outcomes (mean difference, odds ratios and correlation 
coefficients), which carry more statistical weight. The statistical measures were in a consistent 
manner as we converted all data to mean and standard deviation from other forms before analysis. 
Secondly, in addition to previously published work, ucOC, the active form of OC in mice, was 
investigated in regards to its relationships with metabolic parameters and the incidence of developing 
T2DM in the meta-analysis. To our knowledge, the present study is the first review to give insights 
into the association between ucOC and HOMA-IR using a meta-analysis and collecting the risk 
estimates of OR with ucOC and the development of T2DM. Additionally, we included a greater 
number of eligible studies for meta-analysis of the mean difference between T2DM and NGC than 
previously published papers. Thirdly, there was a comprehensive assessment of sources of 
heterogeneity of the investigated measurements, involving the following potentially explanatory 
factors: study type, mean age of overall subjects, sex, proportion of females (and proportion of 
postmenopausal women), proportion of T2DM, study location, sources of participants, assays of 
TOC, ethnicity, matched variables between cases and controls, use of anti-glycaemic drugs, and the 
intake of medications affecting bone metabolism. Both subgroup analyses and meta-regression 
analyses were implemented in the review of categorical variables and continuous variables, 
respectively. Fourthly, the present study was the first to apply a contour-enhanced funnel plot with a 
trim-fill method to detect any publication bias in the meta-analysis of OC and diabetes. Publication 
bias can be more clearly and easily viewed by the visual observations of the provided modified funnel 
plots in the current review. Finally, the computing processes and methods of the meta-analysis with 
heterogeneity tests are available to be replicated, which is critically useful for future investigations. 
 
The main limitation was causality cannot be established as these are only observational studies. 
Therefore, the presented evidence of reduced levels of OC in T2DM or the altered associations 
between OC and insulin or glucose parameters in T2DM cannot be used to support interventional 
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research. Similarly, the study did not confirm that lower levels of OC are one of the factors causing 
T2DM via the physiological pathway. Another limitation, and also an important recommendation, of 
our review, is that additional sources of heterogeneity may need to be considered for future studies. 
We hypothesise that there are unmeasured confounders that may affect the relationship between OC 
and T2DM such as specific medications for diabetes, such as thiazolidinediones, that have been 
previously observed to affect the skeleton adversely. Secondly, we did not investigate the influence of 
vitamin D (VD) in the links between skeleton and glucose controls in T2DM. It has been reported that 
the glycaemic control in patients with diabetes might change with seasons via VD, which plays an 
essential role in the pathways for the development of the disease (218,219). As a VD supplement has 
been used in some cases to help patients with T2DM improve their glucose metabolism parameters, 
an examination of whether the included subjects had VD intake might be interesting and could 
explain the heterogeneity in the meta-analyses to some extent. As our meta-analyses were based on an 
aggregational design, we were not able to collect enough data regarding the supplementation of VD in 
subjects, but future meta-analysis might be interested in this point with individual patient data. 
Thirdly, we assumed that the conflicting results might be associated with diabetes complications and 
the severity of the disease. Although most of the studies in the literature support the hypothesis that 
patients with T2DM have reduced serum TOC levels, the heterogeneity still existed even after we 
considered the influence of study location, ethnicity, the proportion of T2DM, sex and age. However, 
in those studies that reported higher levels of OC in T2DM, the patients with T2DM had early stage 
diabetes or had not yet developed any complication, such as Charcot neuroarthropathy. This may 
explain the conflicting results in investigations of the relationships between OC and T2DM, in which 
the patients with T2DM were variable in terms of the severity of the disease and the presence of 
complications.The role of vitamin D or vitamin K was less investigated in observational studies 
reporting on the associations between OC and T2DM, although both vitamins could affect OC levels. 
Future studies may provide information on the influence of VD and VK on the relationship between 
OC and glucose metabolism in humans. 
CHAPTER FIVE: CONCLUSION 
In conclusion, this present thesis demonstrated a significant difference of serum OC levels between 
patients with T2DM and non-diabetic controls; serum OC was weakly correlated with parameters of 
glucose/insulin metabolism in patients with T2DM, and it was still unclear whether serum levels of 
OC are associated with the risk of having T2DM. Apart from the investigation on subjects with 
T2DM, patients with PD also showed significantly lower levels compared with non-diabetic controls.  
 
The findings of lower levels of OC (including TOC and ucOC) in patients with T2DM or PD were 
based on the meta-analyses with large sample size and statistically significant result. These findings 
suggest that patients with insulin resistance are likely to have a lower bone turnover status and need 
attention. It may contribute to the later-on bone fragility or related diseases in those patients. 
Reconsidering the increased incidence of osteoporosis or fractures occurred in patients with T2DM, it 
may be explained partially by the low bone turnover status as the levels of OC were significantly 
lower.  
 
The findings of weak associations between OC and glucose/ insulin metabolism parameters in 
patients with T2DM suggest interesting links between OC and glucose metabolism. Further studies 
are needed to assess how to apply those links clinically in patients with diabetes. On the other hand, 
the correlation between OC and FPG/ HbA1c was weak. Thereby, it is also possible that other type of 
biochemical markers related to bone and skeleton may be associated with glucose metabolism.  
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We found from meta-analysing six studies that higher levels of serum TOC were associated with the 
lower incidences of having T2DM. However, there was substantial unexplained heterogeneity with 
small numbers of eligible studies. Furthermore, ucOC, the active form of OC in preventing the occurs 
of diabetes in mice experiments, was not associated with a lower risk of developing diabetes, but this 
may be due to smaller numbers of studies available.  
 
As cross-sectional studies contributed to the majority of the data for this review, the evidence is 
weaker than longitudinal studies and does not allow inference of the temporal nature of the 
relationship. At the study level, as there were fewer prospective studies or case-control studies than 
cross-sectional studies. Therefore, future studies focusing on long-term measurement and testing of 
the associations between OC and T2DM are needed.  
 
Importantly, in this review, we explored the sources of the heterogeneity comprehensively, but there 
was still inconsistency at the study level. However, we found that articles reporting contrasting results 
on associations between T2DM and  OC recruited different cohorts of participants regarding their 
T2DM status. Thus, future human research may need to consider the characteristics of T2DM, such as 
the severity and duration of the T2DM and any complications of diabetes. Interestingly, we also found 
that the assays of OC might impact on the effect size of the levels of TOC in T2DM and controls.  
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ABSTRACT 
Introduction  
The global burden of type 2 diabetes (T2DM) is steadily increasing. Experimental studies have 
demonstrated a novel bone-cell secreted hormone, osteocalcin(OC), can stimulate beta-cell 
proliferation and improve insulin sensitivity in mice. Observational studies in humans have 
investigated the relationship between osteocalcin (OC) and metabolic parameters and T2DM. 
 78 
Importantly, few studies report on the undercarboxylated form of OC (ucOC), which is the putative 
active form of OC suggested to affect glucose metabolism.  
Objectives 
We will conduct a systematic review and meta-analysis to: 1) compare the serum OC and ucOC 
between T2DM and normal glucose tolerant controls (NGC); 2) to investigate the risk ratios between 
serum OC and ucOC and T2DM; 3) to determine the correlation coefficient between OC and ucOC 
and fasting insulin levels (FINS), homeostatic model assessment-insulin resistance (HOMA-IR), 
haemoglobin A1c (HbA1c) and fasting glucose levels (FPG); 4) to explore potential sources of 
between-study heterogeneity. A secondary objective is to compare the serum OC and ucOC between 
prediabetes (PD) and NGC, and between T2DM and PD.   
Methods and analysis 
This study will report items in line with the guidelines outlined in PRISMA and MOOSE (25,26). We 
will include observational studies (cohort, case-control and cross-sectional studies) and intervention 
studies with baseline data. Three databases (MEDLINE, EMBASE, and SCOPUS) will be searched 
from 1946 until July 2018 without language restrictions. Two reviewers will independently screen the 
titles and abstracts and conduct a full-text assessment to identify eligible studies. Discrepancies will 
be resolved by consensus with a third reviewer. The risk of bias assessment would be conducted by 
two reviewers independently based on the Newcastle-Ottawa Scale (NOS). Potential sources of 
between-study heterogeneity will be tested by meta-regression/subgroup analyses. Contour-enhanced 
funnel plots and Egger’s test will be used to identify potential publication bias. 
Registration number in PROSPERO 
 CRD42017073127 
Keywords 
osteocalcin, type 2 diabetes, prediabetes, meta-analysis 
Strengths and limitations of this study 
• This review will undertake a sensitive search strategy to include more eligible observational 
studies (cohort, case-control and cross-sectional studies) than previous meta-analyses.  
• The review will assess and synthesise data on both forms of OC (TOC and ucOC), potentially 
being more relevant to the endocrine function in humans. 
• The design of the review considers early to late stages of diabetes which will indicate whether 
the relationship between OC and impaired glucose metabolism is altered during progressively poorer 
glucose control. 
• Sources of heterogeneity will be explored using meta-regression/subgroups analyses.  
• The main limitation of the current study is only including observational studies (cohort, case-
control and cross-sectional studies). 
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INTRODUCTION 
Type 2 diabetes (T2DM) results from the body becoming progressively more resistant to the effects of 
insulin. This is termed insulin resistance. With the influence of long-term progress, blood sugar 
exceeds the normal levels and patients are diagnosed with T2DM. The disease now ranks 9th in the 
world  global health threats list (1). Currently, around 425 million people have diabetes, with 90% of 
these having T2DM (1). It is estimated that by 2045, this figure will have increased to 629 million 
people (1).   
Patients with T2DM have increased levels of glucose parameters/insulin resistance indices (2). 
Accordingly, the methods for diagnosing diabetes are based on measuring fasting plasma glucose 
(FPG), haemoglobin A1c (HbA1c), fasting insulin levels (FINS) and the homeostatic model 
assessment-insulin resistance (HOMA-IR) (3). Patients with T2DM have increased risks of other 
complications such as heart attacks, strokes, diabetic retinopathy and renal disease (3). Interestingly, 
other diabetic complications include impaired bone remodelling and fracture risk (4,5). Although the 
bone mineral density (BMD) in T2DM is generally reported to be normal or slightly  higher than 
healthy age-matched individuals, large numbers of studies have reported an increased risk of hip 
fractures in people with T2DM (6,7).  
Osteocalcin (OC) is an osteoblast secreted protein that plays a role in the communication between the 
skeleton and glucose homeostasis. There are two forms of OC: undercarboxylated osteocalcin (ucOC) 
and carboxylated osteocalcin (cOC) (8). The cOC contributes to extracellular bone matrix while ucOC 
is likely the active form of OC in the circulation (9). Both cOC and ucOC are present in the 
circulation, and the amount of them is known as total osteocalcin (TOC) (9). TOC is considered a 
marker of bone turnover (10).  
A potential endocrine function of OC was first suggested in 2007. Lee et al. and Ferron et al. reported 
OC mediated glucose homeostasis via stimulating beta-cell proliferation and adiponectin secretion in 
mice (11,12). The endocrine actions of OC involve increasing insulin synthesis and secretion by beta-
cells and improved insulin sensitivity by promoting adiponectin secretion in adipocytes (11,12).  The 
high-fat diet experimental study revealed that bone could become insulin resistant by inhibiting the 
activation of OC (13). However, reported associations between OC and T2DM in humans have 
yielded conflicting results. (14–17).  Lerchbaum et al. reported high OC was associated with reduced  
risk of developing T2DM in a population-based study (OR:0.57;95%CI:[0.46,0.70]) (18). Achemlal et 
al. reported, in a cross-sectional study of patients with poorly controlled T2DM, serum levels of OC 
were significantly lower in T2DM compared with age-matched controls (19).While Bao et al. 
observed increased serum levels of OC were associated with improved glucose control (20). Yeap et 
al. found both TOC and ucOC were associated with reduced risk of developing diabetes in a cohort of 
community-dwelling elderly men (OR:0.60; 95%CI:[0.50,0.72] for TOC, and OR:0.55; 
95%CI:[0.47,0.64] for ucOC) (21). In contrast, a case-control study by Zwakenberg et al. with 1,635 
participants indicated there was no association between TOC/ucOC and the risk of T2DM (OR:0.97; 
95%CI:[0.69,1.36] for TOC, and OR:0.88; 95%CI:[0.61,1.27] for ucOC) (22).  
Two previously published systematic reviews/meta-analyses have reported decreased levels of serum 
TOC in people with T2DM compared to controls. However,  these reviews only found a small number 
of the published studies and did not investigate ucOC (23–25). The mean differences in T2DM 
compared with normal glucose tolerance controls from the three reviews showed similar results (-
3.31ng/ml [-4.04, -2.57] from Kunutsor et al.; -2.87 ng/ml [-3.76,-1.98] from Liu C et al. , and -2.51 
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ng/ml [-3.01,-2.01] from Hygum et al.) (23–25). Both of the reviews by Kunutsor et al and Liu C et 
al. only found a small number (n=4) of cohort studies (23,24).. Additionally, studies reporting the 
associations between ucOC and glucose homeostasis in T2DM have not been adequately meta-
analysed (24).  
Some observational studies have reported decreased OC concentrations in pre-diabetics (PD) 
compared to normal glucose tolerance controls, while Aoki et al. indicated an increase of OC 
concentration in the early stage of diabetes (26–28). Therefore, conducting meta-analyses comparing 
the OC levels between PD and normal glucose controls and comparing OC levels between T2DM and 
PD may contribute to the investigation between OC and glucose homeostasis in patients with 
diabetes. Another unsolved issue in the previously published meta-analyses are the high between-
study heterogeneity. Previous reviews explored different sources of heterogeneity with modest 
success (23,24). Starup-Linde et al. conducted subgroup analysis according to sex, age and 
menopausal status in women, (29). Liu C et al. attempted to explain the heterogeneity by sex and OC 
assay methods (24). Kunutsor et al. conducted subgroup analyses according to study design and 
degree of confounders of risk estimates (23). Hygum et al. performed a meta-regression analysis to 
investigate the extent to which heterogeneity was explained by haemoglobin A1c(HbA1c) levels (25). 
Therefore, the present systematic review/meta-analysis will use a more comprehensive search strategy 
to identify more prospective studies, thereby increasing statistical power. Secondly, we will search for 
studies reporting the association between ucOC and glucose metabolism. Thirdly, we will identify 
studies comparing the OC concentrations between PD and normal glucose controls, and between 
T2DM and PD. Lastly, by systematically exploring potential sources of heterogeneity we may explain 
previous conflicting findings.  
OBJECTIVES 
The present systematic review and meta-analysis aims to: 1) compare the serum OC and ucOC 
between T2DM and normal glucose tolerant controls (NGC); 2) investigate the risk ratios between 
serum OC and ucOC and T2DM; 3) determine the correlation coefficient between OC and ucOC and 
fasting insulin levels (FINS), homeostatic model assessment-insulin resistance (HOMA-IR), 
haemoglobin A1c (HbA1c) and fasting glucose levels (FPG); 4) explore potential sources of between-
study heterogeneity. A secondary objective is to compare the serum OC and ucOC between 
prediabetes (PD) and NGC, and between T2DM and PD.   
 
METHODS & ANALYSIS 
We designed this systematic review and meta-analysis in adherence to the guidelines of Preferred 
Reporting Items for Systematic review and Meta-analysis (PRISMA) and Meta-analysis of 
observational studies in epidemiology (MOOSE) (30,31).The process of the proposed protocol is 
shown in Figure.1, and PRISMA-checklist shows in Appendix 1. 
Protocol and registration 
This protocol is registered and available on PROSPERO (CRD42017073127). 
Patient and public involvement statement 
 There is no patient or public involved in this systematic review/meta-analysis.  
Eligibility criteria for studies included in the review 
Inclusion and exclusion criteria  
Participants 
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Participants should be adult humans (older than 18 years old), with T2DM at baseline or developed 
T2DM afterward; not have any conditions that can affect bone metabolism or with medications that 
affect bone metabolism; could be with anti-diabetic treatments.   
Exclude: 
1. Children or adolescents (younger than 18 years old), pregnant or lactating women because of 
altered bone turnover markers levels. 
2. Patients with a disease that either affects bone metabolism or glucose metabolism: 
3. Patients with type 1 diabetes and/or gestational diabetes as they are pathophysiologically 
different from patients with T2DM. 
4. Patients with Cushing's disease or Cushing's syndrome as they have a disordered metabolism. 
5. Patients with hormonal disorders. For instance, growth-hormone deficiency or excess.  
6. Patients with hyperparathyroidism or hypoparathyroidism or other diseases that affect thyroid 
function because of increased OC levels and changes in metabolism. 
7. Patients with liver dysfunction (alanine transaminase > 3 times upper limit of normal).  
8. Patients with impaired kidney function as described below: 
• A chronic renal disease when glomerular filtration rate of impaired renal function patients is 
below 30ml/min • 1.73 m2 at stage four or five, or 
• A chronic renal illness when serum creatinine over 2.07 mg/dL, or renal osteodystrophy, or 
kidney transplant as 21% to 50% of kidney transplant recipients may develop secondary 
hyperparathyroidism after kidney transplantation or when treated with dialysis or haemodialysis.   
9. Patients with Paget’s disease as they have disordered bone metabolism. 
10. Patients with osteomalacia as it is a severe bone disease and affects bone metabolism. 
11. Patients with cancer or tumours. For example, bone cancer metastases could mediate bone 
turnover marker levels. 
12. Patients with human immunodeficiency virus (HIV).  
13. Patients with sepsis as they have disordered immune response caused by infections.  
14. Patients with medications that affect bone metabolism: 
• Antiresorptive or anabolic therapy for osteoporosis and selective estrogen receptor 
modulators (such as bisphosphonates, alendronate, etidronate, raloxifene, denosumab and 
teriparatide). 
• Estrogen replacement therapy. 
• Glucocorticoids and thiazide diuretics. 
15. Patients treated with surgery that directly affected hormone or thyroid function (i.e., 
thyroidectomy, oophorectomy and hysterectomy). 
Note:  
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1) We include intervention studies that reported baseline data of OC and T2DM. Accordingly, 
we will eliminate observational studies with more than 20% of the cohort taking above non-eligible 
therapy. 
2) We included T2DM with diabetic medications, but they will be assessed using subgroup 
analysis by the medication status. Anti-diabetic medications that affect OC/ucOC levels include 
insulin therapy, glucagon-like peptide-1 (GLP-1) receptor analogist and thiazolidinediones. 
 
Study types 
Observational studies are eligible for inclusion: cohort studies (both prospective and retrospective 
cohort studies), case-control study and cross-sectional study. Reporting eligible exposure(s) and 
outcome(s). 
We will exclude reviews, commentaries, short survey, case reports, and letters. 
Interventional studies (including randomised control trials) will be used if they provide eligible cross-
sectional data at baseline before intervention.  
 
Exposure(s) 
OC levels are identified from enzyme-linked immunoassay (ELISA or EIA), Electro-
chemiluminescence immunoassay (ECLIA), Immunoradiometric assay (IRMA), radioimmunoassay 
(RIA) and hydroxylapatite binding assay (HAP). The standard unit for OC is ng/ml; thus, other 
presented groups for OC (eg. nmol/l) will be converted to ng/ml.  
Measures of OC 
• Total serum osteocalcin levels (ng/ml). 
• Undercarboxylated osteocalcin levels(ng/ml). 
• OC categorized as low (reference) and high groups. Tertile, quartile, or quantile are the 
common categories used for classing different levels of TOC or ucOC.  
Outcome(s) 
Measures of T2DM 
• Diabetes status categorized as type 2 diabetes disease or normal controls (reference)  
• As some studies may categorize diabetes states as insulin-dependent diabetes mellitus (IDDM) and 
non-insulin dependent diabetes mellitus (NIDDM), NIDDM will be used and presented as T2DM.  
Exclude Type 1 diabetes and gestational diabetes as they are pathophysiological different compared 
with T2DM. 
Secondary outcome(s) 
• IGT /IFG that is the pre-diabetic state and has a higher risk of developing T2DM  
• HbA1c percentages categorized as type 2 diabetes, prediabetes and healthy controls (reference) by 
HbA1c rates over 6.5%, between 5.7% and 6.5% and below 5.7% respectively. 
• Fasting plasma glucose levels categorized as diabetes, prediabetes and healthy controls (reference) 
by FPG levels over 126mg/dl, between 100 and 126 mg/dl, and below 100 mg/dl respectively.  
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Study design 
Search strategies 
A comprehensive literature search within MEDLINE, EMBASE and SCOPUS databases will be 
conducted to source all possible relevant studies for the present review. There is no language 
restriction, and non-English articles will be translated when possible and evaluated for eligibility. 
There is no time restriction. We may include conference proceedings and abstracts if necessary. We 
will further conduct reference list searches of each available paper. If duplicate publications of the 
same study are retrieved, the most relevant and up to date paper with more complete data will be 
included. The detailed search strategy shows in Table.1 
Table 1. Detailed search strategy in databases: Medline, Embase and Scopus. 
Medline (Ovid SP) Embase (Ovid SP) Scopus 
1. exp osteocalcin 
2. osteocalcin.mp 
3. bone gla protein.mp 
4. vitamin k?dependent bone protein*.mp 
5. 1 and 2 and 3 and 4 
6. exp diabetes mellitus, Type 2/II 
7.diabetes mellitus type 2/II.mp 
8. (T2D* or NIDDM or “type 2” or “type II”)).tw 
 
9. (non insulin$ depend$ or nonsinulin$depend$ or non insulin?depend$ or noninsulin?depend$).tw 
10.exp Hyperglycemia 
11. hyperglycemia.mp 
12. hypergly?emi*.tw 
13. exp Hemoglobin A/ or exp Hemoglobin A，Glycosylated 
14. HbA1c.mp 
15. (“HbA(1c)” or HbA1c or “HbA 1c” or ((glycosylated or glycated) adj h?emoglobin)).tw 
16. 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 
17. 5 and 16 
18. limit 17 to humans 1. exp osteocalcin 
2. osteocalcin.mp 
3.bone gla protein.mp 
4.vitamin k?dependent bone protein*.mp 
5. 1 and 2 and 3 and 4 
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6. exp non insulin dependent diabetes mellitus 
7. exp diabetes mellitus 2/II 
8. (T2D* or NIDDM or “type 2” or “type II”).tw 
9. (prediabet* or pre diabet*).tw 
10. hyperglyc?emi*.tw 
11. 6 or 7 or 8 or 9 or 10 
12. 5 and 11 
13. limit 13 to (human and exclude medline journals) ( KEY ( 'osteocalcin' )   
OR  KEY ( 'bone  AND gla  AND protein' )   
OR  KEY ( 'bone  AND turnover  AND markers' ) )   
AND  ( KEY ( 'diabetes  AND mellitus' )   
OR  KEY ( 'hemoglobin  AND a1c' )   
OR  KEY ( 'fasting  AND plasma  AND glucose' ) )   
AND  KEY ( 'human' )  AND  ( LIMIT-TO ( DOCTYPE ,  "ar" ) )  
 
 
Process for selecting studies 
One author will set up the search strategy and store the search results to Endnote X7. The search 
strategy and recorded search results will then be checked by another investigator. Two or more 
independent investigators will go through the abstract screening (to remove duplicate records of the 
same report and to include eligible articles), and full-text assessment (to acquire full-texts of available 
studies and to construct citation lists of eligible items). If a discrepancy arises, the disagreement will 
be shared with investigators by email or face-to-face meetings before reaching a final decision. 
Data extraction 
One author will extract data from studies that are eligible for full-text assessment. Obtained data will 
be examined for a second time by the same author to correct any mistakes. All extracted data will be 
saved in an excel spreadsheet. 
Eligible extracted items: author and publication year, study design, study base, sample size, sex and 
postmenopausal status in females, age, ethnicity, country, osteocalcin assay methods, obesity 
measurements (body mass index or waist circumference), diabetic duration, anti-diabetic medications 
status, vitamin K supplementation/anti-vitamin K drugs, vitamin D supplementation, TOC/ucOC 
levels in groups, any risk estimate between TOC/ucOC and T2DM, any association between 
TOC/ucOC and HbA1c and/or FPG in T2DM, any association between TOC/ucOC and prediabetes 
and/or impaired glucose tolerance/impaired fasting glucose, any association between TOC/ucOC and 
standard glucose controls, any association between TOC/ucOC and HOMA-IR or HOMA-beta in 
T2DM.  
Risk of bias assessment 
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The methodological quality will be assessed by Newcastle-Ottawa Scale (NOS). Cohort and case-
control studies can be assessed by three main parts in the NOS: selection, comparability and 
outcome/exposure (32). The maximum score is nine points (32). The higher the score indicates a 
better methodological quality of the individual study (32). Cross-sectional studies can be assessed by 
modified NOS (33). The maximum score is ten points for the modified NOS, representing the highest 
quality (33). The quality assessment template can be found in supplementary materials. 
Statistical analysis and data synthesis  
Mean differences (MDs) with 95% CI will be calculated between T2DM and NGC, between PD and 
NGT, and between T2DM and PD. Estimates of effect size will be expressed as Relative Risk (RR) 
with 95% confidence intervals (95% CI) in cohort studies and Odds Ratio (OR) with 95% CI in case-
control and cross-sectional studies. OR is expressed as one increased standard deviation (SD) of OC 
to the risk of developing T2DM. Papers reporting other forms of OR will be translated to per 
increased SD of OC if there is logistic regression model. Pearson correlation coefficient will be 
analysed by investigating the relationships between TOC or ucOC and fasting insulin levels (FINS). 
Studies that only have medians and ranges or interquartile ranges (IQRs) will be transformed to 
means and standard deviations (34,35). Furthermore, log-transformed data will be converted to raw 
statistics before subjecting to analyses (36). We will assess publication bias of MD and risk estimates 
by visual inspection of the funnel plots if there are the minimum number of studies (37,38)). Egger’s 
test will be used to assess the publication bias when there are a large number of studies (37).We will 
examine heterogeneity employing the I2 statistic by study ID which quantifies inconsistency across 
studies to assess the impact of heterogeneity on the meta-analysis (39). I2 represents the degree of 
heterogeneity. I2 thresholds of 0%-40%, 30%-60%, 50%-90% and 75%-100% indicate possibilities of 
low, moderate, substantial and be considerable heterogeneity (39). All meta-analyses are conducted 
by Rstudio (Version 1.1.419-2009-2019 Rstudio, Inc.). Metafor package will be used to produce 
meta-regression analyses, meta-bias analyses and assessing heterogeneities (40). Each P value below 
0.05 indicates statistically significant. 
Meta-regression/subgroup analysis  
Meta-regression analysis and subgroup analysis will be applied to assess the sources of heterogeneity. 
Meta-regression will be used for continuous factors such as age, sample size and proportion of 
postmenopausal in women. We will use subgroup analyses to identify potential sources of clinical, 
methodological or statistical heterogeneity for categorical variables. We will also generate mix-effect 
models to see the influence of multiple factors on the effect size. Random-effects models will be used, 
and p-values of < 0.01 will be considered statistically significant for subgroup analyses. Pre-planned 
subgroup analyses to explore statistical heterogeneity will include stratification by: 
• Subgroups based on study design. 
• Subgroups based on age.  
• Subgroups based on sex. Additionally, a subset based on menopausal status will be conducted 
in females. 
• Subgroups based on ethnicity or race. 
• Subgroups based on diabetic status (normal, prediabetes, T2DM). 
• Subgroups based on anti-diabetic medication status in T2DM. 
• Subgroups based on obesity measurements (body mass index/waist circumference).   
• Subgroups based on OC assay methods.  
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• Subgroups based on the fasting measures and spot measures. 
• Subgroups based on vitamin K supplementation/anti-vitamin K drugs or vitamin D 
supplementation if data available. 
 
Publication bias & Confidence in cumulative evidence 
Publication bias assessment is based on graphical test (funnel plots) and Egger & Begg tests (37,38). 
The asymmetry of funnel plot suggests a higher risk of publication bias and vice versa (37). 
Statistically, Egger’s and Begg’s test will be conducted respectively in Rstudio.  
We will provide assurance of the quality of our results by applying the Grading of Recommendations 
Assessment Development and Evaluation (GRADE) tool. We also will present an evidence profile 
summary with GRADEpro software (http://ims.cochrane.org/gradepro). The quality checklist includes 
the following items: risk of bias assessment, consistency of results, directness of evidence and 
precision of the results.  
DISCUSSION 
The current systematic review/meta-analysis is an update and improvement to the current literature in 
several ways. Firstly, we will provide more evidence compared to previous investigations in analysing 
the potential role/s OC plays in T2DM by increasing the number of eligible studies included in our 
up-to-date analysis. Secondly, we are investigating the sources of heterogeneity, explicitly by an 
increase in the number of factors such as age, sex, postmenopausal status in women, study design, 
ethnicity or regions, OC assays and medications on T2DM. This comprehensive analysis on 
heterogeneity may uncover the factor(s) responsible for the difference among already published 
studies. Thirdly, we are producing a report not only on total osteocalcin (TOC) levels but also on 
undercarboxylated osteocalcin (ucOC) levels. By including investigations on ucOC, it is possible we 
can determine the endocrine roles of both OC and ucOC in humans, if any.  Additionally, 
investigating the relationship in a subgroup of patients with prediabetes will provide more details 
regarding the influence of OC (or ucOC) on glucose levels in a progressive T2DM status. The major 
limitation of this review is that we will only be including observational studies as there is insufficient 
evidence from clinical trials, which will restrict study results in specific analyses. Despite this 
disadvantage, there are still a large number of studies that could be used to pool a quantitative analysis 
and provide evidence according to concerns with heterogeneity. Our review will contribute to public 
health and clinical research for further investigations regarding the gap in the current literature. 
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Appendix 2: the additional results 
Figure 23 The forest plot of the mean difference of ucOC in T2DM vs. and NGC across nine studies 
 
Figure 24 The forest plot of the mean difference of TOC in T2DM and PD across seven studies 
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Figure 25 The forest plot of the mean difference of TOC in PD and NGC across nine studies 
 
 
 
 92 
Figure 26 The forest plot of the correlation coefficient between TOC and FINS across 14 studies 
 
 
 
 
 93 
Figure 27 The forest plot of the correlation coefficient between TOC and HOMA-IR across 19 studies 
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Figure 28 The forest plot of the correlation coefficient between TOC and HbA1c across 30 studies 
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Figure 29 The forest plot of the correlation coefficient between TOC and FPG across 29 studies 
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Figure 30 The contour-enhanced funnel plot of the MD of TOC in PD vs. NGC across 10 studies 
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Figure 31 The contour-enhanced funnel plot of the MD of TOC in T2DM vs. NGC across seven 
studies 
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Figure 32 The trim-filled contour-enhanced funnel plot of the correlation coefficient between TOC 
and FINS across 17 studies 
 
Figure 33 The trim-filled contour-enhanced funnel plot of the correlation coefficient between TOC and 
HbA1c across 30 studies 
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Figure 34 The contour-enhanced funnel plot of the correlation coefficient between TOC and FPG 
across 29 studies 
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Figure 35 The contour-enhanced funnel plot of the correlation coefficient between TOC and HOMA-
IR across 19 studies 
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Appendix 3: the additional tables and figures 
Table 6. The comments of 21 discrepancy articles. 
Author, year YH L comments YH L XY L JLW Final 
comment 
Cantini,1992 r between OC vs 
Hb/diabetes years 
and T2DM 
(NIDDM) 
available 
include exclude Most likely to be eligible 
but it is in Italian. Do 
you have a translated 
version. If not perhaps 
we can exclude non-
english papers 
exclude 
Cuttica,1997 OC levels at 
baseline in 
participants but 
there is no 
composition and 
no related 
investigated 
association 
exclude include Exclude no testing of the 
relationship between OC 
and outcomes 
exclude 
Flammer,2012 OR between OCN 
cells and HbA1c 
include exclude Exclude the reported 
relationship is between 
osteocalcin expressing 
mononuclear cells (cells 
expressing OC on 
surface) and glycated 
hemoglobin not OC 
(circulating protein) 
exclude 
Juanola-
Falgarona,2013 
OC levels are in 
patients with 
normal glucose 
metabolism and 
impaired fasting 
glucose 
include exclude Include correlations 
reported Figure 1  
include 
Kanazawa,2008 r between HbA1c 
levels and OC is 
reported in 
patients with 
T2DM  
include exclude Appear eligible- please 
check all of the 
Kanazawas as there are 
multiple reports from the 
same cohorts. As such 
you will need to make 
sure you only report the 
correlation from the 
largest studies within 
each cohort. 
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Author, year YH L comments YH L XY L JLW Final 
comment 
Kanazawa,2009 r between OC and 
HbA1c is 
reported  in all 
T2DM. 
include exclude   
Kanazawa,2009  r between changes 
of OC and FPG is 
reported in 
patients of 
T2DM.  
include exclude   
Kanazawa,2011 r between changes 
of OC and HbA1c 
is reported in 
T2DM.  
include exclude   
Kanazawa,2011  r between OC and 
FPG and HbA1c is 
reported in T2DM 
include exclude   
Kim,2016 logOC levels in 
diabetes and non-
diabetes group 
include exclude Exclude this report only 
on CABG and CAC not 
diabetes. 
exclude 
Kovacs,2013 Language is 
Hungry, but OC 
levels comparison 
between healthy 
controls and 
T2DM can be find 
in table 2 
include exclude Most likely to be eligible 
but it is in Hungarian. Do 
you have a translated 
version. If not perhaps 
we can exclude non-
English papers 
exclude 
Lerchbaum,2015 OR of T2DM and 
OC in men and 
women 
include exclude Eligible look at 
supplementary data 
include 
Liao,2013 participants have 
metabolic 
syndrome, but 
spearsman 
correlation 
coefficient 
between OC and 
glucose reported. 
include exclude Eligible include 
Maggi,2014 no statistical 
related association 
between OC and 
diabetes reported 
exclude include Exclude no reported 
association 
exclude 
Mori,2012 r between ucOC 
and M and 
include exclude Include in qualitative 
analysis – FOR 
include 
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Author, year YH L comments YH L XY L JLW Final 
comment 
M/I values are 
reported. M and 
M/I values are for 
measuring insulin 
resistance.  
DISCUSSION about 
between study 
differences 
Mori,2015 this study is for 
association 
between VD and 
bone metabolism, 
did not report 
relevant 
investigated 
association 
between OC and 
T2DM. 
exclude include Exclude no reported 
association 
exclude 
Piaggesi,2002 OC levels between 
diabetes groups 
and non-diabetes 
are reported. 
include exclude Include Table 2 include 
Piepkorn,1997 this is a review, so 
exclude 
exclude include Exclude review exclude 
Rico,1989 basal OC levels 
reported in NIDD 
and controls 
include exclude Include Table 2 include 
Rosato,1998 basal OC levels 
reported in NIDD 
and controls, r 
between OC and 
HbA1c in NIDD 
reported. 
include exclude Eligible - abstract include 
Yoda,2012 OC levels are 
reported in T2DM 
and non-DM 
include exclude  include 
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Table 7. The characteristics of individual studies. 
First Author, 
Year 
Study Type 
Sample 
size 
Location Ethnicity 
 
Assays 
TOC ucOC 
Achemlal, 2005 cross-sectional 70 Morocco Caucasian ECLIA  
Akin, 2003 case-control 77 Turkey Caucasian ELISA  
Alfadda, 2013 cross-sectional 203 Saudi Arabia Caucasian ELISA EIA 
Alselami, 2015 case-control 85 Saudi Arabia Caucasian   
Aoki, 2011 cross-sectional 55 Japan Asian ELISA  
Ardawi, 2013 cross-sectional 964 Saudi Arabia Caucasian   
Bador, 2016 cross-sectional 90 Malaysia Asian ECLIA  
Bao, 2011 
baseline of 
intervention 
59 China Asian ECLIA  
 
 
Barghash, 2014 
 
 
case-control 
 
 
120 
 
 
Saudi Arabia 
 
 
Caucasian 
 
 
ELISA 
 
Berberoglu, 
2007 
baseline of 
intervention 
82 Turkey Caucasian ECLIA  
Bhattoa, 2013 case-control 136 Hungary Caucasian ECLIA  
Bothy, 2016 cross-sectional 207 Belgium Caucasian ECLIA  
Bouillon, 1995 cross-sectional 156 USA Caucasian RIA  
Buday, 2013 cross-sectional 291 Hungary Caucasian IHC  
Bullo, 2012 cohort 79 Spain Caucasian ECLIA ECLIA 
Cakatay, 1998 case-control 70 Turkey Caucasian RIA  
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First Author, 
Year 
Study Type 
Sample 
size 
Location Ethnicity 
 
Assays 
TOC ucOC 
Chen, 2014 cross-sectional 160 China Asian ELISA ELISA 
Chen-H, 2013 cross-sectional 82 China Asian RIA  
Chen-L, 2013 cross-sectional 1729 China Asian RIA  
Choudhury, 
2014 
case-control 200 India Asian ELISA  
Cui, 2014 cross-sectional 98 China Asian ELISA  
Cutrim, 2007 case-control 66 Brazil Caucasian IRMA  
De-Araujo, 
2017 
cross-sectional 78 Brazil Caucasian EIA  
Diaz-L, 2013 case-control 459 Spain Caucasian  EIA 
Dobnig, 2006 cohort 1664 Austria Caucasian ELISA  
Furuyso, 2013 cross-sectional 3658 Japan Asian  ECLIA 
Garcia-M, 2011 cross-sectional 54 Spain Caucasian ECLIA  
 
 
Garcia-M, 2012 
 
 
cross-sectional 
 
 
124 
 
 
Spain 
 
 
Caucasian 
 
 
RIA 
 
Gennari, 2012 cross-sectional 102 Italy Caucasian ELISA  
Gerdhem, 2005 cross-sectional 1028 Sweden Caucasian ECLIA  
Gonzalez-G, 
2015 
cross-sectional 531 USA Latino ELISA  
Gradinaru, 2009 cross-sectional 75 Romania Caucasian ELISA  
Gregorio, 1994 cross-sectional 160 Italy Caucasian RIA  
 106 
First Author, 
Year 
Study Type 
Sample 
size 
Location Ethnicity 
 
Assays 
TOC ucOC 
Hwang, 2012 cross-sectional 425 Korea Asian IRMA  
Hwang, 2012 cohort 1229 Korea Asian ELISA  
Iglesias, 2011 case-control 64 Spain Caucasian ECLIA  
Iki, 2012 cross-sectional 1597 Japan Asian IRMA ECLIA 
Im, 2008 cross-sectional 339 Korea Asian ECLIA  
Inaba, 1999 cross-sectional 19 Japan Asian IRMA  
Inukai, 1997 cross-sectional 164 Japan Asian RIA  
Ivaska, 2017 cross-sectional 46 Finland Caucasian ELISA HAP 
Juanola-F, 2013 cross-sectional 423 Spain Caucasian ECLIA ECLIA 
Jung, 2016 cross-sectional 470 Korea Asian IRMA  
Kanazawa, 2008 cross-sectional 163 Japan Asian RIA  
Kanazawa, 2009 cross-sectional 328 Japan Asian RIA  
Kanazawa, 2011 cross-sectional 253 Japan Asian IRMA  
Karar, 2007 cross-sectional 121 Kuwait Caucasian ELISA  
Kindblom, 2009 cross-sectional 1010 Sweden Caucasian ECLIA  
Klimontov, 
2016 
cross-sectional 160 Russia Caucasian EIA  
Lerchbaum, 
2015 
cross-sectional 2671 Germany Caucasian ECLIA  
Levinger, 2011 
baseline of 
intervention 
28 Australia Caucasian ECLIA ECLIA 
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First Author, 
Year 
Study Type 
Sample 
size 
Location Ethnicity 
 
Assays 
TOC ucOC 
Liang, 2016 cohort 2353 China Asian ECLIA  
Liao, 2015 cross-sectional 2424 China Asian ECLIA  
Liatis, 2014 cohort 307 Greece Caucasian ELISA  
Lopes, 2015 cross-sectional 43 Brazil Caucasian ELISA  
Ma, 2015 cross-sectional 985 China Asian ECLIA  
Maghbooli, 
2016 
cross-sectional 33 Iran Caucasian ECLIA  
Maghbooli, 
2016 
case-control 204 Iran Caucasian ECLIA  
Malecha-J, 2012 cross-sectional 70 Poland Caucasian ELISA  
Manavalan, 
2012 
cross-sectional 45 USA mix ELISA ELISA 
Maser, 2015 cross-sectional 50 USA mix ELISA ELISA 
Mori, 2012 cross-sectional 129 Japan Asian  ECLIA 
Movahed, 2012 cross-sectional 382 Iran Caucasian ELISA  
Nan, 2016 case-control 80 Romania Caucasian ECLIA  
Ngarmukos, 
2012 
cohort 126 Thailand Asian ECLIA ELISA 
Ogawa-F, 2013 cross-sectional 228 Japan Asian IRMA ECLIA 
Oren, 2011 cross-sectional 20 USA mix ELISA  
Oz, 2006 cross-sectional 100 Turkey Caucasian ECLIA  
Pietschmann, 
1988 
cross-sectional 55 Austria Caucasian RIA  
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First Author, 
Year 
Study Type 
Sample 
size 
Location Ethnicity 
 
Assays 
TOC ucOC 
Pooruk, 2009 cross-sectional 156 Thailand Asian   
Raska, 2017 cross-sectional 283 
Czech 
Republic 
Caucasian ECLIA  
Reyes-G, 2013 cross-sectional 133 Spain Caucasian RIA  
Rico, 1989 cross-sectional 41 Spain Caucasian RIA  
Rivera-L, 2015 case-control 250 Mexico 
Hispanic 
Latino 
ELISA  
Rosato, 1998 case-control 40 USA mix RIA  
Rui, 2014 cross-sectional 739 China Asian RIA  
Sahin, 2002 case-control 134 Turkey Caucasian ELISA  
Sakai, 2013 cohort 110 Japan Asian  ECLIA 
Sanchez-E, 
2017 
cross-sectional 140 Mexico 
Hispanic 
Latino 
 ELISA 
Sarkar, 2012 cross-sectional 112 India Asian ELISA  
Sarkar, 2013 case-control 158 India Asian ELISA  
Shanbhogue, 
2016 
cross-sectional 102 Denmark Caucasian ECLIA  
Sheng, 2013 cross-sectional 817 China Asian RIA  
Shu, 2012 cross-sectional 50 USA mix ELISA  
Sosa, 1996 cross-sectional 299 Spain Caucasian RIA  
Starup-L, 2016 cross-sectional 96 Denmark Caucasian ECLIA ELISA 
Suzuki, 2005 cross-sectional 264 Japan Asian ELISA  
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First Author, 
Year 
Study Type 
Sample 
size 
Location Ethnicity 
 
Assays 
TOC ucOC 
Takashi, 2017 cross-sectional 50 Japan Asian  ECLIA 
Takizawa, 2008 cross-sectional 199 Japan Asian ELISA  
Tonks, 2017 cross-sectional 69 Australia Caucasian ECLIA  
Villafan-B, 
2014 
cross-sectional 240 Mexico 
Hispanic 
Latino 
 ELISA 
Wang, 2013 cross-sectional 66 China Asian RIA ELISA 
Weiler, 2013 cross-sectional 368 Canada mix ELISA  
Witzke, 2011 cross-sectional 80 USA mix ELISA  
Xuan, 2015 cross-sectional 195 China Asian ECLIA  
Yamamoto, 
2012 
case-control 495 Japan Asian ECLIA  
Ye, 2012 cross-sectional 128 China Asian ELISA  
Yeap, 2015 cross-sectional 2966 Australia Caucasian ECLIA ECLIA 
Yoda, 2012 
baseline of 
intervention 
20 Japan Asian IRMA  
Zhou, 2009 cross-sectional 500 China Asian ECLIA  
Zhou, 2010 cross-sectional 1579 China Asian IRMA  
Zhou, 2013 cross-sectional 490 China Asian IRMA  
Zhukouskaya, 
2015 
case-control 206 Italy Caucasian ELISA  
Zwakenberg, 
2015 
case-control 1635 Netherlands Caucasian HAP HAP 
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First Author, Year Sources of Population Baseline Population 
Matched Variables 
Cases & Controls 
Achemlal, 2005 
Internal medicine 
department 
T2DM, NGC age 
Akin, 2003 Outpatient clinic T2DM, NGC age 
Alfadda, 2013 
Diabetes outpatient 
clinic 
T2DM  
Alselami, 2015 
Medical 
administration at King 
Abdul Aziz University 
T2DM, NGC age 
Aoki, 2011 
Social Insurance 
General Omiya 
Hospital 
T2DM, NGC, PD  
Ardawi, 2013 Diabetic clinics T2DM, NGC age, sex 
Bador, 2016 Phlebotomy clinic 
MetS with/without 
T2DM 
 
Bao, 2011 
Outpatient department 
of the Shanghai 
Clinical Centre for 
Diabetes 
T2DM  
Barghash, 2014 
Cases: Diabetes 
Centre; 
Controls: volunteers 
from the OPD at 
Taibah University 
T2DM, NGC; lean/ 
obese/overweight 
groups 
age 
Berberoglu, 2007 NG T2DM, NGC 
age, BMI, body 
composition 
Bhattoa, 2013 
Diabetes outpatient 
division 
T2DM, NGC age, sex 
Bothy, 2016 NG T2DM, NGC  
Bouillon, 1995 NG T2DM, NGC age 
Buday, 2013 
Diabetes outpatient 
clinic 
T2DM, NGC, PD  
Bullo, 2012 
Community-dwelling 
men from one of the 
PREDIMED Centres 
T2DM, overweight/ 
obese groups 
 
Cakatay, 1998 NG T2DM, NGC age, sex 
Chen, 2014 
The West China 
Hospital 
T2DM, NGC, PD  
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First Author, Year Sources of Population Baseline Population 
Matched Variables 
Cases & Controls 
Chen-H, 2013 NG T2DM, NGC age, sex 
Chen-L, 2013 
Subsamples from 
Shanghai communities 
T2DM, NGC, PD, 
MetS 
 
Choudhury, 2014 
Case: outpatient 
department of NSCB 
Medical College and 
Hospital; 
Controls: routine 
health check-up in the 
hospital 
T2DM, NGC age, BMI 
Cui, 2014 
Shanghai Tehnth 
Hospital 
T2DM  
Cutrim, 2007 
Diabetes mellitus 
outpatient clinic of the 
University Hospital 
T2DM, NGC age, sex, height 
De-Araujo, 2017 NG  age, sex 
Diaz-L, 2013 
Prevención con Dieta 
Mediter- ránea 
(PREDIMED) trial 
T2DM, NGC age. sex. BMI 
Dobnig, 2006 
Nursing homes in four 
counties in Austria 
T2DM, NGC  
Furuyso, 2013 
Residents of Kasuya 
Town 
  
Garcia-M, 2011 
Endocrinology and 
Nutrition Department 
of the University 
Hospital 
NGC  
Garcia-M, 2012 
Cases: outpatient 
clinic from community 
clinics for treatment of 
diabetes; 
Controls: the general 
community in the 
same period  
T2DM, NGC age 
Gennari, 2012 
Cases: Diabetes Unit 
of the departments; 
Controls: volunteers 
T2DM, NGC age, sex 
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First Author, Year Sources of Population Baseline Population 
Matched Variables 
Cases & Controls 
Gerdhem, 2005 The osteoporosis 
prospective risk 
assessment (OPRA) 
study; randomly from 
the city files of Malmo 
T2DM, NGC age 
Gonzalez-G, 2015 
Arizona Insulin 
Resistance Registry 
  
Gradinaru, 2009 
Hospitalised in “Ana 
Aslan” National 
Institute of 
Gerontology and 
Geriatrics 
T2DM, NGC, PD  
Gregorio, 1994 NG T2DM, NGC age, sex, BMI 
Hwang, 2012 
the Kyung Hee 
University Hospital 
T2DM, NGC, PD  
Hwang, 2012 
the Health Promotion 
Centre 
NGC  
Iglesias, 2011 Outpatient clinic T2DM, NGC, PD  
Iki, 2012 
Fujiwarakyo Study 
was enrolled in four 
cities of Nara 
Prefecture, Japan on a 
volunteer basis 
T2DM, NGC  
Im, 2008 
The hospital for a 
periodic health 
checkup in a health 
promotion centre in 
Daejeon 
T2DM, NGC, PD  
Inaba, 1999 NG T2DM, NGC age, sex 
Inukai, 1997 NG T2DM, NGC age 
Ivaska, 2017 
Larger data collections 
named SLEEVEPASS 
(NCT00793143) and 
SleevePET2 
(NCT01373892) 
T2DM, NGC; obese 
and lean groups 
 
Juanola-F, 2013 
The PREDIMED 
study; three Spanish 
centres 
NGC, PD  
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First Author, Year Sources of Population Baseline Population 
Matched Variables 
Cases & Controls 
Jung, 2016 Diabetes clinic at 
Seoul National 
University Bundang 
Hospital 
T2DM  
Kanazawa, 2008 
Shimane University 
Hospital for education, 
evaluation, or 
treatment of diabetes 
T2DM  
 
 
 
Kanazawa, 2009 
 
 
 
Shimane University 
Hospital for education, 
evaluation, or 
treatment of diabetes 
 
 
 
T2DM 
 
Kanazawa, 2011 
 
Shimane University 
Hospital for education, 
evaluation, or 
treatment of diabetes 
T2DM  
Karar, 2007 
AL Razi orthopedic 
hospital and diabetic 
outpatient clinics 
T2DM, NGC  
Kindblom, 2009 
MrOS Sweden study; 
national population 
registers 
T2DM, NGC  
Klimontov, 2016 NG T2DM, NGC  
Lerchbaum, 2015 
The Study of Health in 
Pomerania (SHIP); 
Population-based 
T2DM, NGC, PD  
Levinger, 2011 NG 
T2DM, NGC, PD; 
all obese 
 
Liang, 2016 
The Fangchenggang 
Area Male Health and 
Examination Survey, 
population-based 
T2DM, NGC, PD  
Liao, 2015 
Medical Centre in the 
hospital 
NGC, PD age 
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First Author, Year Sources of Population Baseline Population 
Matched Variables 
Cases & Controls 
Liatis, 2014 
The Greek arm of the 
DE-PLAN 
T2DM, NGC, PD  
Lopes, 2015 Hospital clinics T2DM, NGC  
Ma, 2015 
Endocrine Department 
of the First Hospital 
T2DM  
Maghbooli, 2016 Heart hospital 
CAD with/without 
T2DM 
 
Maghbooli, 2016 
Referral diabetes 
clinic 
T2DM with/without 
nephropathy 
 
Malecha-J, 2012 
Cases: the Department 
of Endocrinology of 
the Medical University 
of Lublin; 
Controls: the routine 
health checks to the 
Department of 
Laboratory 
Diagnostics 
T2DM, NGC  
Manavalan, 2012 
Advertisement at 
Columbia University 
Medical Centre 
T2DM, NGC  
Maser, 2015 Volunteers T2DM  
Mori, 2012 
Diabetes centre at 
Osaka City University 
Hospital 
T2DM  
Movahed, 2012 
Randomly selected 
from 13 clusters in 
Bushehr Port (the 
centre of Bushehr 
province) 
T2DM, NGC  
Nan, 2016 
The patient’s database 
of the National 
Institute of 
Endocrinology “C.I. 
Parhon” 
Osteoporosis 
with/without T2DM 
age 
Ngarmukos, 2012 
 
The Electricity 
Generating Authority 
of Thailand (EGAT) 
cohort 
T2DM, NGC age, BMI 
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First Author, Year Sources of Population Baseline Population 
Matched Variables 
Cases & Controls 
Ogawa-F, 2013 
The Shimane 
University Hospital 
T2DM  
Oren, 2011 
Denver VA Medical 
Centre 
OA with/without 
T2DM 
 
Oz, 2006 
Cases: general internal 
medicine outpatient 
clinic; 
Controls: periodic 
health examination to 
the check-up centre of 
the hospital 
T2DM, NGC age, sex, BMI 
Pietschmann, 1988 NG T2DM, NGC age, sex 
Pooruk, 2009 
Family Medicine Unit 
of Buddhachinaraj 
hospital 
T2DM, NGC  
Raska, 2017 
Attended a preventive 
BMD measurement 
T2DM, NGC  
Reyes-G, 2013 
Cases: outpatient 
clinic from community 
clinics for treatment of 
diabetes; 
Controls: admitted to 
an osteoporosis-
screening program at 
the clinic 
T2DM, NGC  
Rico, 1989 Hospital-based T2DM, NGC  
Rivera-L, 2015 
The Molecular 
Biology Department 
of the University of 
Guadalajara 
T2DM, NGC  
Rosato, 1998 
 
Diabetes OutPatient 
Clinic at Robert Wood 
Johnson University 
Hospital. 
T2DM, NGC  
Rui, 2014 
The Shanghai Tenth 
People’s Hospital 
T2DM  
Sahin, 2002 
Recruited randomly 
from patients 
attending the internal 
T2DM, NGC age, BMI, menopausal 
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First Author, Year Sources of Population Baseline Population 
Matched Variables 
Cases & Controls 
medicine outpatient 
clinic 
Sakai, 2013 Hospital T2DM, NGC  
Sanchez-E, 2017 
The Program for 
Detection and 
Treatment of 
Congenital and 
Acquired Metabolic 
Diseases at a 
university centre 
T2DM, NGC  
Sarkar, 2012 
 
Cases: Out Patient 
Department of NSCB 
Medical College and 
Hospital; 
Controls: routine 
health check-up in 
hospital 
T2DM, NGC age, BMI 
Sarkar, 2013 
Cases: Out Patient 
Department of NSCB 
Medical College and 
Hospital; 
Controls: routine 
health check-up in 
hospital 
T2DM, NGC age, BMI 
Shanbhogue, 2016 
The Funen Diabetic 
Database (FDDB), a 
clinical database 
T2DM, NGC age, sex, height 
Sheng, 2013 
 
The Shanghai 
downtown residential 
areas administered by 
ten residents’ 
committees 
T2DM  
Shu, 2012 
 
The Internal Medicine 
Clinics at Columbia 
University Medical 
Centre 
T2DM, NGC age, race 
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First Author, Year Sources of Population Baseline Population 
Matched Variables 
Cases & Controls 
Sosa, 1996 Cases: Outpatients at 
the bone metabolic 
unit; 
Controls: in a study of 
bone-mineral 
metabolism 
parameters and bone 
mass both with 
DEXAi7 and QCT 
T2DM, NGC age 
Starup-L, 2016 Outpatient clinics T2DM  
Suzuki, 2005 NG T2DM, NGC age 
Takashi, 2017 
Yokohama Rosai 
Hospital 
T2DM  
Takizawa, 2008 NG T2DM, NGC age 
Tonks, 2017 Local advertisements T2DM, NGC, PD glycemia state 
Villafan-B, 2014 NG T2DM, NGC  
Wang, 2013 
Sir Run Run Shaw 
Hospital 
T2DM  
Weiler, 2013 
Manitoba Health 
population registry 
NGC  
Witzke, 2011 NG T2DM age 
Xuan, 2015 NG NGC  
Yamamoto, 2012 
Cases: outpatient 
clinic of Shimane 
University Hospital; 
Controls: underwent 
health screening for 
osteoporosis 
T2DM, NGC age, sex 
Ye, 2012 
Outpatient clinic in 
Second Xiangya 
Hospital 
T2DM, NGC  
Yeap, 2015 
Randomly selected 
from the electoral roll 
T2DM, NGC  
Yoda, 2012 
Unit of Metabolic 
Disease at Osaka City 
University 
  
Zhou, 2009 Six communities T2DM, NGC age, sex, BMI 
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First Author, Year Sources of Population Baseline Population 
Matched Variables 
Cases & Controls 
Zhou, 2010 
Cases: randomly 
selected from among 
inpatients and 
outpatients attending 
the diabetes clinic of 
affiliated hospital 
Controls: the local 
population 
 
T2DM, NGC 
 
age 
Zhou, 2013 
 
Cases: inpatient and 
outpatient of diabetes 
clinic in the hospital; 
Controls: randomly 
selected from subjects 
admitted to the 
hospital for an annual 
physical check-up. 
T2DM, NGC age, BMI, menopausal 
Zhukouskaya, 2015 Outpatient clinic T2DM, NGC  
Zwakenberg, 2015 The EPICNL cohort T2DM, NGC  
 
*TOC: total osteocalcin; ucOC: undercarboxylated osteocalcin; ELISA/EIA: enzyme-linked 
immunoassay; ECLIA: electro-chemiluminescence immunoassay; IRMA: immunoradiometric assay; 
RIA: radioimmunoassay; HAP: hydroxylapatite binding assay; T2DM: type II diabetes; NGC: normal 
glucose tolerance controls; PD: prediabetes (defined by impaired fasting glucose (IFG)/ impaired 
glucose tolerance (IGT)); BMI: body mass index,OA: osteoarthropathy, CAD: cardiovascular disease, 
MetS: metabolic syndrome, NG: not given. 
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Table 8. The characteristics of the population in each study. 
First Author, Year 
T2DM 
(%) 
 
Mean (SD) of Age 
 
Overall T2DM NGC PD 
Achemlal, 2005 50 55.3 (9.5) 57.3 (10.3) 53.2 (8)  
Akin, 2003 74 53.5 (4) 53.2 (4.2) 54.4 (3.2)  
Alfadda, 2013 100 52.5 (9.6) 52.5 (9.6)   
Alselami, 2015 76 50.3 (3.1) 50 (2.5) 51.3 (4.3)  
Aoki, 2011 9 47.6 (10.2) 50.6 (4.3) 47.9 (8.2) 48.6 (8.9) 
Ardawi, 2013 50 58.9 (7.4) 59.6 (7.9) 58.2 (6.7)  
Bador, 2016 56 51.2 (10.7) 53.5 (34.8) 52.4 (9.1)  
Bao, 2011 100 55 (9.1) 55 (9.1)   
Barghash, 2014 67 41.5 (4.2) 41.5 (3.5) 41.5 (5.3)  
Berberoglu, 2007 68 59.3 (6) 59.8 (5.8) 58.4 (6.4)  
Bhattoa, 2013 50 61.4 (4.5) 61.4 (4.5) 61.4 (4.5)  
Bothy, 2016 71 65.5 (10.4) 65.5 (10.4)   
Bouillon, 1995 39 44.7 (5.6) 47.9 (5.6) 42.7 (4.5)  
Buday, 2013 59 45.6 (11.7) 49.9 (8.9) 39.3 (12.4)  
Bullo, 2012 48 68.5 (6.2)    
Cakatay, 1998 50 52.4 (7) 53.3 (8.1) 51.6 (5.4)  
Chen, 2014 39 48 (11) 48 (11) 48 (10) 50 (10) 
Chen-H, 2013 67     
Chen-L, 2013 17 65.5 (8.9)    
Choudhury, 2014 49 50.8 (0.3) 50.9 (8.8) 50.7 (7.8)  
Cui, 2014 100 60.3 (13.6) 60.3 (13.6)   
Cutrim, 2007 64 48.4 (6.2) 49.5 (6.3) 46.5 (5.4)  
De-Araujo, 2017 36 53.6 (8.9) 52 (8) 55 (7)  
Diaz-L, 2013 33 66.3 (6) 66.3 (5.8) 66.3 (6.1)  
Dobnig, 2006 35 83.7 (6.2) 82.8 (5.9) 84.2 (6.3)  
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First Author, Year 
T2DM 
(%) 
 
Mean (SD) of Age 
 
Overall T2DM NGC PD 
Furuyso, 2013 0 54.3 (9.2)  54.3 (9.2)  
Garcia-M, 2011 0 56.1 (3.5)    
Garcia-M, 2012 60 57.2 (6.3) 57.7 (6.5) 56.4 (6)  
Gennari, 2012 39 63 (7.4) 62.7 (8.2) 63.2 (6.9)  
Gerdhem, 2005 7 75 (0) 75 (0) 75 (0)  
Gonzalez-G, 2015 100 36.3 (0.5) 36.3 (0.5)   
Gradinaru, 2009 24 70 (8)    
Gregorio, 1994 69 67.5 (1)    
Hwang, 2012 59 53 (12)    
Hwang, 2012 0 47.5 (5.8)    
Iglesias, 2011 38 57.6 (11.7) 61.3 (12) 53.4 (12.4) 57.3 (9.7) 
Iki, 2012 18 73 (5.2)    
Im, 2008 9 56.5 (6) 57.4 (6.3) 56.1 (5.9) 58.1 (6.3) 
Inaba, 1999 47 54.5 (10.3) 56 (4.3) 53.2 (13.4)  
Inukai, 1997 61 57.8 (14.7) 58 (12) 57.6 (16.8)  
Ivaska, 2017 59 44.9 (9.5) 49 (7.2) 42.4 (10.2)  
Juanola-F, 2013 0 66.3 (6.2)  66.3 (6.3) 66.2 (5.3) 
Jung, 2016 100 62.6 (8.3) 62.6 (8.3)   
Kanazawa, 2008 100 57.7 (12.8) 57.7 (12.8)   
Kanazawa, 2009 100 65.7 (8.6) 65.7 (8.6)   
Kanazawa, 2011 100 59.7 (12) 59.7 (12)   
Karar, 2007 65 55.3 (4) 54.9 (3.7) 56.1 (4.5)  
Kindblom, 2009 15 75.3 (3.2) 75.1 (3.3) 75.3 (3.2)  
Klimontov, 2016 88  62.3 (5.7)   
Lerchbaum, 2015 14 54.4 (17.5)    
Levinger, 2011 54 52.1 (6.4)    
Liang, 2016 3 37.6 (10.9) 46 (11) 37 (11) 44 (12) 
Liao, 2015 0 36.7 (11.9)    
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First Author, Year 
T2DM 
(%) 
 
Mean (SD) of Age 
 
Overall T2DM NGC PD 
Liatis, 2014 12 54.4 (10.2)    
Lopes, 2015 53 58.9 (3.9) 59.8 (4.2) 57.8 (3.3)  
Ma, 2015 100 59.7 (11.2) 59.7 (11.2)   
Maghbooli, 2016 45 60.8 (1.5) 63.8 (1.8) 62.5 (2.1)  
Maghbooli, 2016 100 56.9 (1.6) 56.9 (1.6)   
Malecha-J, 2012 64 59.7 (11) 60.7 (10.3) 57.6 (11.9)  
Manavalan, 2012 40 57.4 (5.4) 58 (6) 57 (5)  
Maser, 2015 100 63.2 (9.9) 63.2 (9.9)   
Mori, 2012 100 54.9 (12.3) 54.9 (12.3)   
Movahed, 2012 27 57.7 (7.5) 59.7 (7) 58.5 (9.1)  
Nan, 2016 50 64.2 (8.9) 64.8 (9) 63.7 (8.7)  
Ngarmukos, 2012 50 47.5 (0.7) 47.8 (0.8) 47.2 (0.5)  
Ogawa-F, 2013 100 64.4 (9) 64.4 (9)   
Oren, 2011 100 61.5 (8.8) 63 (6.7) 59.9 (10.3)  
Oz, 2006 52 53.1 (6.1) 53.9 (6) 52.2 (6)  
Pietschmann, 1988 69 62 (12.3) 62 (12.3) 62 (12.4)  
Pooruk, 2009 81  69 (5.8)   
Raska, 2017 60 65 (9.5) 65.6 (9.4) 64 (9.5)  
Reyes-G, 2013 59 56.7 (6.8) 57.8 (6.4) 55.1 (7.1)  
Rico, 1989 39 51 (4.9) 51 (6) 51 (4)  
Rivera.Leon, 2015 50 47.7 (8.4) 50.8 (7.3) 44.5 (8.2)  
Rosato, 1998 50 56 (12.8) 57.3 (13.5) 54.7 (11.9)  
Rui, 2014 100 68 (10.4) 68 (10.4)   
Sahin, 2002 61 61.7 (7.7) 62.7 (7.5) 60 (7.8)  
Sakai, 2013 11 69.3 (9.5) 67.3 (9) 69.5 (9.6)  
Sanchez-E, 2017 50 51.1 (6.4) 50.4 (5) 51.8 (7.4)  
Sarkar, 2012 50 52.3 (8.2) 52.2 (8.3) 52.4 (8.1)  
Sarkar, 2013 68 51.2 (8.9) 51.4 (9.3) 50.6 (7.9)  
 122 
First Author, Year 
T2DM 
(%) 
 
Mean (SD) of Age 
 
Overall T2DM NGC PD 
Shanbhogue, 2016 50 58.1 (11.6) 58.2 (11.6) 58.1 (11.6)  
Sheng, 2013 100 61.5 (11.6) 61.5 (11.6)   
Shu, 2012 50 61.9 (11.2) 63.4 (7) 60.4 (14)  
Sosa, 1996 16 59.2 (8.3) 61.3 (7) 58.8 (8.5)  
Starup-L, 2016 100 65.2 (7.7) 65.2 (7.7)   
Suzuki, 2005 64 54.9 (11.4) 55 (11.7) 54.7 (10.7)  
Takashi, 2017 100 59.2 (1.4) 59.2 (1.4)   
Takizawa, 2008 76 55.1 (13.6) 55.4 (14.8) 54.1 (9)  
Tonks, 2017 25 57.4 (9) 61.1 (8.5) 56.1 (9)  
Villafan-B, 2014 33 50.2 (8) 51.5 (9.3) 49.5 (7.1)  
Wang, 2013 100 51.9 (13.3) 51.9 (13.3)   
Weiler, 2013 0 45.3 (13.6)    
Witzke, 2011 63 55.3 (9) 57.8 (9.3) 52.9 (7.7)  
Xuan, 2015 0 54.9 (11.1)  54.9 (11.1)  
Yamamoto, 2012 52 64.8 (8.3) 64.7 (8.6) 64.8 (8.1)  
Ye, 2012 64 49.1 (8.5) 49.6 (8.2) 48.1 (8.9)  
Yeap, 2015 15 80 (4)    
Yoda, 2012 50 64.5 (13.5) 62 (12.9) 67 (13.7)  
Zhou, 2009 51 54.4 (11.9) 54.7 (11.8) 54.2 (11.9)  
Zhou, 2010 56 57.2 (4.8) 57.3 (5.3) 57 (4.1)  
Zhou, 2013 54 58.1 (6.8) 58.4 (5.7) 57.7 (7.8)  
Zhukouskaya, 2015 48 65.1 (7.8) 65.7 (7.3) 64.5 (8.2)  
Zwakenberg, 2015 51 53.8 (3.9) 57 (1.8) 50.5 (2.6)  
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First 
Author, 
Year 
Sex 
(male/ 
female/ 
both) 
Female 
(%) 
Women 
postmenopausal 
(%) 
Impaired 
renal 
function 
(Y/N/NG) 
Any anti-
diabetic 
medications 
(Y/N/NG) 
Any 
medications 
affect bone 
metabolism 
(Y/N/NG) 
Achemlal, 
2005 
male   N Y N 
Akin, 2003 female 100 100 NG NG N 
Alfadda, 
2013 
both   NG NG N 
Alselami, 
2015 
female 100 100 NG NG NG 
Aoki, 2011 both 18 100 NG N N 
Ardawi, 2013 female 100 100 N Y N 
Bador, 2016 both 34 97 NG Y N 
Bao, 2011 both 51 67 NG Y N 
Barghash, 
2014 
male   N Y N 
Berberoglu, 
2007 
female 100 100 NG NG N 
Bhattoa, 2013 male   N Y N 
Bothy, 2016    NG NG NG 
Bouillon, 
1995 
both   NG Y NG 
Buday, 2013 both 47  NG NG N 
Bullo, 2012 male   NG Y N 
Cakatay, 
1998 
both 54  N Y N 
Chen, 2014 male   N NG N 
Chen-H, 
2013 
both 61  Y NG N 
Chen-L, 2013 both 55 100 NG NG N 
Choudhury, 
2014 
female 100 48 NG N N 
Cui, 2014 male   NG NG N 
Cutrim, 2007 both 50 3 N Y N 
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First 
Author, 
Year 
Sex 
(male/ 
female/ 
both) 
Female 
(%) 
Women 
postmenopausal 
(%) 
Impaired 
renal 
function 
(Y/N/NG) 
Any anti-
diabetic 
medications 
(Y/N/NG) 
Any 
medications 
affect bone 
metabolism 
(Y/N/NG) 
De-Araujo, 
2017 
both 58  N N N 
Diaz-L, 2013 both 53  NG NG Y 
Dobnig, 2006 female 100 100 NG Y Y 
Furuyso, 
2013 
both 62 71 NG N N 
Garcia-M, 
2011 
female 100 100 N N N 
Garcia-M, 
2012 
both 48  NG NG N 
Gennari, 
2012 
both 51 0 N Y N 
Gerdhem, 
2005 
female 100 100 Y NG NG 
Gonzalez-G, 
2015 
both 64  NG NG NG 
Gradinaru, 
2009 
both 75 0 NG Y N 
Gregorio, 
1994 
both 54 100 N Y N 
Hwang, 2012 both 48  NG NG N 
Hwang, 2012 male   NG NG N 
Iglesias, 2011 both 53  NG Y N 
Iki, 2012 male   NG NG N 
Im, 2008 female 100 100 NG NG N 
Inaba, 1999 male   N Y N 
Inukai, 1997 both 54  Y Y N 
Ivaska, 2017 both 91  NG NG N 
Juanola-F, 
2013 
both 52 100 NG NG N 
Jung, 2016 both 59  N N N 
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First 
Author, 
Year 
Sex 
(male/ 
female/ 
both) 
Female 
(%) 
Women 
postmenopausal 
(%) 
Impaired 
renal 
function 
(Y/N/NG) 
Any anti-
diabetic 
medications 
(Y/N/NG) 
Any 
medications 
affect bone 
metabolism 
(Y/N/NG) 
Kanazawa, 
2008 
male   N Y N 
Kanazawa, 
2009 
both 45 100 N Y N 
Kanazawa, 
2011 
both 40  N N N 
Karar, 2007 female 100 100 N Y N 
Kindblom, 
2009 
male   NG Y NG 
Klimontov, 
2016 
female 100  N Y N 
Lerchbaum, 
2015 
both 46 60 NG Y N 
Levinger, 
2011 
male   NG Y Y 
Liang, 2016 male   N Y N 
Liao, 2015 male   NG Y N 
Liatis, 2014 both 50  N NG N 
Lopes, 2015 female 100 100 NG Y N 
Ma, 2015 both 50 100 NG Y N 
Maghbooli, 
2016 
both 61  NG NG N 
Maghbooli, 
2016 
both 53  NG NG N 
Malecha-J, 
2012 
both 51  N NG NG 
Manavalan, 
2012 
female 100 100 N Y N 
Maser, 2015 both 58  NG Y NG 
Mori, 2012 both 39  NG Y N 
Movahed, 
2012 
female 100 100 N Y N 
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First 
Author, 
Year 
Sex 
(male/ 
female/ 
both) 
Female 
(%) 
Women 
postmenopausal 
(%) 
Impaired 
renal 
function 
(Y/N/NG) 
Any anti-
diabetic 
medications 
(Y/N/NG) 
Any 
medications 
affect bone 
metabolism 
(Y/N/NG) 
Nan, 2016 female 100 100 N NG N 
Ngarmukos, 
2012 
male   NG NG NG 
Ogawa-F, 
2013 
both 48 100 NG NG N 
Oren, 2011 male   NG NG N 
Oz, 2006 both 71 85 N Y N 
Pietschmann, 
1988 
both 35  N Y N 
Pooruk, 2009 female 100 100 NG NG NG 
Raska, 2017 female 100 100 N NG N 
Reyes-G, 
2013 
both 49  N NG N 
Rico, 1989 both 61  NG Y N 
Rivera.Leon, 
2015 
both 59  NG NG N 
Rosato, 1998 both 45 100 N NG N 
Rui, 2014 both 58 100 NG NG N 
Sahin, 2002 female 100 100 N NG N 
Sakai, 2013 female 100 100 NG Y N 
Sanchez-E, 
2017 
both 58  NG NG N 
Sarkar, 2012 male   N Y N 
Sarkar, 2013 both 47  NG N N 
Shanbhogue, 
2016 
both 59 75 N Y N 
Sheng, 2013 both 53 100 NG Y NG 
Shu, 2012 female 100 100 N Y N 
Sosa, 1996 female 100 99 N NG N 
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First 
Author, 
Year 
Sex 
(male/ 
female/ 
both) 
Female 
(%) 
Women 
postmenopausal 
(%) 
Impaired 
renal 
function 
(Y/N/NG) 
Any anti-
diabetic 
medications 
(Y/N/NG) 
Any 
medications 
affect bone 
metabolism 
(Y/N/NG) 
Starup-L, 
2016 
male  100 Y Y N 
Suzuki, 2005 male  100 N Y N 
Takashi, 
2017 
both 18 100 NG Y N 
Takizawa, 
2008 
male  100 N Y N 
Tonks, 2017 both 51 71 NG Y N 
Villafan-B, 
2014 
both 50 18 NG Y N 
Wang, 2013 both 30 85 NG NG N 
Weiler, 2013 female 100  NG NG NG 
Witzke, 2011 male   N NG N 
Xuan, 2015 female 100 63 NG N N 
Yamamoto, 
2012 
both 63 100 N Y N 
Ye, 2012 both 48 48 N NG N 
Yeap, 2015 male   NG Y N 
Yoda, 2012 both 35  N Y N 
Zhou, 2009 both 49 73 N N N 
Zhou, 2010 female 100 100 N Y N 
Zhou, 2013 female 100 100 N Y N 
Zhukouskaya, 
2015 
female 100 100 N NG N 
Zwakenberg, 
2015 
both 77 48 NG Y N 
       
 
*Y: yes; N: no; NG: not given.
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Figure 36 The quality assessment of 78 cross-sectional studies based on Newcastle-Ottawa-Scale 
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Figure 37 The quality assessment of 7 cohort studies based on Newcastle-Ottawa-Scale 
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Figure 38 The quality assessment of case-control studies based on Newcastle-Ottawa-Scale 
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Appendix 5: the PRISMA checklist 
 
Section/topic  # Checklist item  
Reported 
on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or 
both.  
Page I 
ABSTRACT   
Structured 
summary  
2 Provide a structured summary including, as applicable: 
background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis 
methods; results; limitations; conclusions and implications of 
key findings; systematic review registration number.  
Page 1 - 2 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is 
already known.  
Page 3 - 15 
Objectives  4 Provide an explicit statement of questions being addressed 
with reference to participants, interventions, comparisons, 
outcomes, and study design (PICOS).  
Page 15 -
16 
METHODS   
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be 
accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
Page 16 
Eligibility 
criteria  
6 Specify study characteristics (e.g., PICOS, length of follow-
up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, 
giving rationale.  
Page 16 -
19 
Information 
sources  
7 Describe all information sources (e.g., databases with dates of 
coverage, contact with study authors to identify additional 
studies) in the search and date last searched.  
Page 19 
Search  8 Present full electronic search strategy for at least one 
database, including any limits used, such that it could be 
repeated.  
Page 19 -
21 
Study selection  9 State the process for selecting studies (i.e., screening, 
eligibility, included in systematic review, and, if applicable, 
included in the meta-analysis).  
Page 22 
Data collection 
process  
10 Describe method of data extraction from reports (e.g., piloted 
forms, independently, in duplicate) and any processes for 
obtaining and confirming data from investigators.  
Page 22 - 
23 
Data items  11 List and define all variables for which data were sought (e.g., 
PICOS, funding sources) and any assumptions and 
simplifications made.  
Page 23 - 
24 
Risk of bias in 
individual 
12 Describe methods used for assessing risk of bias of individual 
studies (including specification of whether this was done at 
Page 24 
 145 
studies  the study or outcome level), and how this information is to be 
used in any data synthesis.  
Summary 
measures  
13 State the principal summary measures (e.g., risk ratio, 
difference in means).  
Page 24 - 
25 
Synthesis of 
results  
14 Describe the methods of handling data and combining results 
of studies, if done, including measures of consistency (e.g., I2) 
for each meta-analysis.  
Page 25 
 
Risk of bias 
across studies  
15 Specify any assessment of risk of bias that may affect the cumulative 
evidence (e.g., publication bias, selective reporting within studies).  
Page 25 - 
26 
Additional 
analyses  
16 Describe methods of additional analyses (e.g., sensitivity or subgroup 
analyses, meta-regression), if done, indicating which were pre-
specified.  
Page 26 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and 
included in the review, with reasons for exclusions at each stage, 
ideally with a flow diagram.  
Page 27 – 
30, 
Appendix 
3 
Study 
characteristics  
18 For each study, present characteristics for which data were extracted 
(e.g., study size, PICOS, follow-up period) and provide the citations.  
Page 30 – 
32, 
Appendix 
3 
Risk of bias 
within studies  
19 Present data on risk of bias of each study and, if available, any 
outcome level assessment (see item 12).  
Page 50 - 
51 
Results of 
individual 
studies  
20 For all outcomes considered (benefits or harms), present, for each 
study: (a) simple summary data for each intervention group (b) effect 
estimates and confidence intervals, ideally with a forest plot.  
Page 33 -
47, 
Appendix 
2 
Synthesis of 
results  
21 Present results of each meta-analysis done, including confidence 
intervals and measures of consistency.  
Page 33 -
47, 
Appendix 
2 
Risk of bias 
across studies  
22 Present results of any assessment of risk of bias across studies (see 
Item 15).  
Page 47 - 
50 
Additional 
analysis  
23 Give results of additional analyses, if done (e.g., sensitivity or 
subgroup analyses, meta-regression [see Item 16]).  
Page 47 -
50, 
Appendix 
3 
DISCUSSION   
Summary of 
evidence  
24 Summarize the main findings including the strength of evidence for 
each main outcome; consider their relevance to key groups (e.g., 
healthcare providers, users, and policy makers).  
Page 51- 
56 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and 
at review-level (e.g., incomplete retrieval of identified research, 
reporting bias).  
Page 56- 
57 
Conclusions  26 Provide a general interpretation of the results in the context of other 
evidence, and implications for future research.  
Page 57- 
58 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other 
support (e.g., supply of data); role of funders for the systematic 
review.  
Appendix 
1 protocol 
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From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097  
For more information, visit: www.prisma-statement.org.  
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Appendix 6: the Newcastle-Ottawa Scale guidelines 
NEWCASTLE - OTTAWA QUALITY ASSESSMENT SCALE 
CASE CONTROL STUDIES 
Note: A study can be awarded a maximum of one star for each numbered item within the Selection and 
Exposure categories. A maximum of two stars can be given for Comparability. 
Selection 
1) Is the case definition adequate? 
a) yes, with independent validation ¯ 
b) yes, eg record linkage or based on self reports 
c) no description 
2) Representativeness of the cases 
a) consecutive or obviously representative series of cases ¯ 
b) potential for selection biases or not stated 
3) Selection of Controls 
a) community controls ¯ 
b) hospital controls 
c) no description 
4) Definition of Controls 
a) no history of disease (endpoint) ¯ 
b) no description of source 
Comparability 
1) Comparability of cases and controls on the basis of the design or analysis 
a) study controls for _______________ (Select the most important factor.) ¯ 
b) study controls for any additional factor ¯ (This criteria could be modified to indicate specific 
control for a second important factor.) 
Exposure 
1) Ascertainment of exposure 
a) secure record (eg surgical records) ¯ 
b) structured interview where blind to case/control status ¯ 
c) interview not blinded to case/control status 
d) written self report or medical record only 
e) no description 
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2) Same method of ascertainment for cases and controls 
a) yes ¯ 
b) no 
3) Non-Response rate 
a) same rate for both groups ¯ 
b) non respondents described 
c) rate different and no designation 
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NEWCASTLE - OTTAWA QUALITY ASSESSMENT SCALE 
COHORT STUDIES 
Note: A study can be awarded a maximum of one star for each numbered item within the Selection and 
Outcome categories. A maximum of two stars can be given for Comparability 
Selection 
1) Representativeness of the exposed cohort 
a) truly representative of the average _______________ (describe) in the community ¯ 
b) somewhat representative of the average ______________ in the community ¯ 
c) selected group of users eg nurses, volunteers 
d) no description of the derivation of the cohort 
2) Selection of the non exposed cohort 
a) drawn from the same community as the exposed cohort ¯ 
b) drawn from a different source 
c) no description of the derivation of the non exposed cohort 
3) Ascertainment of exposure 
a) secure record (eg surgical records) ¯ 
b) structured interview ¯ 
c) written self report 
d) no description 
4) Demonstration that outcome of interest was not present at start of study 
a) yes ¯ 
b) no 
Comparability 
1) Comparability of cohorts on the basis of the design or analysis 
a) study controls for _____________ (select the most important factor) ¯ 
b) study controls for any additional factor ¯ (This criteria could be modified to indicate specific 
control for a second important factor.) 
Outcome 
1) Assessment of outcome 
a) independent blind assessment ¯ 
b) record linkage ¯ 
c) self report 
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d) no description 
2) Was follow-up long enough for outcomes to occur 
a) yes (select an adequate follow up period for outcome of interest) ¯ 
b) no 
3) Adequacy of follow up of cohorts 
a) complete follow up - all subjects accounted for ¯ 
b) subjects lost to follow up unlikely to introduce bias - small number lost - > ____ % (select an 
adequate %) follow up, or description provided of those lost) ¯ 
c) follow up rate < ____% (select an adequate %) and no description of those lost 
d) no statement 
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NEWCASTLE - OTTAWA QUALITY ASSESSMENT SCALE  
(adapted for cross sectional studies)  
Selection: (Maximum 5 stars)  
1) Representativeness of the sample:  
a) Truly representative of the average in the target population. * (all subjects or random 
sampling)  
b) Somewhat representative of the average in the target population. * (non-random sampling)  
c) Selected group of users.  
d) No description of the sampling strategy.  
2) Sample size:  
a) Justified and satisfactory. *  
b) Not justified.  
3) Non-respondents:  
a) Comparability between respondents and non-respondents characteristics is established, and the 
response rate is satisfactory. *  
b) The response rate is unsatisfactory, or the comparability between respondents and non-
respondents is unsatisfactory.  
c) No description of the response rate or the characteristics of the responders and the non-
responders.  
4) Ascertainment of the exposure (risk factor):  
a) Validated measurement tool. **  
b) Non-validated measurement tool, but the tool is available or described.*  
c) No description of the measurement tool.  
Comparability: (Maximum 2 stars)  
1) The subjects in different outcome groups are comparable, based on the study design or 
analysis. Confounding factors are controlled.  
a) The study controls for the most important factor (select one). *  
b) The study control for any additional factor. *  
Outcome: (Maximum 3 stars)  
1) Blood test. ** 
a) Independent blind assessment. **  
b) Record linkage. **  
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c) Self report. *  
d) No description.  
2) Statistical test:  
a) The statistical test used to analyze the data is clearly described and appropriate, and the 
measurement of the association is presented, including confidence intervals and the probability 
level (p value). *  
b) The statistical test is not appropriate, not described or incomplete. PA Modesti et al. Panethnic 
differences in blood pressure in europe: a systematic review and meta-analysis. S1 Text  
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Appendix 7: the codes in Rstudio for data synthesis 
---2017/11/01--2018/03/01 
# Practice meta analysis 2 after armando's help 
--- 
 
# Loading r packages ------------------- 
library(compute.es)  # to compute effect sizes which is a value that reflects  
#the magnitude of a relationship(or differebce) between two variables 
library(MAd) 
library(metafor) 
library(rmeta) 
library(meta) 
settings.meta("revman5") 
settings.meta("jama") 
 
# read csv file--------------------- 
getwd() 
setwd("/Users/yihuiliu/Downloads/") 
#define the workbook by csv which is more feasible than read excel 
dfoc <- read.csv('123456impro.csv') 
dfoc 
# Give 'NA' to categorical variables -------- 
    dfoc[dfoc==""]=NA  
 
 
###============TOC SECTION  
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# A: MD TOC T2DM vs. NGC ------------------------------- 
 
#-----(1) MD random effect TOC 
  dfoc1 <- escalc(n2i = nc, n1i = nt, m2i = mtoc, m1i = mto,  
                    sd2i = sdmtoc, sd1i = sdmto, data = dfoc, measure = "MD",  
                    append = TRUE) 
  dfoc1 <- dfoc1[!is.na(dfoc1$yi) & !is.na(dfoc1$vi),] 
  model1 <- rma(yi,vi,data=dfoc1) 
  summary(model1) 
   
  par(mar=c(4,5,0.5,5)) 
  forest(model1, 
         ilab=dfoc1$ss, ilab.xpos = -50, 
         order=order(dfoc1$ye,dfoc1$au), 
         slab=paste(dfoc1$au, as.character(dfoc1$ye),sep=','), font=1,cex=0.75, 
         showweights = TRUE) 
   
  # add text with Q-value, dfs,p-value, and I2 statistics for subgroups 
  text(-70,-1,pos=4,cex=0.75,bquote(paste("(Q=",.(formatC(model1$QE,digits=2,format="f")),",df 
=",.(model1$k - 
model1$p),",p=",.(formatC(model1$QEp,digits=2,format="f")),";",I^2,"=",.(formatC(model1$I2,digit
s=1,format="f")),"%)"))) 
  #generate names for items 
  text(-60,66,'Sample Size',pos=4,cex=0.8,font=4) 
  text(-88,66,'Author(s) and Year',pos=4,cex=0.8,font=4) 
  text(50,66,'Mean Difference[95% CI]',pos=4,cex=0.8,font=4) 
  text(45,66,'Weights(%)',pos=4,cex=0.8,font=4) 
   
   
## heterogeneity tests(Radial plot, Baujat plot)------- 
  #Radial plot ## galbraith 
  radial(model1, level=0.95,xlab="Inverse of standard error",zlab="Standardised effect size (z-score) 
") 
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  #Baujat plot 
  baujat(model1,xlab="Contribution to overall heterogeneity",ylab="Influence on overall result") 
   
   
## publication bias analysis-------- 
  #random version of Egger's test, for class 'rma' 
  rega <-regtest(model1, model="rma", ret.fit=FALSE) 
   
  #funnel plots contour-enhanced funnel plot centreed at 0 (see Peters et al., 2008) 
  par(mar=c(5,5,4,2),mfrow=c(1, 1)) 
  trfa <- trimfill(model1) 
  funnel(trfa,comb.rma=TRUE,level=c(90, 95, 99), shade=c("light blue", "blue", "dark 
blue"),refline=0) 
  legend(15, -0.25, 
         c("p>0.1", "0.05 < p < 0.1","0.01 < p < 0.05", "p< 0.01","studies","added studies"), 
         #p shows the significance/non-significance of effect 
         fill=c("light blue", "blue", "dark blue","light grey","black","white"))     
   
  #label eggers'regression test 
  text(-25,0.5,cex=0.85,pos=1,"Egger's regression test: ") 
  text(-25,1.25,cex=0.85,pos=1,bquote(paste("p=",.(formatC(rega$pval,digits=2)),", 
z=",.(formatC(rega$zval,digits=2))))) 
 
  title(main="The trim-filled contour-enhanced funnel plot of the MD of TOC in T2DM 
vs.NGC.across 64 studies",cex.main=1) 
  
    # A: meta-regression-------------- 
          #-for mean difference 
          #-can include moderators/predictors/covariates in the model 
          #-to account for heterogeneity 
          # from a to n 
 
        # A.a.study type (st)------- 
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      factor(dfoc1$st) ##---remove NA value in level 
     
      dfoc1.a <- dfoc1[!is.na(dfoc1$yi) & !is.na(dfoc1$vi) & !is.na(dfoc1$st),] 
      summary(dfoc1.a) 
       
      model1.a <- rma(yi,vi,mods=~factor(st), data=dfoc1.a,'REML') 
      model1.a 
       
        # A.b.proportion of T2DM (pt)------- 
      dfoc1.b <- dfoc1[!is.na(dfoc1$yi) & !is.na(dfoc1$vi) & !is.na(dfoc1$pt),] 
      summary(dfoc1.b) 
       
      model1.b <- rma(yi,vi,mods= ~pt, data=dfoc1.b,'REML') 
      model1.b 
       
        # A.c.mean age overall(ma)-------- 
      dfoc1.c <- dfoc1[!is.na(dfoc1$ma),] 
      summary(dfoc1.c) 
       
      model1.c <- rma(yi,vi,mods= ~ma, data=dfoc1.c,'REML') 
      model1.c 
       
        # A.d.sex(sex)------- 
      factor(dfoc1$sex)  
      dfoc1.d <- dfoc1[!is.na(dfoc1$yi) & !is.na(dfoc1$vi) & !is.na(dfoc1$sex),] 
      summary(dfoc1.d) 
       
      model1.d <- rma(yi,vi,mods= ~factor(sex), data=dfoc1.d,'REML') 
      model1.d 
       
        # A.e.proportion of female(pof)-------- 
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      dfoc1.e <- dfoc1[!is.na(dfoc1$pof),] 
      summary(dfoc1.e) 
       
      model1.e <- rma(yi,vi,mods= ~pof, data=dfoc1.e,'REML') 
      model1.e 
       
        # A.f.proportion of postmenopausal (ppom)-------- 
      dfoc1.f <- dfoc1[!is.na(dfoc1$ppom),] 
      summary(dfoc1.f) 
       
      model1.f <- rma(yi,vi,mods= ~ppom, data=dfoc1.f,'REML') 
      model1.f 
       
        # A.g.continent (cont)-------- 
      factor(dfoc1$cont)  
      dfoc1.g <- dfoc1[!is.na(dfoc1$yi) & !is.na(dfoc1$vi) & !is.na(dfoc1$cont),] 
      summary(dfoc1.g) 
       
      model1.g <- rma(yi,vi,mods= ~factor(cont), data=dfoc1.g,'REML') 
      model1.g 
   
        # A.h.ethnicity (eth)----------- 
      factor(dfoc1$eth)  
      dfoc1.h <- dfoc1[!is.na(dfoc1$yi) & !is.na(dfoc1$vi) & !is.na(dfoc1$eth),] 
      summary(dfoc1.h) 
       
      model1.h <- rma(yi,vi,mods= ~factor(eth), data=dfoc1.h,'REML') 
      model1.h 
   
        # A.i.matched variable(s) (mv)----------- 
      factor(dfoc1$mv)  
      dfoc1.i <- dfoc1[!is.na(dfoc1$yi) & !is.na(dfoc1$vi) & !is.na(dfoc1$mv),] 
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      summary(dfoc1.i) 
       
      model1.i <- rma(yi,vi,mods= ~factor(mv), data=dfoc1.i,'REML') 
      model1.i 
       
        # A.j.use ofantidiabetic drugs (atd)---------- 
      factor(dfoc1$atd)  
      dfoc1.j <- dfoc1[!is.na(dfoc1$yi) & !is.na(dfoc1$vi) & !is.na(dfoc1$atd),] 
      summary(dfoc1.j) 
       
      model1.j <- rma(yi,vi,mods= ~factor(atd), data=dfoc1.j,'REML') 
      model1.j 
     
        # A.k.use drugs mediate bone metabolism (bmd)---------- 
      factor(dfoc1$bmd)  
      dfoc1.k <- dfoc1[!is.na(dfoc1$yi) & !is.na(dfoc1$vi) & !is.na(dfoc1$bmd),] 
      summary(dfoc1.k) 
       
      model1.k <- rma(yi,vi,mods= ~factor(bmd), data=dfoc1.k,'REML') 
      model1.k 
       
        # A.l.assays for toc (asto)------------ 
      factor(dfoc1$asto)  
      dfoc1.l <- dfoc1[!is.na(dfoc1$yi) & !is.na(dfoc1$vi) & !is.na(dfoc1$asto),] 
      summary(dfoc1.l) 
       
      model1.l <- rma(yi,vi,mods= ~factor(asto), data=dfoc1.l) 
      model1.l 
       
      anova(model1.l,btt=2:7) 
   
        # A.m.study base (stba)----------- 
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      factor(dfoc1$stba)  
      dfoc1.m <- dfoc1[!is.na(dfoc1$yi) & !is.na(dfoc1$vi) & !is.na(dfoc1$stba),] 
      summary(dfoc1.m) 
       
      model1.m <- rma(yi,vi,mods= ~factor(stba), data=dfoc1.m) 
      model1.m 
       
        # A.n.imparied renal function (renal)--------- 
      factor(dfoc1$renal)  
      dfoc1.n <- dfoc1[!is.na(dfoc1$yi) & !is.na(dfoc1$vi) & !is.na(dfoc1$renal),] 
      summary(dfoc1.n) 
       
      model1.n <- rma(yi,vi,mods= ~factor(renal), data=dfoc1.n) 
      model1.n 
       
    # A: mixed effect model test with backward stepwise regression----------- 
    ### ma, mv, asto    
      #step 1. incldue all variables in one model 
      dfoc1.o <- dfoc1[!is.na(dfoc1$yi) & !is.na(dfoc1$vi) & !is.na(dfoc1$ma) & !is.na(dfoc1$mv) 
& !is.na(dfoc1$asto),] 
      summary(dfoc1.o) 
      model1.o <- rma(yi,vi,mods= ~ma + factor(asto)+factor(mv), data=dfoc1.o) 
      model1.o 
       
      #step 2. compute the overall p values for each variables 
      # overall p value for ma 
      anova(model1.o,btt=1) 
      # overall p value for asto 
      anova(model1.o, btt = 2:5) 
      # overall p value for mv 
      anova(model1.o, btt = 6:12) 
       
      #step3. remove ma from model as it got the biggest p value 
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      model1.o.2 <- rma(yi,vi,mods= ~ factor(asto)+factor(mv), data=dfoc1.o) 
      model1.o.2 
       
      #step 4. compute the overall p values for each variables 
      # overall p value for asto 
      anova(model1.o.2, btt = 2:5) 
      # overall p value for mv 
      anova(model1.o.2, btt = 6:12) 
       
      #step 5. remove mv with p=0.166 
      model1.o.3 <- rma(yi,vi,mods= ~ factor(asto), data=dfoc1.o) 
      model1.o.3 
       
      #compute the overall p values for each variables 
      # overall p value for asto 
      anova(model1.o.3, btt = 1:5) 
       
      #removal action stopped as the p value <0.0001. asto is selected 
       
    # A: subgroup analysis based on "asto" for MD-------------- 
       
      #remove asto of "EIA","IHC" and "HAP" as they dont have engough number of studies 
      dfoc1.l.reM <- dfoc1.l[!dfoc1.l$asto=="EIA" & !dfoc1.l$asto=="IHC" & !dfoc1.l$asto=="HAP",]  
       
      model1.fnf <- rma(yi,vi,data = dfoc1.l.reM,method='REML') #final model after removal  
       
      par(mar=c(4,5,0.5,5)) 
       
      forest(model1.fnf, 
             xlim=c(-80,50),ylim=c(0,79), 
             order=order(dfoc1.l.reM$asto,dfoc1.l.reM$ye, dfoc1.l.reM$au), 
             ilab=dfoc1.l.reM$ss, ilab.xpos = -50, 
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             cex=0.75,psize=1.25, 
             refline = 0, 
             rows=c(3:21,27:48,54:60,66:74), 
             slab=paste(dfoc1.l.reM$au, as.character(dfoc1.l.reM$ye),sep=','), font=1) 
      # insert overall heterogeneity to plot 
      text(-70,-
1,pos=4,cex=0.65,bquote(paste("(Q=",.(formatC(model1.fnf$QE,digits=2,format="f")),",df 
=",.(model1.fnf$k - 
model1.fnf$p),",p=",.(formatC(model1.fnf$QEp,digits=2,format="f")),";",I^2,"=",.(formatC(model1.f
nf$I2,digits=1,format="f")),"%)"))) 
       
      #generate subgroups based on asto 
      eclia.1 <- rma(yi,vi,data=dfoc1.l.reM,measure='MD',subset=(asto=='ECLIA'),method='REML') 
      elisa.1 <- rma(yi,vi,data=dfoc1.l.reM,measure='MD',subset=(asto=='ELISA'),method='REML') 
      irma.1 <-  rma(yi,vi,data=dfoc1.l.reM,measure='MD',subset=(asto=='IRMA'),method='REML') 
      ria.1 <-  rma(yi,vi,data=dfoc1.l.reM,measure='MD',subset=(asto=='RIA'),method='REML') 
       
      #generate subgroup measurements results 
      addpoly(eclia.1,row=1,cex=0.75,font=4) 
      addpoly(elisa.1,row=25,cex=0.75,font=4) 
      addpoly(irma.1,row=52,cex=0.75,font=4) 
      addpoly(ria.1,row=64,cex=0.75,font=4) 
       
       
      #give names to items 
      text(-50,78,'Sample Size',pos=4,cex=0.8,font=4) 
      text(-80,78,'Author(s) and Year',pos=4,cex=0.8,font=4) 
      text(-80,23,'ECLIA',pos=4,cex=0.8,font=4) 
      text(-80,50,'ELISA',pos=4,cex=0.8,font=4) 
      text(-80,62,'IRMA',pos=4,cex=0.8,font=4) 
      text(-80,76,'RIA',pos=4,cex=0.8,font=4) 
      text(27,78,'Mean Difference[95% CI]',pos=4,cex=0.8,font=4) 
       
      # add text with Q-value, dfs,p-value, and I2 statistics for subgroups 
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      text(-70,1,pos=4,cex=0.65,bquote(paste("(Q=",.(formatC(eclia.1$QE,digits=2,format="f")),",df 
=",.(eclia.1$k - 
eclia.1$p),",p=",.(formatC(eclia.1$QEp,digits=2,format="f")),";",I^2,"=",.(formatC(eclia.1$I2,digits=
1,format="f")),"%)"))) 
      text(-70,25,pos=4,cex=0.65,bquote(paste("(Q=",.(formatC(elisa.1$QE,digits=2,format="f")),",df 
=",.(elisa.1$k - 
elisa.1$p),",p=",.(formatC(elisa.1$QEp,digits=2,format="f")),";",I^2,"=",.(formatC(elisa.1$I2,digits=
1,format="f")),"%)"))) 
      text(-70,52,pos=4,cex=0.65,bquote(paste("(Q=",.(formatC(irma.1$QE,digits=2,format="f")),",df 
=",.(irma.1$k - 
irma.1$p),",p=",.(formatC(irma.1$QEp,digits=2,format="f")),";",I^2,"=",.(formatC(irma.1$I2,digits=
1,format="f")),"%)"))) 
      text(-70,64,pos=4,cex=0.65,bquote(paste("(Q=",.(formatC(ria.1$QE,digits=2,format="f")),",df 
=",.(ria.1$k - 
ria.1$p),",p=",.(formatC(ria.1$QEp,digits=2,format="f")),";",I^2,"=",.(formatC(ria.1$I2,digits=1,form
at="f")),"%)"))) 
   
    # A: subgroup analysis based on "st" for MD-------------- 
       #remove asto of "baseline of intervention" they do not have engough number of studies 
          #Beberglu 2007 [7], Yoda2012 [59] 
      dfoc1.a.reM <- dfoc1.a[-cbind(7,59),]  
       
      model1.fna <- rma(yi,vi,data = dfoc1.a.reM,method='REML') #final model after removal  
       
      par(mar=c(4,5,0,3)) 
       
      forest(model1.fna, 
             xlim=c(-80,50),ylim=c(0,79), 
             order=order(dfoc1.a.reM$st,dfoc1.a.reM$ye, dfoc1.a.reM$au), 
             ilab=dfoc1.a.reM$ss, ilab.xpos = -50, 
             cex=0.75,psize=1.25, 
             refline = 0, 
             rows=c(3:17,23:25,31:74), 
             slab=paste(dfoc1.a.reM$au, as.character(dfoc1.a.reM$ye),sep=','), font=1) 
      # insert overall heterogeneity to plot 
      text(-70,-
1,pos=4,cex=0.65,bquote(paste("(Q=",.(formatC(model1.fna$QE,digits=2,format="f")),",df 
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=",.(model1.fna$k - 
model1.fna$p),",p=",.(formatC(model1.fna$QEp,digits=2,format="f")),";",I^2,"=",.(formatC(model1.
fna$I2,digits=1,format="f")),"%)"))) 
       
      #generate subgroups based on asto 
      cr.1 <- rma(yi,vi,data=dfoc1.a.reM,measure='MD',subset=(st=='cross.sectional'),method='REML') 
      ca.1 <- rma(yi,vi,data=dfoc1.a.reM,measure='MD',subset=(st=='case.control'),method='REML') 
      co.1 <-  rma(yi,vi,data=dfoc1.a.reM,measure='MD',subset=(st=='cohort'),method='REML') 
       
       
      #generate subgroup measurements results 
      addpoly(cr.1,row=29,cex=0.75,font=4) 
      addpoly(ca.1,row=1,cex=0.75,font=4) 
      addpoly(co.1,row=21,cex=0.75,font=4) 
       
       
      #give names to items 
      text(-55,78,'Sample Size',pos=4,cex=0.8,font=4) 
      text(-80,78,'Author(s) and Year',pos=4,cex=0.8,font=4) 
      text(-80,76,'Cross-sectioanl',pos=4,cex=0.8,font=4) 
      text(-80,27,'Cohort',pos=4,cex=0.8,font=4) 
      text(-80,19,'Case-control',pos=4,cex=0.8,font=4) 
      text(23,78,'Mean Difference[95% CI]',pos=4,cex=0.8,font=4) 
       
      # add text with Q-value, dfs,p-value, and I2 statistics for subgroups 
      text(-70,1,pos=4,cex=0.65,bquote(paste("(Q=",.(formatC(ca.1$QE,digits=2,format="f")),",df 
=",.(ca.1$k - 
ca.1$p),",p=",.(formatC(ca.1$QEp,digits=2,format="f")),";",I^2,"=",.(formatC(ca.1$I2,digits=1,forma
t="f")),"%)"))) 
      text(-70,21,pos=4,cex=0.65,bquote(paste("(Q=",.(formatC(co.1$QE,digits=2,format="f")),",df 
=",.(co.1$k - 
co.1$p),",p=",.(formatC(co.1$QEp,digits=2,format="f")),";",I^2,"=",.(formatC(co.1$I2,digits=1,forma
t="f")),"%)"))) 
      text(-70,29,pos=4,cex=0.65,bquote(paste("(Q=",.(formatC(cr.1$QE,digits=2,format="f")),",df 
=",.(cr.1$k - 
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cr.1$p),",p=",.(formatC(cr.1$QEp,digits=2,format="f")),";",I^2,"=",.(formatC(cr.1$I2,digits=1,format
="f")),"%)"))) 
   
       
       
       
       
       
# B: r TOC - FINS------------------------------- 
   #(2) r-pearson TOC-fasting insulin-raw 
  dfoc2 <- escalc(ri= pcrtois,ni=ss,measure='COR',data= dfoc,append = TRUE) 
  dfoc2 <- dfoc2[!is.na(dfoc2$yi) & !is.na(dfoc2$vi),] 
  model2 <- rma(yi,vi,data = dfoc2,method='REML') 
  model2 
  forest(model2,slab = paste(dfoc2$au, as.character(dfoc2$ye), sep = ", "), cex=0.75,lwd=1) 
   
## heterogeneity tests(Radial plot, Baujat plot)-------- 
  #Radial plot ## galbraith 
  radial(model2, level=0.95,xlab="Inverse of standard error",zlab="Standardised effect size (z-score) 
") 
   
  #Baujat plot 
  baujat(model2,xlab="Contribution to overall heterogeneity",ylab="Influence on overall result") 
   
   
## publication bias analysis---- 
  #random version of Egger's test, for class 'rma' 
  regb <-regtest(model2, model="rma", ret.fit=FALSE) 
  regb 
  #funnel plots contour-enhanced funnel plot centreed at 0 (see Peters et al., 2008) 
  par(mar=c(5,5,4,2),mfrow=c(1, 1)) 
  trfb <- trimfill(model2) 
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  funnel(trfb,comb.rma=TRUE,level=c(90, 95, 99), shade=c("light blue", "blue", "dark 
blue"),refline=0) 
  legend(0.11, -0.004, 
         c("p>0.1", "0.05 < p < 0.1","0.01 < p < 0.05", "p< 0.01","studies","added studies"), 
         #p shows the significance/non-significance of effect 
         fill=c("light blue", "blue", "dark blue","light grey","black","white"))     
   
  #label eggers'regression test 
  text(-0.3,-0.004,cex=0.85,pos=1,"Egger's regression test: ") 
  text(-0.3,-0.00001,cex=0.85,pos=1,bquote(paste("p=",.(formatC(regb$pval,digits=2)),", 
z=",.(formatC(regb$zval,digits=2))))) 
   
  title(main="The trim-filled contour-enhanced funnel plot of the correlation coefficient between TOC 
and FINS across 17 studies",cex.main=1) 
   
   
    # B: meta-regression model -------- 
        #-for r-pearson TOC-fasting insulin-raw 
        #-can include moderators/predictors/covariates in the model 
        #-to account for heterogeneity 
        # from a to n 
   
   
   
        # B.a.study type (st)--------- 
  
            factor(dfoc2$st) ##---remove NA value in level 
   
            dfoc2.a <- dfoc2[!is.na(dfoc2$yi) & !is.na(dfoc2$vi) & !is.na(dfoc2$st),] 
            summary(dfoc2.a) 
             
            model2.a <- rma(yi,vi,mods=~factor(st), data=dfoc2.a,'REML') 
            model2.a 
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        # B.b.proportion of T2DM (pt)-------- 
            dfoc2.b <- dfoc2[!is.na(dfoc2$yi) & !is.na(dfoc2$vi) & !is.na(dfoc2$pt),] 
            summary(dfoc2.b) 
             
            model2.b <- rma(yi,vi,mods= ~pt, data=dfoc2.b,'REML') 
            model2.b 
             
        # B.c.mean age overall(ma)--------- 
            dfoc2.c <- dfoc2[!is.na(dfoc2$ma),] 
            summary(dfoc2.c) 
             
            model2.c <- rma(yi,vi,mods= ~ma, data=dfoc2.c,'REML') 
            model2.c 
 
        # B.d.sex(sex)----------- 
            factor(dfoc2$sex)  
            dfoc2.d <- dfoc2[!is.na(dfoc2$yi) & !is.na(dfoc2$vi) & !is.na(dfoc2$sex),] 
            summary(dfoc2.d) 
             
            model2.d <- rma(yi,vi,mods= ~factor(sex), data=dfoc2.d,'REML') 
            model2.d 
 
        # B.e.proportion of female(pof)--------- 
            dfoc2.e <- dfoc2[!is.na(dfoc2$pof),] 
            summary(dfoc2.e) 
             
            model2.e <- rma(yi,vi,mods= ~pof, data=dfoc2.e,'REML') 
            model2.e 
   
        # B.f.proportion of postmenopausal (ppom)--------- 
            dfoc2.f <- dfoc2[!is.na(dfoc2$ppom),] 
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            summary(dfoc2.f) 
             
            model2.f <- rma(yi,vi,mods= ~ppom, data=dfoc2.f,'REML') 
            model2.f 
             
        # B.g.continent (cont)--------- 
            factor(dfoc2$cont)  
            dfoc2.g <- dfoc2[!is.na(dfoc2$yi) & !is.na(dfoc2$vi) & !is.na(dfoc2$cont),] 
            summary(dfoc2.g) 
             
            model2.g <- rma(yi,vi,mods= ~factor(cont), data=dfoc2.g,'REML') 
            model2.g 
   
   
        # B.h.ethnicity (eth)--------- 
            factor(dfoc2$eth)  
            dfoc2.h <- dfoc2[!is.na(dfoc2$yi) & !is.na(dfoc2$vi) & !is.na(dfoc2$eth),] 
            summary(dfoc2.h) 
   
            model2.h <- rma(yi,vi,mods= ~factor(eth), data=dfoc2.h,'REML') 
            model2.h 
   
        # B.i.matched variable(s) (mv)--------- 
            factor(dfoc2$mv)  
            dfoc2.i <- dfoc2[!is.na(dfoc2$yi) & !is.na(dfoc2$vi) & !is.na(dfoc2$mv),] 
            summary(dfoc2.i) 
             
            model2.i <- rma(yi,vi,mods= ~factor(mv), data=dfoc2.i,'REML') 
            model2.i 
   
        # B.j.use ofantidiabetic drugs (atd)--------- 
            factor(dfoc2$atd)  
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            dfoc2.j <- dfoc2[!is.na(dfoc2$yi) & !is.na(dfoc2$vi) & !is.na(dfoc2$atd),] 
            summary(dfoc2.j) 
             
            model2.j <- rma(yi,vi,mods= ~factor(atd), data=dfoc2.j,'REML') 
            model2.j 
   
        # B.k.use drugs mediate bone metabolism (bmd)-------- 
            factor(dfoc2$bmd)  
            dfoc2.k <- dfoc2[!is.na(dfoc2$yi) & !is.na(dfoc2$vi) & !is.na(dfoc2$bmd),] 
            summary(dfoc2.k) 
            ##ALL THE STUDIES HAS 'NO' for bmd 
        # B.l.assays for toc (asto)------------ 
            factor(dfoc2$asto)  
            dfoc2.l <- dfoc2[!is.na(dfoc2$yi) & !is.na(dfoc2$vi) & !is.na(dfoc2$asto),] 
            summary(dfoc2.l) 
             
            model2.l <- rma(yi,vi,mods= ~factor(asto), data=dfoc2.l) 
            model2.l 
   
        # B.m.study base (stba)---------- 
            factor(dfoc2$stba)  
            dfoc2.m <- dfoc2[!is.na(dfoc2$yi) & !is.na(dfoc2$vi) & !is.na(dfoc2$stba),] 
            summary(dfoc2.m) 
             
            model2.m <- rma(yi,vi,mods= ~factor(stba), data=dfoc2.m) 
            model2.m 
   
        # B.n.imparied renal function (renal)---------- 
            factor(dfoc2$renal)  
            dfoc2.n <- dfoc2[!is.na(dfoc2$yi) & !is.na(dfoc2$vi) & !is.na(dfoc2$renal),] 
            summary(dfoc2.n) 
            ## model not applicable as only three studies with all' n' for renal 
 169 
  
    # B: mixed effect model test with backward stepwise regression------------- 
    ### sex asto st ppom pt ma   
    #step 1. incldue all variables in one model 
    dfoc2.o <- dfoc2[!is.na(dfoc2$yi) & !is.na(dfoc2$vi) & !is.na(dfoc2$sex) & !is.na(dfoc2$asto) 
& !is.na(dfoc2$st) & !is.na(dfoc2$pt) & !is.na(dfoc2$ma),] 
    summary(dfoc2.o) 
    model2.o <- rma(yi,vi,mods= ~ factor(sex) + factor(asto)+factor(st) + pt +ma, data=dfoc2.o) 
    model2.o 
     
    #step 2. compute the overall p values for each variables 
    # overall p value for sex 
    anova(model2.o,btt=2:3) 
    # overall p value for asto 
    anova(model2.o, btt = 4:5) 
    # overall p value for st 
    anova(model2.o, btt = 6) 
    # overall p value for pt 
    anova(model2.o, btt = 7) 
    # overall p value for ma 
    anova(model2.o, btt = 8) 
     
     
    #step3. remove st from model as it got the biggest p value 
    model2.o.2 <- rma(yi,vi,mods= ~ factor(sex)+factor(asto) +pt +ma, data=dfoc2.o) 
    model2.o.2 
     
    #step4. compute the overall p values for each variables 
    # overall p value for sex 
    anova(model2.o.2,btt=2:3) 
    # overall p value for asto 
    anova(model2.o.2, btt = 4:5) 
    # overall p value for pt 
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    anova(model2.o.2, btt = 6) 
    # overall p value for ma 
    anova(model2.o.2, btt = 7) 
   
    #step5. remove ma from model as it got the biggest p value 
    model2.o.3 <- rma(yi,vi,mods= ~ factor(sex)+factor(asto) +pt, data=dfoc2.o) 
    model2.o.3 
     
    #step6. compute the overall p values for each variables 
    # overall p value for sex 
    anova(model2.o.3,btt=2:3) 
    # overall p value for asto 
    anova(model2.o.3, btt = 4:5) 
    # overall p value for pt 
    anova(model2.o.3, btt = 6) 
   
    #step7. remove asto from model as it got the biggst p value 
    model2.o.4 <- rma(yi,vi,mods= ~ factor(sex) +pt, data=dfoc2.o) 
    model2.o.4 
     
    #step8. compute the overall p values for each variables 
    # overall p value for sex 
    anova(model2.o.3,btt=2:3) 
    # overall p value for pt 
    anova(model2.o.3, btt = 4) 
     
     
    # B:fit the final model with forest plot-------- 
     
    dfoc2.o.re <- dfoc2.o[-cbind(3,11,12),] #remove "Choudhury pre" from data frame with 
consideration of duplication 
    model2.fn <- rma(yi,vi,data = dfoc2.o.re,method='REML') 
    model2.fn 
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    # generate forest plot 
     
    par(mar=c(4,0.5,0.5,1.5)) 
    forest(model2.fn, 
           xlim=c(-6,5),ylim=c(-1,17), 
           ilab=dfoc2.o.re$ss, ilab.xpos = -2.5, 
           cex=1,psize=1, 
           refline = 0, 
           slab=paste(dfoc2.o.re$au, as.character(dfoc2.o.re$ye),sep=','), font=1, 
           order = order(dfoc2.o.re$ye,dfoc2.o.re$au), 
           showweights = TRUE, 
           cex.lab  = 0.75) 
    text(-4.65,-
1,pos=4,cex=0.75,bquote(paste("(Q=",.(formatC(model2.fn$QE,digits=2,format="f")),",df 
=",.(model2.fn$k - 
model2.fn$p),",p=",.(formatC(model2.fn$QEp,digits=2,format="f")),";",I^2,"=",.(formatC(model2.fn
$I2,digits=1,format="f")),"%)"))) 
     
    #give names to items 
    text(-3,15.5,'Sample size',pos=4,cex=0.8,font=4) 
    text(-6,15.5,'Author(s) and Year',pos=4,cex=0.8,font=4) 
    text(2,15.5,'Coefficient   [95% CI]',pos=4,cex=0.8,font=4) 
    text(2,15.9,'Correlation',pos=4,cex=0.8,font=4) 
    text(0.85,15.5,'Weights',pos=4,cex=0.8,font=4) 
     
    funnel(model2.fn) # funnel plot 
     
        # B: how sex and pt expalined the heterogeneity in model 
            model2.o.3.re <- rma(yi,vi,mods= ~ factor(sex)+ pt, data=dfoc2.o.re) 
            model2.o.3.re 
            #after removing "Choudhury pre"------ 
            # R^2 = 64.11%, I^2 = 63.74% 
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    # B:subgroup analyses in men and postmenopausal women --------- 
    # B:subgroup analyses based on T2DM status ï¼ˆT2DM, all, healthy controlsï¼‰  ------- 
             
           dfoc2.ch <- dfoc2[-cbind(3,12),]# remove choudhury 2014 preM, Kindblom 2009 healthy 
            model2.ch <- rma(yi,vi, data=dfoc2.ch, "REML") 
            model2.ch 
            par(mar=c(4,2,0.5,2)) 
            factor(dfoc2.ch$tmoral)  
            forest(model2.ch, 
                   xlim=c(-6,3),ylim=c(-1,25), 
                   order=order(dfoc2.ch$tmoral,dfoc2.ch$ye,dfoc2.ch$au), 
                   ilab=dfoc2.ch$ss, ilab.xpos = -2.5, 
                   cex=1,psize=1, 
                   refline = 0, 
                   rows=c(2:6,11:20), 
                   slab=paste(dfoc2.ch$au, as.character(dfoc2.ch$ye),sep=','), font=1, 
                   cex.lab = .8) 
           <- rma(yi,vi,data=dfoc2.ch,measure='COR',subset=(tmoral=='T2DM'),method='REML') 
            al.2 <- rma(yi,vi,data=dfoc2.ch,measure='COR',subset=(tmoral=='all'),method='REML') 
            text(-4.8,-
1,pos=4,cex=0.85,bquote(paste("(Q=",.(formatC(model2.ch$QE,digits=2,format="f")),",df 
=",.(model2.ch$k - 
model2.ch$p),",p=",.(formatC(model2.ch$QEp,digits=2,format="f")),";",I^2,"=",.(formatC(model2.ch
$I2,digits=1,format="f")),"%)"))) 
             
            #generate subgroup measurements results 
            addpoly(al.2,row=0.7,cex=1,font=4) 
            addpoly(td.2,row=9.7,cex=1,font=4) 
             
            #give names to items 
            text(-3,23.5,'Sample size',pos=4,cex=.85,font=4) 
            text(-6,23.5,'Author(s) and Year',pos=4,cex=.85,font=4) 
            text(-6,7.5,'General population',pos=4,cex=1,font=4) 
            text(-6,22,'T2DM',pos=4,cex=1,font=4) 
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            text(0.6,23.5,'Coeffcient  [95% CI]',pos=4,cex=0.85,font=4) 
            text(0.6,24.5,'Correlation',pos=4,cex=0.85,font=4) 
             
            # add text with Q-value, dfs,p-value, and I2 statistics for subgroups 
            text(-
4.8,9.7,pos=4,cex=0.85,bquote(paste("(Q=",.(formatC(td.2$QE,digits=2,format="f")),",df =",.(td.2$k 
- 
td.2$p),",p=",.(formatC(td.2$QEp,digits=2,format="f")),";",I^2,"=",.(formatC(td.2$I2,digits=1,format
="f")),"%)"))) 
            text(-
4.8,0.7,pos=4,cex=0.85,bquote(paste("(Q=",.(formatC(al.2$QE,digits=2,format="f")),",df =",.(al.2$k 
- 
al.2$p),",p=",.(formatC(al.2$QEp,digits=2,format="f")),";",I^2,"=",.(formatC(al.2$I2,digits=1,format
="f")),"%)"))) 
             
             
             
     
     
             
# C: r TOC - HOMA-IR-------- 
  #----(3) r-pearson TOC-HOMA-IR-raw 
    dfoc3 <- escalc(ri= pcrtohm,ni=ss,measure='COR',data= dfoc,append = TRUE) 
    dfoc3 <- dfoc3[!is.na(dfoc3$yi) & !is.na(dfoc3$vi),] 
      dfoc3.o.re <- dfoc3[-cbind(3,13,14),] #remove kindblomT2 &HC,Choudhury preM 
    model3.fn <- rma(yi,vi,data = dfoc3.o.re,method='REML') 
    model3.fn 
     
    par(mar=c(4,2,0.5,2)) 
    forest(model3.fn, 
           xlim=c(-6,5),ylim=c(-1,22), 
           ilab=dfoc3.o.re$ss, ilab.xpos = -2.3, 
           cex=1,psize=1, 
           refline = 0, 
           slab=paste(dfoc3.o.re$au, as.character(dfoc3.o.re$ye),sep=','), font=1, 
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           order = order(dfoc3.o.re$ye,dfoc3.o.re$au), 
           showweights = TRUE, 
           cex.lab  = 0.75) 
    text(-4.5,-
1,pos=4,cex=0.75,bquote(paste("(Q=",.(formatC(model2.fn$QE,digits=2,format="f")),",df 
=",.(model2.fn$k - 
model2.fn$p),",p=",.(formatC(model2.fn$QEp,digits=2,format="f")),";",I^2,"=",.(formatC(model2.fn
$I2,digits=1,format="f")),"%)"))) 
     
    #give names to items 
    text(-3,20.5,'Sample size',pos=4,cex=0.8,font=4) 
    text(-6,20.5,'Author(s) and Year',pos=4,cex=0.8,font=4) 
    text(1.9,20.5,'Coefficient    [95% CI]',pos=4,cex=0.8,font=4) 
    text(1.9,20.95,'Correlation',pos=4,cex=0.8,font=4) 
    text(0.85,20.5,'Weights',pos=4,cex=0.8,font=4) 
 
     
## heterogeneity tests(Radial plot, Baujat plot)-------- 
    #Radial plot ## galbraith 
    radial(model3.fn, level=0.95,xlab="Inverse of standard error",zlab="Standardised effect size (z-
score) ") 
     
    #Baujat plot 
    baujat(model3.fn,xlab="Contribution to overall heterogeneity",ylab="Influence on overall result") 
     
     
## publication bias analysis---- 
    #random version of Egger's test, for class 'rma' 
    regc <-regtest(model3.fn, model="rma", ret.fit=FALSE) 
    regc 
    #funnel plots contour-enhanced funnel plot centreed at 0 (see Peters et al., 2008) 
    par(mar=c(5,5,4,2),mfrow=c(1, 1)) 
    trfc <- trimfill(model3.fn) 
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    funnel(trfc,comb.rma=TRUE,level=c(90, 95, 99), shade=c("light blue", "blue", "dark 
blue"),refline=0) 
    
    legend(0.17, -0.004, 
           c("p>0.1", "0.05 < p < 0.1","0.01 < p < 0.05", "p< 0.01","studies","added studies"), 
           #p shows the significance/non-significance of effect 
           fill=c("light blue", "blue", "dark blue","light grey","black","white"))     
     
    #label eggers'regression test 
    text(-0.3,-0.007,cex=0.85,pos=1,"Egger's regression test: ") 
    text(-0.3,-0.00001,cex=0.85,pos=1,bquote(paste("p=",.(formatC(regc$pval,digits=2)),", 
z=",.(formatC(regc$zval,digits=2))))) 
     
    title(main="The trim-filled contour-enhanced funnel plot of the correlation coefficient between 
TOC and HOMA-IR across 17 studies",cex.main=1) 
     
     
     
    # C: meta-regression model--------- 
    #-for r-pearson TOC-HOMA-IR-raw 
    #-can include moderators/predictors/covariates in the model 
    #-to account for heterogeneity 
    # from a to n 
   
        # C.a.study type (st)---------- 
         
            factor(dfoc3$st) ##---remove NA value in level 
             
            dfoc3.a <- dfoc3[!is.na(dfoc3$yi) & !is.na(dfoc3$vi) & !is.na(dfoc3$st),] 
            summary(dfoc3.a) 
             
            model3.a <- rma(yi,vi,mods=~factor(st), data=dfoc3.a,'REML') 
            model3.a 
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        # C.b.proportion of T2DM (pt)--------- 
            dfoc3.b <- dfoc3[!is.na(dfoc3$yi) & !is.na(dfoc3$vi) & !is.na(dfoc3$pt),] 
            summary(dfoc3.b) 
             
            model3.b <- rma(yi,vi,mods= ~pt, data=dfoc3.b,'REML') 
            model3.b 
       
        # C.c.mean age overall(ma)------------ 
          dfoc3.c <- dfoc3[!is.na(dfoc3$ma),] 
          summary(dfoc3.c) 
           
          model3.c <- rma(yi,vi,mods= ~ma, data=dfoc3.c,'REML') 
          model3.c 
       
        # C.d.sex(sex)----------- 
          factor(dfoc3$sex)  
          dfoc3.d <- dfoc3[!is.na(dfoc3$yi) & !is.na(dfoc3$vi) & !is.na(dfoc3$sex),] 
          summary(dfoc3.d) 
           
          model3.d <- rma(yi,vi,mods= ~factor(sex), data=dfoc3.d,'REML') 
          model3.d 
       
        # C.e.proportion of female(pof)---------- 
          dfoc3.e <- dfoc3[!is.na(dfoc3$yi) & !is.na(dfoc3$vi) &!is.na(dfoc3$pof),] 
          summary(dfoc3.e) 
           
          model3.e <- rma(yi,vi,mods= ~pof, data=dfoc3.e,'REML') 
          model3.e 
       
        # C.f.proportion of postmenopausal (ppom)---------- 
          dfoc3.f <- dfoc3[!is.na(dfoc3$yi) & !is.na(dfoc3$vi) &!is.na(dfoc3$ppom),] 
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          summary(dfoc3.f) 
           
          model3.f <- rma(yi,vi,mods= ~ppom, data=dfoc3.f,'REML') 
          model3.f 
   
        # C.g.continent (cont)-------- 
      factor(dfoc3$cont)  
      dfoc3.g <- dfoc3[!is.na(dfoc3$yi) & !is.na(dfoc3$vi) & !is.na(dfoc3$cont),] 
      summary(dfoc3.g) 
       
      model3.g <- rma(yi,vi,mods= ~factor(cont), data=dfoc3.g,'REML') 
      model3.g 
   
        # C.h.ethnicity (eth)---------- 
      factor(dfoc3$eth)  
      dfoc3.h <- dfoc3[!is.na(dfoc3$yi) & !is.na(dfoc3$vi) & !is.na(dfoc3$eth),] 
      summary(dfoc3.h) 
       
      model3.h <- rma(yi,vi,mods= ~factor(eth), data=dfoc3.h,'REML') 
      model3.h 
        # C.i.matched variable(s) (mv)--------- 
    factor(dfoc3$mv)  
    dfoc3.i <- dfoc3[!is.na(dfoc3$yi) & !is.na(dfoc3$vi) & !is.na(dfoc3$mv),] 
    summary(dfoc3.i) 
     
    model3.i <- rma(yi,vi,mods= ~factor(mv), data=dfoc3.i,'REML') 
    model3.i 
   
        # C.j.use ofantidiabetic drugs (atd)-------- 
    factor(dfoc3$atd)  
    dfoc3.j <- dfoc3[!is.na(dfoc3$yi) & !is.na(dfoc3$vi) & !is.na(dfoc3$atd),] 
    summary(dfoc3.j) 
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    model3.j <- rma(yi,vi,mods= ~factor(atd), data=dfoc3.j,'REML') 
    model3.j 
        # C.k.use drugs mediate bone metabolism (bmd)--------- 
      factor(dfoc3$bmd)  
      dfoc3.k <- dfoc3[!is.na(dfoc3$yi) & !is.na(dfoc3$vi) & !is.na(dfoc3$bmd),] 
      summary(dfoc3.k) 
       
      model3.k <- rma(yi,vi,mods= ~factor(bmd), data=dfoc3.k,'REML') 
      model3.k 
        # C.l.assays for toc (asto)-------- 
      factor(dfoc3$asto)  
      dfoc3.l <- dfoc3[!is.na(dfoc3$yi) & !is.na(dfoc3$vi) & !is.na(dfoc3$asto),] 
      summary(dfoc3.l) 
       
      model3.l <- rma(yi,vi,mods= ~factor(asto), data=dfoc3.l) 
      model3.l 
        # C.m.study base (stba)-------- 
      factor( dfoc3$stba)  
      dfoc3.m <- dfoc3[!is.na(dfoc3$yi) & !is.na(dfoc3$vi) & !is.na(dfoc3$stba),] 
      summary(dfoc3.m) 
       
      model3.m <- rma(yi,vi,mods= ~factor(stba), data=dfoc3.m) 
      model3.m 
        # C.n.imparied renal function (renal)------- 
      factor(dfoc3$renal)  
      dfoc3.n <- dfoc3[!is.na(dfoc3$yi) & !is.na(dfoc3$vi) & !is.na(dfoc3$renal),] 
      summary(dfoc3.n) 
        ## model not applicable as only three studies with all' n' for renal 
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  #   C: mixed effect model test with backward stepwise regression------------- 
      ### pof st sex asto atd 
      #step 1. incldue all variables in one model 
      dfoc3.o <- dfoc3[!is.na(dfoc3$yi) & !is.na(dfoc3$vi) & !is.na(dfoc3$pof) & !is.na(dfoc3$st) 
& !is.na(dfoc3$sex) & !is.na(dfoc3$asto) & !is.na(dfoc3$atd),] 
      summary(dfoc3.o) 
      model3.o <- rma(yi,vi,mods= ~ pof +factor(st) + factor(sex) + factor(asto) + factor(atd), 
data=dfoc3.o) 
      model3.o 
       
      #step 2. remove pof as it gots the bigges p-value and then generate a new dataset 
      dfoc3.o.p <- dfoc3.o.re[!is.na(dfoc3.o.re$yi) & !is.na(dfoc3.o.re$vi) & !is.na(dfoc3.o.re$st) 
& !is.na(dfoc3.o.re$sex) & !is.na(dfoc3.o.re$asto) & !is.na(dfoc3.o.re$atd),] 
      model3.o.p <- rma(yi,vi,mods= ~ +factor(st) + factor(sex) + factor(asto) + factor(atd), 
data=dfoc3.o.p) 
      model3.o.p 
       
      #step 4. compute the overall p values for each variables 
      # overall p value for st 
      anova(model3.o.p,btt=2) 
      # overall p value for sex 
      anova(model3.o.p, btt = 3:4) 
      # overall p value for asto 
      anova(model3.o.p, btt = 5:6) 
      # overall p value for atd 
      anova(model3.o.p, btt = 7) 
       
      #step 5. remove st as it gots biggest p-value and compute the overall p values for each variables 
      model3.o.d <- rma(yi,vi,mods= ~  factor(sex)  + factor(asto) +factor(atd), data=dfoc3.o.p) 
      model3.o.d 
      # overall p value for sex 
      anova(model3.o.d,btt=2:3) 
      # overall p value for asto 
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      anova(model3.o.d, btt = 4:5) 
      # overall p value for atd 
      anova(model3.o.d, btt = 6) 
       
      #step 6. remove atd as it gots biggest p-value and compute the overall p values for each variables 
      model3.o.s <- rma(yi,vi,mods= ~ + factor(sex) + factor(asto), data=dfoc3.o.p) 
      model3.o.s 
      # overall p value for sex 
      anova(model3.o.s,btt=2:3) 
      # overall p value for asto 
      anova(model3.o.s, btt = 4:5) 
       
      #step 7. remove sex from model and only remained asto 
        #compute the over p-value for asto based on the 'model3.l' 
      model3.o.t <- rma(yi,vi,mods= ~ factor(asto), data=dfoc3.o.p) 
      model3.o.t 
      anova(model3.o.t,btt=2:3) 
      #p=0.05, significant, only asto remained in the final model. 
       
  # fit the final model by  
       
      funnel(model3) 
       
       
       
  #   C:subgroup analyses in IRMA, ECLIA, ELISA------- 
       
      model3.fnf <- rma(yi,vi,data = dfoc3.o.re,method='REML')  
       
      par(mar=c(4,2,0.5,2)) 
      forest(model3.fnf, 
             xlim=c(-6,3),ylim=c(-1,30), 
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             order=order(dfoc3.o.re$asto,dfoc3.o.re$ye,dfoc3.o.re$au), 
             ilab=dfoc3.o.re$ss, ilab.xpos = -2.5, 
             cex=1,psize=1, 
             refline = 0, 
             rows=c(2:7,11:16,20:26), 
             slab=paste(dfoc3.o.re$au, as.character(dfoc3.o.re$ye),sep=','), font=1, 
             cex.lab = .8) 
      model3.ir <- rma(yi,vi,data=dfoc3.o.re,measure='COR',subset=(asto=='IRMA'),method='REML') 
      model3.ec <- 
rma(yi,vi,data=dfoc3.o.re,measure='COR',subset=(asto=='ECLIA'),method='REML') 
      model3.el <- rma(yi,vi,data=dfoc3.o.re,measure='COR',subset=(asto=='ELISA'),method='REML') 
       
      text(-4.75,-
1,pos=4,cex=0.85,bquote(paste("(Q=",.(formatC(model3.fnf$QE,digits=2,format="f")),",df 
=",.(model3.fnf$k - 
model3.fnf$p),",p=",.(formatC(model3.fnf$QEp,digits=2,format="f")),";",I^2,"=",.(formatC(model3.f
nf$I2,digits=1,format="f")),"%)"))) 
       
      #generate subgroup measurements results 
      addpoly(model3.ir,row=19,cex=1,font=4) 
      addpoly(model3.ec,row=10,cex=1,font=4) 
      addpoly(model3.el,row=1,cex=1,font=4) 
       
      #give names to items 
      text(-3,28.5,'Sample size',pos=4,cex=.85,font=4) 
      text(-6,28.5,'Author(s) and Year',pos=4,cex=.85,font=4) 
      text(-6,27,'IRMA',pos=4,cex=1,font=4) 
      text(-6,17,'ECLIA',pos=4,cex=1,font=4) 
      text(-6,8,'ELISA',pos=4,cex=1,font=4) 
      text(0.25,29.25,'Correlation',pos=4,cex=0.85,font=4) 
      text(0.25,28.5,'Coefficient    [95% CI]',pos=4,cex=0.85,font=4) 
       
      # add text with Q-value, dfs,p-value, and I2 statistics for subgroups 
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      text(-
4.8,19,pos=4,cex=0.85,bquote(paste("(Q=",.(formatC(model3.ir$QE,digits=2,format="f")),",df 
=",.(model3.ir$k - 
model3.ir$p),",p=",.(formatC(model3.ir$QEp,digits=2,format="f")),";",I^2,"=",.(formatC(model3.ir$I
2,digits=1,format="f")),"%)"))) 
      text(-
4.8,10,pos=4,cex=0.85,bquote(paste("(Q=",.(formatC(model3.ec$QE,digits=2,format="f")),",df 
=",.(model3.ec$k - 
model3.ec$p),",p=",.(formatC(model3.ec$QEp,digits=2,format="f")),";",I^2,"=",.(formatC(model3.ec
$I2,digits=1,format="f")),"%)"))) 
      text(-
4.8,1,pos=4,cex=0.85,bquote(paste("(Q=",.(formatC(model3.el$QE,digits=2,format="f")),",df 
=",.(model3.el$k - 
model3.el$p),",p=",.(formatC(model3.el$QEp,digits=2,format="f")),";",I^2,"=",.(formatC(model3.el$
I2,digits=1,format="f")),"%)"))) 
       
  #   C:subgroup analyses baseon on T2DM status (T2DM, controls, general population)------ 
      
 
      dfoc3.ch <- dfoc3.o.re <- dfoc3[-3,] #remove Choudhury 2014 prem from model 
       
      model3.ch <- rma(yi,vi,data = dfoc3.ch,method='REML')  
       
      par(mar=c(4,5,0.5,5)) 
      forest(model3.ch, 
             xlim=c(-6,3),ylim=c(-1,36), 
             order=order(dfoc3.ch$tmoral,dfoc3.ch$ye,dfoc3.ch$au), 
             ilab=dfoc3.ch$ss, ilab.xpos = -2.5, 
             cex=0.8,psize=1, 
             refline = 0, 
             rows=c(2:7,13:14,20:31), 
             slab=paste(dfoc3.ch$au, as.character(dfoc3.ch$ye),sep=','), font=1, 
             cex.lab = .8) 
      model3.td <- 
rma(yi,vi,data=dfoc3.ch,measure='COR',subset=(tmoral=='T2DM'),method='REML') 
      model3.hc <- 
rma(yi,vi,data=dfoc3.ch,measure='COR',subset=(tmoral=='controls'),method='REML') 
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      model3.al <- rma(yi,vi,data=dfoc3.ch,measure='COR',subset=(tmoral=='all'),method='REML') 
       
      text(-5,-
1,pos=4,cex=0.85,bquote(paste("(Q=",.(formatC(model3.ch$QE,digits=2,format="f")),",df 
=",.(model3.ch$k - 
model3.ch$p),",p=",.(formatC(model3.ch$QEp,digits=2,format="f")),";",I^2,"=",.(formatC(model3.ch
$I2,digits=1,format="f")),"%)"))) 
       
      #generate subgroup measurements results 
      addpoly(model3.td,row=18.85,cex=0.85,font=4) 
      addpoly(model3.hc,row=11.85,cex=0.85,font=4) 
      addpoly(model3.al,row=0.85,cex=0.85,font=4) 
       
      #give names to items 
      text(-3,35.25,'Sample size',pos=4,cex=.85,font=4) 
      text(-6,35.25,'Author(s) and Year',pos=4,cex=.85,font=4) 
      text(-6,33,'T2DM',pos=4,cex=1,font=4) 
      text(-6,16,'Healthy Population',pos=4,cex=1,font=4) 
      text(-6,9,'General Population',pos=4,cex=1,font=4) 
      text(0.45,36.25,'Correlation',pos=4,cex=0.85,font=4) 
      text(0.45,35.25,'Coefficient    [95% CI]',pos=4,cex=0.85,font=4) 
       
      # add text with Q-value, dfs,p-value, and I2 statistics for subgroups 
      text(-
4.8,18.85,pos=4,cex=0.8,bquote(paste("(Q=",.(formatC(model3.td$QE,digits=2,format="f")),",df 
=",.(model3.td$k - 
model3.td$p),",p=",.(formatC(model3.td$QEp,digits=2,format="f")),";",I^2,"=",.(formatC(model3.td$
I2,digits=1,format="f")),"%)"))) 
      text(-
4.8,11.85,pos=4,cex=0.8,bquote(paste("(Q=",.(formatC(model3.hc$QE,digits=2,format="f")),",df 
=",.(model3.hc$k - 
model3.hc$p),",p=",.(formatC(model3.hc$QEp,digits=2,format="f")),";",I^2,"=",.(formatC(model3.hc
$I2,digits=1,format="f")),"%)"))) 
      text(-
4.8,0.85,pos=4,cex=0.8,bquote(paste("(Q=",.(formatC(model3.al$QE,digits=2,format="f")),",df 
=",.(model3.al$k - 
model3.al$p),",p=",.(formatC(model3.al$QEp,digits=2,format="f")),";",I^2,"=",.(formatC(model3.al$
I2,digits=1,format="f")),"%)"))) 
 184 
       
       
       
# D: r TOC - HbA1c ------------------------------- 
  #-----(4) r-pearson toc-hba1c pearson crude 
    dfoc4 <- escalc(ri= pcrtohc,ni=ss,measure='COR',data= dfoc) 
    dfoc4 <- dfoc4[!is.na(dfoc4$yi) & !is.na(dfoc4$vi),] 
    model4.ch <- rma(yi,vi,data=dfoc4,method="REML")  # this model aims for the subgroup analysis 
based on T2DM 
     
    dfoc4 <- dfoc4[-cbind(24,25,30),]#remove duplicate studies: Oren.HC2011, Manavalan.T2 & HC 
    model4 <- rma(yi,vi,data = dfoc4,method='REML') 
    model4 
     
    par(mar=c(3.5,2,0.05,2)) 
    forest(model4, 
           xlim=c(-6,3),ylim=c(-1,33), 
           order=order(dfoc4$ye, dfoc4$au), 
           ilab=dfoc4$ss, ilab.xpos = -2.5, 
           cex=0.9,psize=1, 
           refline = 0, 
           slab=paste(dfoc4$au, as.character(dfoc4$ye),sep=','), font=1, 
           cex.lab = .8) 
     
    text(-4.75,-1,pos=4,cex=0.85,bquote(paste("(Q=",.(formatC(model4$QE,digits=2,format="f")),",df 
=",.(model4$k - 
model4$p),",p=",.(formatC(model4$QEp,digits=2,format="f")),";",I^2,"=",.(formatC(model4$I2,digit
s=1,format="f")),"%)"))) 
   
     
    #give names to items 
    text(-3,31.5,'Sample size',pos=4,cex=.85,font=4) 
    text(-6,31.5,'Author(s) and Year',pos=4,cex=.85,font=4) 
    text(0.65,32.25,'Correlation',pos=4,cex=0.85,font=4) 
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    text(0.65,31.5,'Coefficient   [95% CI]',pos=4,cex=0.85,font=4) 
     
     
## heterogeneity tests(Radial plot, Baujat plot)-------- 
    #Radial plot ## galbraith 
    radial(model4, level=0.95,xlab="Inverse of standard error",zlab="Standardised effect size (z-score) 
") 
     
    #Baujat plot 
    baujat(model4,xlab="Contribution to overall heterogeneity",ylab="Influence on overall result") 
     
     
## publication bias analysis---- 
    #random version of Egger's test, for class 'rma' 
    regd <-regtest(model4, model="rma", ret.fit=FALSE) 
    regd 
    #funnel plots contour-enhanced funnel plot centreed at 0 (see Peters et al., 2008) 
    par(mar=c(5,5,4,2),mfrow=c(1, 1)) 
    trfd <- trimfill(model4) 
    funnel(trfd,comb.rma=TRUE,level=c(90, 95, 99), shade=c("light blue", "blue", "dark 
blue"),refline=0) 
    legend(0.3, -0.004, 
           c("p>0.1", "0.05 < p < 0.1","0.01 < p < 0.05", "p< 0.01","studies","added studies"), 
           #p shows the significance/non-significance of effect 
           fill=c("light blue", "blue", "dark blue","light grey","black","white"))     
     
    #label eggers'regression test 
    text(-0.5,0.004,cex=0.85,pos=1,"Egger's regression test: ") 
    text(-0.5,0.015,cex=0.85,pos=1,bquote(paste("p=",.(formatC(regd$pval,digits=2)),", 
z=",.(formatC(regd$zval,digits=2))))) 
     
    title(main="The trim-filled contour-enhanced funnel plot of the correlation coefficient between 
TOC HbA1c across 30 studies",cex.main=1) 
     
 186 
     
    # D: meta-regression model------- 
    #-for r-pearson TOC-HbA1c-raw 
    #-can include moderators/predictors/covariates in the model 
    #-to account for heterogeneity 
    # from a to n 
   
        # D.a.study type (st)--------- 
       
          factor(dfoc4$st) ##---remove NA value in level 
           
          dfoc4.a <- dfoc4[!is.na(dfoc4$yi) & !is.na(dfoc4$vi) & !is.na(dfoc4$st),] 
          summary(dfoc4.a) 
           
          model4.a <- rma(yi,vi,mods=~factor(st), data=dfoc4.a,'REML') 
          model4.a 
       
        # D.b.proportion of T2DM (pt)------- 
            dfoc4.b <- dfoc4[!is.na(dfoc4$yi) & !is.na(dfoc4$vi) & !is.na(dfoc4$pt),] 
            summary(dfoc4.b) 
             
            model4.b <- rma(yi,vi,mods= ~pt, data=dfoc4.b,'REML') 
            model4.b 
         
        # D.c.mean age overall(ma)------- 
            dfoc4.c <- dfoc4[!is.na(dfoc4$ma),] 
            summary(dfoc4.c) 
             
            model4.c <- rma(yi,vi,mods= ~ma, data=dfoc4.c,'REML') 
            model4.c 
         
        # D.d.sex(sex)--------- 
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            factor(dfoc4$sex)  
            dfoc4.d <- dfoc4[!is.na(dfoc4$yi) & !is.na(dfoc4$vi) & !is.na(dfoc4$sex),] 
            summary(dfoc4.d) 
             
            model4.d <- rma(yi,vi,mods= ~factor(sex), data=dfoc4.d,'REML') 
            model4.d 
         
        # D.e.proportion of female(pof)----------- 
            dfoc4.e <- dfoc4[!is.na(dfoc4$pof),] 
            summary(dfoc4.e) 
             
            model4.e <- rma(yi,vi,mods= ~pof, data=dfoc4.e,'REML') 
            model4.e 
         
        # D.f.proportion of postmenopausal (ppom)------- 
            dfoc4.f <- dfoc4[!is.na(dfoc4$ppom),] 
            summary(dfoc4.f) 
             
            model4.f <- rma(yi,vi,mods= ~ppom, data=dfoc4.f,'REML') 
            model4.f 
         
        # D.g.continent (cont)--------- 
            factor(dfoc4$cont)  
            dfoc4.g <- dfoc4[!is.na(dfoc4$yi) & !is.na(dfoc4$vi) & !is.na(dfoc4$cont),] 
            summary(dfoc4.g) 
             
            model4.g <- rma(yi,vi,mods= ~factor(cont), data=dfoc4.g,'REML') 
            model4.g 
         
        # D.h.ethnicity (eth)--------- 
            factor(dfoc4$eth)  
            dfoc4.h <- dfoc4[!is.na(dfoc4$yi) & !is.na(dfoc4$vi) & !is.na(dfoc4$eth),] 
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            summary(dfoc4.h) 
             
            model4.h <- rma(yi,vi,mods= ~factor(eth), data=dfoc4.h,'REML') 
            model4.h 
         
        # D.i.matched variable(s) (mv)------ 
            factor(dfoc4$mv)  
            dfoc4.i <- dfoc4[!is.na(dfoc4$yi) & !is.na(dfoc4$vi) & !is.na(dfoc4$mv),] 
            summary(dfoc4.i$mv) 
            #only three studies available after removing mv  
         
        # D.j.use ofantidiabetic drugs (atd)--------- 
            factor(dfoc4$atd)  
            dfoc4.j <- dfoc4[!is.na(dfoc4$yi) & !is.na(dfoc4$vi) & !is.na(dfoc4$atd),] 
            summary(dfoc4.j$atd) 
             
            model4.j <- rma(yi,vi,mods= ~factor(atd), data=dfoc4.j,'REML') 
            model4.j 
         
        # D.k.use drugs mediate bone metabolism (bmd)------- 
            factor(dfoc4$bmd)  
            dfoc4.k <- dfoc4[!is.na(dfoc4$yi) & !is.na(dfoc4$vi) & !is.na(dfoc4$bmd),] 
            summary(dfoc4.k$bmd) 
              ##### all "y" for bmd 
         
        # D.l.assays for toc (asto)-------- 
            factor(dfoc4$asto)  
            dfoc4.l <- dfoc4[!is.na(dfoc4$yi) & !is.na(dfoc4$vi) & !is.na(dfoc4$asto),] 
            summary(dfoc4.l$asto) 
             
            model4.l <- rma(yi,vi,mods= ~factor(asto), data=dfoc4.l) 
            model4.l 
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        # D.m.study base (stba)------- 
            factor(dfoc4$stba)  
            dfoc4.m <- dfoc4[!is.na(dfoc4$yi) & !is.na(dfoc4$vi) & !is.na(dfoc4$stba),] 
            summary(dfoc4.m) 
             
            model4.m <- rma(yi,vi,mods= ~factor(stba), data=dfoc4.m) 
            model4.m 
         
        # D.n.imparied renal function (renal)------ 
            factor(dfoc4$renal)  
            dfoc4.n <- dfoc4[!is.na(dfoc4$yi) & !is.na(dfoc4$vi) & !is.na(dfoc4$renal),] 
            summary(dfoc4.n$renal) 
            ## model not applicable as only three studies with all' n' for renal 
       
       
         
    #   D: mixed effect model test with backward stepwise regression------------- 
            ### pof st stba 
            #step 1. incldue all variables in one model 
            dfoc4.o <- dfoc4[!is.na(dfoc4$yi) & !is.na(dfoc4$vi) & !is.na(dfoc4$ppom) & !is.na(dfoc4$st) 
& !is.na(dfoc4$stba),] 
            summary(dfoc4.o) 
            model4.o <- rma(yi,vi,mods= ~ pof +factor(st) + factor(stba), data=dfoc4.o) 
            model4.o 
             
            #step 2. remove ppom as it gots the bigges p-value and then generate a new dataset 
            dfoc4.o.p <- dfoc4[!is.na(dfoc4$yi) & !is.na(dfoc4$vi) & !is.na(dfoc4$st) 
& !is.na(dfoc4$stba),] 
            model4.o.p <- rma(yi,vi,mods= ~ factor(st)+ factor(stba), data=dfoc4.o.p) 
            model4.o.p 
             
            #step 3. compute the overall p values for each variables 
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            # overall p value for st 
            anova(model4.o.p,btt=2:3) 
            # overall p value for stba 
            anova(model4.o.p, btt = 4:5) 
             
            #step 4. stopped as 'st' and 'stba' were both significant 
              # P(st)=0.0219, P(stba) =0.0292 
             
      #   D:subgroup analyses in stba (a &c)------- 
             
            dfoc4.fn <- dfoc4[!is.na(dfoc4$yi) & !is.na(dfoc4$vi) & !is.na(dfoc4$stba),] 
            #remove Gradinaru as it is the only b in 'stba' and cannot do the analyses 
            dfoc4.re <- dfoc4.fn[-5,] 
             
            model4.fnf <- rma(yi,vi,data = dfoc4.re,method='REML')  
             
            par(mar=c(4,2,0.5,2)) 
            forest(model4.fnf, 
                   xlim=c(-6,3),ylim=c(-1,36), 
                   order=order(dfoc4.re$stba,dfoc4.re$ye,dfoc4.re$au), 
                   ilab=dfoc4.re$ss, ilab.xpos = -2.5, 
                   cex=1,psize=1, 
                   refline = 0, 
                   rows=c(2:24,28:31), 
                   slab=paste(dfoc4.re$au, as.character(dfoc4.re$ye),sep=','), font=1, 
                   cex.lab = .8) 
            model4.ho <- rma(yi,vi,data=dfoc4.re,measure='COR',subset=(stba=='a'),method='REML') 
            model4.po <- rma(yi,vi,data=dfoc4.re,measure='COR',subset=(stba=='c'),method='REML') 
             
             
            text(-4.75,-
1,pos=4,cex=0.85,bquote(paste("(Q=",.(formatC(model4.fnf$QE,digits=2,format="f")),",df 
=",.(model4.fnf$k - 
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model4.fnf$p),",p=",.(formatC(model4.fnf$QEp,digits=2,format="f")),";",I^2,"=",.(formatC(model4.f
nf$I2,digits=1,format="f")),"%)"))) 
             
            #generate subgroup measurements results 
            addpoly(model4.ho,row=1,cex=1,font=4) 
            addpoly(model4.po,row=27,cex=1,font=4) 
     
             
            #give names to items 
            text(-3,35,'Sample size',pos=4,cex=.85,font=4) 
            text(-6,35,'Author(s) and Year',pos=4,cex=.85,font=4) 
            text(-6,25.5,'Outpatient clinics',pos=4,cex=1,font=4) 
            text(-6,32.5,'Population-based/communities/databases',pos=4,cex=1,font=4) 
            text(0.56,35.8,'Correlation',pos=4,cex=0.85,font=4) 
            text(0.56,35,'Coefficient    [95% CI]',pos=4,cex=0.85,font=4) 
             
            # add text with Q-value, dfs,p-value, and I2 statistics for subgroups 
            text(-
4.8,1,pos=4,cex=0.85,bquote(paste("(Q=",.(formatC(model4.ho$QE,digits=2,format="f")),",df 
=",.(model4.ho$k - 
model4.ho$p),",p=",.(formatC(model4.ho$QEp,digits=2,format="f")),";",I^2,"=",.(formatC(model4.h
o$I2,digits=1,format="f")),"%)"))) 
            text(-
4.8,27,pos=4,cex=0.85,bquote(paste("(Q=",.(formatC(model4.po$QE,digits=2,format="f")),",df 
=",.(model4.po$k - 
model4.po$p),",p=",.(formatC(model4.po$QEp,digits=2,format="f")),";",I^2,"=",.(formatC(model4.p
o$I2,digits=1,format="f")),"%)"))) 
            
      #   D:subgroup analyses in st (cohort/case-control & cross-sectional)------- 
             
            dfoc4.fnc <- dfoc4[!is.na(dfoc4$yi) & !is.na(dfoc4$vi) & !is.na(dfoc4$st),] 
             
            #remove Berberoglu 2007 as it is the only study of 'baseline.intervention' for st, 
              #remove Hwang 2012 as it is the only study of 'cohort' for st 
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            par(mar=c(4,2,0,2)) 
            forest(model4.fnc, 
                   xlim=c(-6,3),ylim=c(-1,38), 
                   order=order(dfoc4.fnc$st,dfoc4.fnc$ye,dfoc4.fnc$au), 
                   ilab=dfoc4.fnc$ss, ilab.xpos = -2.5, 
                   cex=1,psize=1, 
                   refline = 0, 
                   rows=c(2:4,9:33), 
                   slab=paste(dfoc4.fnc$au, as.character(dfoc4.fnc$ye),sep=','), font=1, 
                   cex.lab = .8) 
            model4.ca <- rma(yi,vi,data=dfoc4.fnc,measure='COR',subset=(st== 
'case.control'),method='REML') 
            model4.cr <- 
rma(yi,vi,data=dfoc4.fnc,measure='COR',subset=(st=='cross.sectional'),method='REML') 
             
             
            text(-4.75,-
1,pos=4,cex=0.85,bquote(paste("(Q=",.(formatC(model4.fnc$QE,digits=2,format="f")),",df 
=",.(model4.fnc$k - 
model4.fnc$p),",p=",.(formatC(model4.fnc$QEp,digits=2,format="f")),";",I^2,"=",.(formatC(model4.
fnc$I2,digits=1,format="f")),"%)"))) 
             
            #generate subgroup measurements results 
            addpoly(model4.ca,row=0.75,cex=1,font=4) 
            addpoly(model4.cr,row=7.65,cex=1,font=4) 
             
             
            #give names to items 
            text(-3,36.75,'Sample size',pos=4,cex=.85,font=4) 
            text(-6,36.75,'Author(s) and Year',pos=4,cex=.85,font=4) 
            text(-6,6,'Case-control studies',pos=4,cex=1,font=4) 
            text(-6,35,'Cross-sectional studies',pos=4,cex=1,font=4) 
            text(0.65,37.85,'Correlation',pos=4,cex=0.85,font=4) 
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            text(0.65,36.75,'Coefficient    [95% CI]',pos=4,cex=0.85,font=4) 
             
            # add text with Q-value, dfs,p-value, and I2 statistics for subgroups 
            text(-
4.8,1,pos=4,cex=0.75,bquote(paste("(Q=",.(formatC(model4.ca$QE,digits=2,format="f")),",df 
=",.(model4.ca$k - 
model4.ca$p),",p=",.(formatC(model4.ca$QEp,digits=2,format="f")),";",I^2,"=",.(formatC(model4.ca
$I2,digits=1,format="f")),"%)"))) 
            text(-
4.8,7.65,pos=4,cex=0.85,bquote(paste("(Q=",.(formatC(model4.cr$QE,digits=2,format="f")),",df 
=",.(model4.cr$k - 
model4.cr$p),",p=",.(formatC(model4.cr$QEp,digits=2,format="f")),";",I^2,"=",.(formatC(model4.cr$
I2,digits=1,format="f")),"%)"))) 
             
            
      #   D:subgroup analyses based on T2DM status----           
              
            par(mar=c(4,7,0.5,6)) 
            forest(model4.ch, 
                   xlim=c(-6,3),ylim=c(-1,45), 
                   order=order(dfoc4$tmoral,dfoc4$ye,dfoc4$au), 
                   ilab=dfoc4$ss, ilab.xpos = -2.5, 
                   cex=0.7,psize=1, 
                   refline = 0, 
                   rows=c(2:8,12:14,18:41), 
                   slab=paste(dfoc4$au, as.character(dfoc4$ye),sep=','), font=1, 
                   cex.lab = .8) 
            model4.td <- 
rma(yi,vi,data=dfoc4,measure='COR',subset=(tmoral=='T2DM'),method='REML') 
            model4.hc <- 
rma(yi,vi,data=dfoc4,measure='COR',subset=(tmoral=='controls'),method='REML') 
            model4.al <- rma(yi,vi,data=dfoc4,measure='COR',subset=(tmoral=='all'),method='REML') 
             
            text(-5,-
1,pos=4,cex=0.7,bquote(paste("(Q=",.(formatC(model4.ch$QE,digits=2,format="f")),",df 
=",.(model4.ch$k - 
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model4.ch$p),",p=",.(formatC(model4.ch$QEp,digits=2,format="f")),";",I^2,"=",.(formatC(model4.ch
$I2,digits=1,format="f")),"%)"))) 
             
            #generate subgroup measurements results 
            addpoly(model4.al,row=1,cex=0.7,font=4) 
            addpoly(model4.hc,row=11,cex=0.7,font=4) 
            addpoly(model4.td,row=17,cex=0.7,font=4) 
             
            #give names to items 
            text(-3,44,'Sample size',pos=4,cex=.75,font=4) 
            text(-6,44,'Author(s) and Year',pos=4,cex=.75,font=4) 
            text(-6,42,'T2DM',pos=4,cex=0.75,font=4) 
            text(-6,15.45,'Non-diabetic subjects',pos=4,cex=0.75,font=4) 
            text(-6,9.45,'General population',pos=4,cex=0.75,font=4) 
            text(0.56,44.9,'Correlation',pos=4,cex=0.75,font=4) 
            text(0.56,44,'Coefficient   [95% CI]',pos=4,cex=0.75,font=4) 
             
            # add text with Q-value, dfs,p-value, and I2 statistics for subgroups 
            text(-
5,1,pos=4,cex=0.6,bquote(paste("(Q=",.(formatC(model4.al$QE,digits=2,format="f")),",df 
=",.(model4.al$k - 
model4.al$p),",p=",.(formatC(model4.al$QEp,digits=2,format="f")),";",I^2,"=",.(formatC(model4.al$
I2,digits=1,format="f")),"%)"))) 
            text(-
5,11,pos=4,cex=0.6,bquote(paste("(Q=",.(formatC(model4.hc$QE,digits=2,format="f")),",df 
=",.(model4.hc$k - 
model4.hc$p),",p=",.(formatC(model4.hc$QEp,digits=2,format="f")),";",I^2,"=",.(formatC(model4.hc
$I2,digits=1,format="f")),"%)"))) 
            text(-
5,17,pos=4,cex=0.6,bquote(paste("(Q=",.(formatC(model4.td$QE,digits=2,format="f")),",df 
=",.(model4.td$k - 
model4.td$p),",p=",.(formatC(model4.td$QEp,digits=2,format="f")),";",I^2,"=",.(formatC(model4.td$
I2,digits=1,format="f")),"%)"))) 
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# E: r TOC - FPG ------------------------------- 
  #-----(5) r-pearson toc-FPG pearson crude 
    dfoc5 <- escalc(ri= pcrtofpg,ni=ss,measure='COR',data= dfoc) 
    dfoc5 <- dfoc5[!is.na(dfoc5$yi) & !is.na(dfoc5$vi),] 
    dfoc5.re <- dfoc5[-cbind(3,20,21,31,32),] #remove kindblomT2 &HC,Choudhury 
preM,Sanchez2017 T2&HC 
    model5 <- rma(yi,vi,data = dfoc5.re,method='REML') 
    model5 
     
    par(mar=c(4,2,0.5,2)) 
    forest(model5, 
           xlim=c(-6,5),ylim=c(-1,32), 
           ilab=dfoc5.re$ss, ilab.xpos = -2.3, 
           cex=1,psize=1, 
           refline = 0, 
           slab=paste(dfoc5.re$au, as.character(dfoc5.re$ye),sep=','), font=1, 
           order = order(dfoc5.re$ye,dfoc5.re$au), 
           showweights = TRUE, 
           cex.lab  = 0.75) 
    text(-4.5,-1,pos=4,cex=0.75,bquote(paste("(Q=",.(formatC(model5$QE,digits=2,format="f")),",df 
=",.(model5$k - 
model5$p),",p=",.(formatC(model5$QEp,digits=2,format="f")),";",I^2,"=",.(formatC(model5$I2,digit
s=1,format="f")),"%)"))) 
     
    #give names to items 
    text(-3,31,'Sample size',pos=4,cex=0.8,font=4) 
    text(-6,31,'Author(s) and Year',pos=4,cex=0.8,font=4) 
    text(2.25,31,'Coefficient  [95% CI]',pos=4,cex=0.8,font=4) 
    text(2.25,31.65,'Correlation',pos=4,cex=0.8,font=4) 
    text(1.2,31,'Weights',pos=4,cex=0.8,font=4) 
     
     
## heterogeneity tests(Radial plot, Baujat plot)-------- 
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    #Radial plot ## galbraith 
    radial(model5, level=0.95,xlab="Inverse of standard error",zlab="Standardised effect size (z-score) 
") 
     
    #Baujat plot 
    baujat(model5,xlab="Contribution to overall heterogeneity",ylab="Influence on overall result") 
     
     
## publication bias analysis---- 
    #random version of Egger's test, for class 'rma' 
    rege <-regtest(model5, model="rma", ret.fit=FALSE) 
    rege 
    #funnel plots contour-enhanced funnel plot centreed at 0 (see Peters et al., 2008) 
    par(mar=c(5,5,4,2),mfrow=c(1, 1)) 
    trfe <- trimfill(model5) 
    funnel(trfe,comb.rma=TRUE,level=c(90, 95, 99), shade=c("light blue", "blue", "dark 
blue"),refline=0) 
    legend(0.2, -0.004, 
           c("p>0.1", "0.05 < p < 0.1","0.01 < p < 0.05", "p< 0.01","studies"), 
           #p shows the significance/non-significance of effect 
           fill=c("light blue", "blue", "dark blue","light grey","black"))     
     
    #label eggers'regression test 
    text(-0.5,0.004,cex=0.85,pos=1,"Egger's regression test: ") 
    text(-0.5,0.015,cex=0.85,pos=1,bquote(paste("p=",.(formatC(rege$pval,digits=2)),", 
z=",.(formatC(rege$zval,digits=2))))) 
     
    title(main="The trim-filled contour-enhanced funnel plot of the correlation coefficient between 
TOC and FPG across 29 studies",cex.main=1) 
     
  
   
    # E: meta-regression model-------- 
      #-for r-pearson TOC-FPG-raw 
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      #-can include moderators/predictors/covariates in the model 
      #-to account for heterogeneity 
      # from a to n 
   
        # E.a.study type (st)--------- 
         
            factor(dfoc5$st) ##---remove NA value in level 
             
            dfoc5.a <- dfoc5[!is.na(dfoc5$yi) & !is.na(dfoc5$vi) & !is.na(dfoc5$st),] 
            summary(dfoc5.a) 
             
            model5.a <- rma(yi,vi,mods=~factor(st), data=dfoc5.a,'REML') 
            model5.a 
         
        # E.b.proportion of T2DM (pt)-------- 
            dfoc5.b <- dfoc5[!is.na(dfoc5$yi) & !is.na(dfoc5$vi) & !is.na(dfoc5$pt),] 
            summary(dfoc5.b) 
             
            model5.b <- rma(yi,vi,mods= ~pt, data=dfoc5.b,'REML') 
            model5.b 
         
        # E.c.mean age overall(ma)-------- 
            dfoc5.c <- dfoc5[!is.na(dfoc5$ma),] 
            summary(dfoc5.c) 
             
            model5.c <- rma(yi,vi,mods= ~ma, data=dfoc5.c,'REML') 
            model5.c 
         
        # E.d.sex(sex)------- 
            factor(dfoc5$sex)  
            dfoc5.d <- dfoc5[!is.na(dfoc5$yi) & !is.na(dfoc5$vi) & !is.na(dfoc5$sex),] 
            summary(dfoc5.d) 
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            model5.d <- rma(yi,vi,mods= ~factor(sex), data=dfoc5.d,'REML') 
            model5.d 
         
        # E.e.proportion of female(pof)-------- 
            dfoc5.e <- dfoc5[!is.na(dfoc5$pof),] 
            summary(dfoc5.e) 
             
            model5.e <- rma(yi,vi,mods= ~pof, data=dfoc5.e,'REML') 
            model5.e 
         
        # E.f.proportion of postmenopausal (ppom)-------- 
            dfoc5.f <- dfoc5[!is.na(dfoc5$ppom),] 
            summary(dfoc5.f) 
             
            model5.f <- rma(yi,vi,mods= ~ppom, data=dfoc5.f,'REML') 
            model5.f 
         
        # E.g.continent (cont)-------- 
            factor(dfoc5$cont)  
            dfoc5.g <- dfoc5[!is.na(dfoc5$yi) & !is.na(dfoc5$vi) & !is.na(dfoc5$cont),] 
            summary(dfoc5.g) 
             
            model5.g <- rma(yi,vi,mods= ~factor(cont), data=dfoc5.g,'REML') 
            model5.g 
         
        # E.h.ethnicity (eth)-------- 
            factor(dfoc5$eth)  
            dfoc5.h <- dfoc5[!is.na(dfoc5$yi) & !is.na(dfoc5$vi) & !is.na(dfoc5$eth),] 
            summary(dfoc5.h) 
             
            model5.h <- rma(yi,vi,mods= ~factor(eth), data=dfoc5.h,'REML') 
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            model5.h 
         
        # E.i.matched variable(s) (mv)--------- 
            factor(dfoc5$mv)  
            dfoc5.i <- dfoc5[!is.na(dfoc5$yi) & !is.na(dfoc5$vi) & !is.na(dfoc5$mv),] 
            summary(dfoc5.i) 
             
            model5.i <- rma(yi,vi,mods= ~factor(mv), data=dfoc5.i,'REML') 
            model5.i 
         
        # E.j.use ofantidiabetic drugs (atd)------- 
            factor(dfoc5$atd)  
            dfoc5.j <- dfoc5[!is.na(dfoc5$yi) & !is.na(dfoc5$vi) & !is.na(dfoc5$atd),] 
            summary(dfoc5.j) 
             
            model5.j <- rma(yi,vi,mods= ~factor(atd), data=dfoc5.j,'REML') 
            model5.j 
             
        # E.k.use drugs mediate bone metabolism (bmd)------ 
            factor(dfoc5$bmd)  
            dfoc5.k <- dfoc5[!is.na(dfoc5$yi) & !is.na(dfoc5$vi) & !is.na(dfoc5$bmd),] 
            summary(dfoc5.k$bmd) 
             ### all 'n' for bmd 
        # E.l.assays for toc (asto)--------- 
            factor(dfoc5$asto)  
            dfoc5.l <- dfoc5[!is.na(dfoc5$yi) & !is.na(dfoc5$vi) & !is.na(dfoc5$asto),] 
            summary(dfoc5.l) 
             
            model5.l <- rma(yi,vi,mods= ~factor(asto), data=dfoc5.l) 
            model5.l 
         
        # E.m.study base (stba)------- 
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            factor(dfoc5$stba)  
            dfoc5.m <- dfoc5[!is.na(dfoc5$yi) & !is.na(dfoc5$vi) & !is.na(dfoc5$stba),] 
            summary(dfoc5.m) 
             
            model5.m <- rma(yi,vi,mods= ~factor(stba), data=dfoc5.m) 
            model5.m 
         
        # E.n.imparied renal function (renal)------- 
            factor(dfoc5$renal)  
            dfoc5.n <- dfoc5[!is.na(dfoc5$yi) & !is.na(dfoc5$vi) & !is.na(dfoc5$renal),] 
            summary(dfoc5.n$renal) 
            ### all 'n' for renal, no model applicable 
 
  #   E: mixed effect model test with backward stepwise regression------------- 
            ### ppom stba cont 
            #step 1. incldue all variables in one model 
            dfoc5.o <- dfoc5.re[!is.na(dfoc5.re$yi) & !is.na(dfoc5.re$vi) & !is.na(dfoc5.re$ppom) 
& !is.na(dfoc5.re$stba) & !is.na(dfoc5.re$cont),] 
            summary(dfoc5.o) 
            model5.o <- rma(yi,vi,mods= ~ ppom +factor(stba) + factor(cont) -1, data=dfoc5.o) 
            model5.o 
             
            #step 2. compute the overall p values for each variables 
            # overall p value for ppom 
            anova(model5.o,btt=1) 
            # overall p value for stba 
            anova(model5.o, btt = 2:4) 
            # overall p value for cont 
            anova(model5.o, btt = 5) 
             
            #step 3. remove 'cont' as it gots the biggest p-value and then generate a new dataset 
            model5.o.p <- rma(yi,vi,mods= ~ ppom + factor(stba)-1, data=dfoc5.o) 
            model5.o.p 
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            #step 4. compute the overall p values for each variables 
            # overall p value for ppom 
            anova(model5.o.p,btt=1) 
            # overall p value for stba 
            anova(model5.o.p, btt = 2:4) 
             
            #step 5. remove ppom as p=0.1, stba remained in the final model. 
             
            ####option two, select stba and cont in the mixed-effect model to include more studies 
            #step 1.incldue all variables in one model 
            dfoc5.sc <- dfoc5.re[!is.na(dfoc5.re$yi) & !is.na(dfoc5.re$vi) & !is.na(dfoc5.re$stba) 
& !is.na(dfoc5.re$cont),] 
            model5.sc <- rma(yi,vi,mods= ~ factor(cont) , data=dfoc5.sc) 
            model5.sc 
             
            #step 2. compute the overall p values for each variables 
            # overall p value for stba 
            anova(model5.sc,btt=1:3) 
            # overall p value for cont 
            anova(model5.sc, btt = 4:5) 
             
            #step3. remove cont as p=0.4, only stba remained in the final model. 
             
 
             
    #   E:subgroup analyses in stba (a &c)------- 
             
            dfoc5.fn <- dfoc5.re[!is.na(dfoc5.re$yi) & !is.na(dfoc5.re$vi) & !is.na(dfoc5.re$stba),] 
            #remove Gradinaru as it is the only b in 'stba' and cannot do the analyses 
            dfoc5.fn <- dfoc5.fn[-7,] 
             
            model5.fnf <- rma(yi,vi,data = dfoc5.fn,method='REML')  
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            par(mar=c(4,2,0.5,2)) 
            forest(model5.fnf, 
                   xlim=c(-6,3),ylim=c(-1,37), 
                   order=order(dfoc5.fn$stba,dfoc5.fn$ye,dfoc5.fn$au), 
                   ilab=dfoc5.fn$ss, ilab.xpos = -2.5, 
                   cex=1,psize=1, 
                   refline = 0, 
                   rows=c(2:21,26:32), 
                   slab=paste(dfoc5.fn$au, as.character(dfoc5.fn$ye),sep=','), font=1, 
                   cex.lab = .8) 
            model5.ho <- rma(yi,vi,data=dfoc5.fn,measure='COR',subset=(stba=='a'),method='REML') 
            model5.po <- rma(yi,vi,data=dfoc5.fn,measure='COR',subset=(stba=='c'),method='REML') 
             
             
            text(-4.75,-
1,pos=4,cex=0.85,bquote(paste("(Q=",.(formatC(model5.fnf$QE,digits=2,format="f")),",df 
=",.(model5.fnf$k - 
model5.fnf$p),",p=",.(formatC(model5.fnf$QEp,digits=2,format="f")),";",I^2,"=",.(formatC(model5.f
nf$I2,digits=1,format="f")),"%)"))) 
             
            #generate subgroup measurements results 
            addpoly(model5.ho,row=1,cex=1,font=4) 
            addpoly(model5.po,row=24.85,cex=1,font=4) 
             
             
            #give names to items 
            text(-3,36,'Sample size',pos=4,cex=.85,font=4) 
            text(-6,36,'Author(s) and Year',pos=4,cex=.85,font=4) 
            text(-6,23,'Outpatient clinics',pos=4,cex=1,font=4) 
            text(-6,33.85,'Population-based/communities/databases',pos=4,cex=1,font=4) 
            text(0.56,36.8,'Correlation',pos=4,cex=0.85,font=4) 
            text(0.56,36,'Coefficient    [95% CI]',pos=4,cex=0.85,font=4) 
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            # add text with Q-value, dfs,p-value, and I2 statistics for subgroups 
            text(-
4.8,0.8,pos=4,cex=0.85,bquote(paste("(Q=",.(formatC(model5.ho$QE,digits=2,format="f")),",df 
=",.(model5.ho$k - 
model5.ho$p),",p=",.(formatC(model5.ho$QEp,digits=2,format="f")),";",I^2,"=",.(formatC(model5.h
o$I2,digits=1,format="f")),"%)"))) 
            text(-
4.8,24.5,pos=4,cex=0.85,bquote(paste("(Q=",.(formatC(model5.po$QE,digits=2,format="f")),",df 
=",.(model5.po$k - 
model5.po$p),",p=",.(formatC(model5.po$QEp,digits=2,format="f")),";",I^2,"=",.(formatC(model5.p
o$I2,digits=1,format="f")),"%)"))) 
             
             
    #   E: subgroup analysis based on the T2DM status------ 
            dfoc5.ch <- dfoc5[-3,] #remove choudhury 2014 preM from model 
            model5.ch <- rma(yi,vi,data = dfoc5.ch,method='REML')  
             
            par(mar=c(4,7,0.5,5)) 
            forest(model5.ch, 
                   xlim=c(-6,3),ylim=c(-1,47), 
                   order=order(dfoc5.ch$tmoral,dfoc5.ch$ye,dfoc5.ch$au), 
                   ilab=dfoc5.ch$ss, ilab.xpos = -2.5, 
                   cex=0.7,psize=1, 
                   refline = 0, 
                   rows=c(2:10,14:18,23:42), 
                   slab=paste(dfoc5.ch$au, as.character(dfoc5.ch$ye),sep=','), font=1, 
                   cex.lab = .8) 
             
            model5.td <- 
rma(yi,vi,data=dfoc5.ch,measure='COR',subset=(tmoral=='T2DM'),method='REML') 
            model5.hc <- 
rma(yi,vi,data=dfoc5.ch,measure='COR',subset=(tmoral=='controls'),method='REML') 
            model5.al <- rma(yi,vi,data=dfoc5.ch,measure='COR',subset=(tmoral=='all'),method='REML') 
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            text(-5,-
1,pos=4,cex=0.7,bquote(paste("(Q=",.(formatC(model5.ch$QE,digits=2,format="f")),",df 
=",.(model5.ch$k - 
model5.ch$p),",p=",.(formatC(model5.ch$QEp,digits=2,format="f")),";",I^2,"=",.(formatC(model5.ch
$I2,digits=1,format="f")),"%)"))) 
             
            #generate subgroup measurements results 
            addpoly(model5.al,row=1,cex=0.7,font=4) 
            addpoly(model5.hc,row=13,cex=0.7,font=4) 
            addpoly(model5.td,row=22,cex=0.7,font=4)  
             
            #give names to items 
            text(-3,45.5,'Sample size',pos=4,cex=.75,font=4) 
            text(-6,45.5,'Author(s) and Year',pos=4,cex=.75,font=4) 
            text(-6,43.5,'T2DM',pos=4,cex=0.75,font=4) 
            text(-6,19.5,'Non-diabetic Subjects',pos=4,cex=0.75,font=4) 
            text(-6,11.5,'General Population',pos=4,cex=0.75,font=4) 
            text(0.3,46.5,'Correlation',pos=4,cex=0.75,font=4) 
            text(0.3,45.5,'Coefficient [95% CI]',pos=4,cex=0.75,font=4) 
             
            # add text with Q-value, dfs,p-value, and I2 statistics for subgroups 
            text(-
4.8,0.8,pos=4,cex=0.65,bquote(paste("(Q=",.(formatC(model5.al$QE,digits=2,format="f")),",df 
=",.(model5.al$k - 
model5.al$p),",p=",.(formatC(model5.al$QEp,digits=2,format="f")),";",I^2,"=",.(formatC(model5.al$
I2,digits=1,format="f")),"%)"))) 
            text(-
4.8,12.8,pos=4,cex=0.65,bquote(paste("(Q=",.(formatC(model5.hc$QE,digits=2,format="f")),",df 
=",.(model5.hc$k - 
model5.hc$p),",p=",.(formatC(model5.hc$QEp,digits=2,format="f")),";",I^2,"=",.(formatC(model5.hc
$I2,digits=1,format="f")),"%)"))) 
            text(-
4.8,21.8,pos=4,cex=0.65,bquote(paste("(Q=",.(formatC(model5.td$QE,digits=2,format="f")),",df 
=",.(model5.td$k - 
model5.td$p),",p=",.(formatC(model5.td$QEp,digits=2,format="f")),";",I^2,"=",.(formatC(model5.td$
I2,digits=1,format="f")),"%)"))) 
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# F: OR TOC T2DM------------------------------- 
#------(7) toc-T2DM odds ratio crude 
   
  dfoc7 <- escalc('OR', yi= log(ortoc),sei=sdor,data=dfoc) 
  dfoc7 <- dfoc7[!is.na(dfoc7$yi) & !is.na(dfoc7$vi),] 
  model7 <- rma(yi,vi,data = dfoc7,method='REML') 
  model7 
   
  par(mar=c(4,0.5,2,0.5)) 
  forest(model7,transf=exp, 
         xlim=c(-3,4),ylim=c(-1,10), 
         ilab=dfoc7$ss, ilab.xpos = -0.5, 
         cex=1.25,psize=1.15, 
         refline = 1, 
         slab=paste(dfoc7$au, as.character(dfoc7$ye),sep=','), font=1, 
         order = order(dfoc7$ye,dfoc7$au), 
         showweights = TRUE, 
         cex.lab = 1) 
  text(-2,-1,pos=4,cex=0.9,bquote(paste("(Q=",.(formatC(model7$QE,digits=2,format="f")),",df 
=",.(model7$k - 
model7$p),",p=",.(formatC(model7$QEp,digits=2,format="f")),";",I^2,"=",.(formatC(model7$I2,digit
s=1,format="f")),"%)"))) 
   
  #give names to items 
  text(-1,8.25,'Sample size',pos=4,cex=1,font=4) 
  text(-3,8.25,'Author(s) and Year',pos=4,cex=1,font=4) 
  text(2.15,8.25,'Odds Ratio [95% CI]',pos=4,cex=1,font=4) 
  text(1.25,8.25,'Weights',pos=4,cex=1,font=4) 
   
   
## heterogeneity tests(Radial plot, Baujat plot)------- 
  #Radial plot ## galbraith 
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  radial(model7, level=0.95,xlab="Inverse of standard error",zlab="Standardised effect size (z-score) 
") 
   
  #Baujat plot 
  baujat(model7,xlab="Contribution to overall heterogeneity",ylab="Influence on overall result") 
   
   
  ## publication bias analysis-------- 
  #random version of Egger's test, for class 'rma' 
  regf <-regtest(model7, model="rma", ret.fit=FALSE) 
   
  #funnel plots contour-enhanced funnel plot centreed at 0 (see Peters et al., 2008) 
  par(mar=c(5,5,2,2),mfrow=c(1, 1)) 
  trff <- trimfill(model7) 
  funnel(trff,comb.rma=TRUE,level=c(90, 95, 99), shade=c("light blue", "blue", "dark 
blue"),,atransf=exp) 
  legend(0.17,0, 
         c("p>0.1", "0.05 < p < 0.1","0.01 < p < 0.05", "p< 0.01","studies"), 
         #p shows the significance/non-significance of effect 
         fill=c("light blue", "blue", "dark blue","light grey","black"))     
   
  #label eggers'regression test 
  text(-0.5,0.01,cex=0.85,pos=1,"Egger's regression test: ") 
  text(-0.5,0.018,cex=0.85,pos=1,bquote(paste("p=",.(formatC(regf$pval,digits=2)),", 
z=",.(formatC(regf$zval,digits=2))))) 
   
  title(main="The trim-filled contour-enhanced funnel plot of the OR of TOC in T2DM 
vs.NGC.across seven studies",cex.main=1) 
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# G: MD ucOC T2DM vs. NGC ---------- 
  #------(8) ucOC-T2DM MD 
      dfoc8 <- escalc(n1i = nt, n2i = nc, m2i = mucc, m1i = muc,  
                      sd2i = sdmucc, sd1i = sdmuc, data = dfoc, measure = "MD",  
                      append = TRUE) 
      dfoc8 <- dfoc8[!is.na(dfoc8$yi) & !is.na(dfoc8$vi),] 
      model8 <- rma(yi,vi,data=dfoc8) 
      summary(model8) 
       
      par(mar=c(6,2,6,2)) 
      forest(model8, 
             ilab=dfoc8$ss,ilab.xpos=-6, 
             slab = paste(dfoc8$au, as.character(dfoc8$ye), sep = ", "),cex=1, 
order=order(dfoc8$ye,dfoc8$au), 
             showweights = TRUE, 
             cex.lab  = 0.75) 
      
      # add text with Q-value, dfs,p-value, and I2 statistics for subgroups 
      text(-10,-1,pos=4,cex=0.75,bquote(paste("(Q=",.(formatC(model8$QE,digits=2,format="f")),",df 
=",.(model8$k - 
model8$p),",p=",.(formatC(model8$QEp,digits=2,format="f")),";",I^2,"=",.(formatC(model8$I2,digit
s=1,format="f")),"%)"))) 
      #generate names for items 
      text(-8,10.5,'Sample Size',pos=4,cex=0.8,font=4) 
      text(-13,10.5,'Author and Year',pos=4,cex=0.8,font=4) 
      text(5,10.5,'Mean Difference[95%CI]',pos=4,cex=0.8,font=4) 
      text(3,10.5,'Weights',pos=4,cex=0.8,font=4) 
       
## heterogeneity tests(Radial plot, Baujat plot)------- 
      #Radial plot ## galbraith 
      radial(model8, level=0.95,xlab="Inverse of standard error",zlab="Standardised effect size (z-
score) ") 
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      #Baujat plot 
      baujat(model8,xlab="Contribution to overall heterogeneity",ylab="Influence on overall result") 
       
       
## publication bias analysis-------- 
      #random version of Egger's test, for class 'rma' 
      regg <-regtest(model8, model="rma", ret.fit=FALSE) 
       
      #funnel plots contour-enhanced funnel plot centreed at 0 (see Peters et al., 2008) 
      par(mar=c(5,5,2,2),mfrow=c(1, 1)) 
      trfg <- trimfill(model8) 
      funnel(trfg,comb.rma=TRUE,level=c(90, 95, 99), shade=c("light blue", "blue", "dark 
blue"),refline=0) 
      legend(1,0, 
             c("p>0.1", "0.05 < p < 0.1","0.01 < p < 0.05", "p< 0.01","studies"), 
             #p shows the significance/non-significance of effect 
             fill=c("light blue", "blue", "dark blue","light grey","black"))     
       
      #label eggers'regression test 
      text(-1.5,0.01,cex=0.85,pos=1,"Egger's regression test: ") 
      text(-1.5,0.05,cex=0.85,pos=1,bquote(paste("p=",.(formatC(regg$pval,digits=2)),", 
z=",.(formatC(regg$zval,digits=2))))) 
       
      title(main="The trim-filled contour-enhanced funnel plot of the MD of ucOC in T2DM 
vs.NGC.across nine studies",cex.main=1) 
       
       
       
     
       
       
       
# H: r ucOC - HOMA-IR--------- 
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     # (9) r-pearson ucoc-hba1c pearson crude 
    dfoc9 <- escalc(ri= pcruchm,ni=ss,measure='COR',data= dfoc) 
    dfoc9 <- dfoc9[!is.na(dfoc9$yi) & !is.na(dfoc9$vi),] 
    model9 <- rma(yi,vi,data = dfoc9,method='REML') 
    model9 
     
     
    par(mar=c(10,2,8,1)) 
    forest(model9, 
           xlim=c(-2.5,2),ylim=c(-1,8), 
           ilab=dfoc9$ss, ilab.xpos = -1, 
           cex=1,psize=1, 
           refline = 0, 
           slab=paste(dfoc9$au, as.character(dfoc9$ye),sep=','), font=1, 
           order = order(dfoc9$ye,dfoc9$au), 
           showweights = TRUE, 
           cex.lab  = 0.8, cex.axis = 1) 
    text(-1.9,-1,pos=4,cex=0.75,bquote(paste("(Q=",.(formatC(model9$QE,digits=2,format="f")),",df 
=",.(model9$k - 
model9$p),",p=",.(formatC(model9$QEp,digits=2,format="f")),";",I^2,"=",.(formatC(model9$I2,digit
s=1,format="f")),"%)"))) 
     
    #give names to items 
    text(-1.35,6.6,'Sample size',pos=4,cex=0.8,font=4) 
    text(-2.5,6.6,'Author(s) and Year',pos=4,cex=0.8,font=4) 
    text(0.8,6.6,'Coefficient  [95% CI]',pos=4,cex=0.8,font=4) 
    text(0.8,7,'Correlation',pos=4,cex=0.8,font=4) 
    text(0.3,6.6,'Weights',pos=4,cex=0.8,font=4) 
     
 
     
    funnel(model9) 
# I: r ucOC - HbA1c --------- 
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    #(10) r-pearson ucoc-hba1c pearson crude 
    dfoc10 <- escalc(ri= pcruchc,ni=ss,measure='COR',data= dfoc) 
    dfoc10 <- dfoc10[!is.na(dfoc10$yi) & !is.na(dfoc10$vi),] 
    model10 <- rma(yi,vi,data = dfoc10,method='REML') 
 
    par(mar=c(10,2,8,1)) 
    forest(model10, 
           xlim=c(-2.6,2),ylim=c(-1,8), 
           ilab=dfoc10$ss, ilab.xpos = -1, 
           cex=1,psize=1, 
           refline = 0, 
           slab=paste(dfoc10$au, as.character(dfoc10$ye),sep=','), font=1, 
           order = order(dfoc10$ye,dfoc10$au), 
           showweights = TRUE, 
           cex.lab  = 0.8, cex.axis = 1) 
    text(-2,-1,pos=4,cex=0.75,bquote(paste("(Q=",.(formatC(model10$QE,digits=2,format="f")),",df 
=",.(model10$k - 
model10$p),",p=",.(formatC(model10$QEp,digits=2,format="f")),";",I^2,"=",.(formatC(model10$I2,d
igits=1,format="f")),"%)"))) 
     
    #give names to items 
    text(-1.35,6.6,'Sample size',pos=4,cex=0.8,font=4) 
    text(-2.65,6.6,'Author(s) and Year',pos=4,cex=0.8,font=4) 
    text(0.9,6.6,'Coefficient  [95% CI]',pos=4,cex=0.8,font=4) 
    text(0.9,7,'Correlation',pos=4,cex=0.8,font=4) 
    text(0.4,6.6,'Weights',pos=4,cex=0.8,font=4) 
     
    funnel(model10) 
     
     
     
# J: OR ucOC-T2DM------ 
    dfoc11 <- escalc ('OR', yi= log(orucoc),sei=sdoru,data=dfoc) 
 211 
    dfoc11 <- dfoc11[!is.na(dfoc11$yi) & !is.na(dfoc7$vi),] 
    model11 <- rma(yi,vi,data=dfoc11, method='REML') 
    model11 
    
    par(mar=c(12,1,12,0.5)) 
    forest(model11,transf=exp, 
           xlim=c(-3.5,4),ylim=c(-1,7), 
           ilab=dfoc11$ss, ilab.xpos = -0.5, 
           cex=1,psize=1.25, 
           refline = 1, 
           slab=paste(dfoc11$au, as.character(dfoc11$ye),sep=','), font=1, 
           order = order(dfoc11$ye,dfoc11$au), 
           showweights = TRUE, 
           cex.lab = 0.8, cex.axis = 0.8) 
    text(-2.6,-1,pos=4,cex=0.9,bquote(paste("(Q=",.(formatC(model11$QE,digits=2,format="f")),",df 
=",.(model11$k - 
model11$p),",p=",.(formatC(model11$QEp,digits=2,format="f")),";",I^2,"=",.(formatC(model11$I2,d
igits=1,format="f")),"%)"))) 
     
    #give names to items 
    text(-1,6,'Sample size',pos=4,cex=0.9,font=4) 
    text(-3.5,6,'Author(s) and Year',pos=4,cex=0.9,font=4) 
    text(2.12,6,'Odds Ratio [95% CI]',pos=4,cex=0.9,font=4) 
    text(1.25,6,'Weights',pos=4,cex=0.9,font=4) 
     
     
     
    funnel(model11) 
     
     
     
     
# K: MD TOC PD NGC-------- 
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    ### MD between prediabetes and healthy controls in terms of TOC 
     
    #-----(12) MD random effect TOC 
    dfoc12 <- escalc(n2i = nc, n1i = np, m2i = mtoc, m1i = mtop,  
                    sd2i = sdmtoc, sd1i = sdmtop, data = dfoc, measure = "MD",  
                    append = TRUE) 
    dfoc12 <- dfoc12[!is.na(dfoc12$yi) & !is.na(dfoc12$vi),] 
    model12 <- rma(yi,vi,data=dfoc12) 
    summary(model12) 
     
    par(mar=c(5,1,0.5,1)) 
    forest(model12, 
           ilab=dfoc12$ss,ilab.xpos = -18, 
           order=order(dfoc12$ye,dfoc12$au), 
           slab = paste(dfoc12$au, as.character(dfoc12$ye), sep = ", "), 
           font=1,cex=1,cex.axis = 1, cex.lab = 0.75, 
           showweights = TRUE, 
           psize=0.85) 
     
    # add text with Q-value, dfs,p-value, and I2 statistics for subgroups 
    text(-33,-1,pos=4,cex=0.75,bquote(paste("(Q=",.(formatC(model12$QE,digits=2,format="f")),",df 
=",.(model12$k - 
model12$p),",p=",.(formatC(model12$QEp,digits=2,format="f")),";",I^2,"=",.(formatC(model12$I2,d
igits=1,format="f")),"%)"))) 
    #generate names for items 
    text(-25,11.5,'Sample Size',pos=4,cex=0.8,font=4) 
    text(-42.5,11.5,'Author(s) and Year',pos=4,cex=0.8,font=4) 
    text(13,11.5,'Mean Difference[95% CI]',pos=4,cex=0.8,font=4) 
    text(4.5,11.5,'Weights',pos=4,cex=0.8,font=4) 
     
     
## heterogeneity tests(Radial plot, Baujat plot)------- 
    #Radial plot ## galbraith 
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    radial(model12, level=0.95,xlab="Inverse of standard error",zlab="Standardised effect size (z-
score) ") 
     
    #Baujat plot 
    baujat(model12,xlab="Contribution to overall heterogeneity",ylab="Influence on overall result") 
     
     
## publication bias analysis-------- 
    #random version of Egger's test, for class 'rma' 
    regk <-regtest(model12, model="rma", ret.fit=FALSE) 
     
    #funnel plots contour-enhanced funnel plot centreed at 0 (see Peters et al., 2008) 
    par(mar=c(5,5,2,2),mfrow=c(1, 1)) 
    trfk <- trimfill(model12) 
    funnel(trfk,comb.rma=TRUE,level=c(90, 95, 99), shade=c("light blue", "blue", "dark 
blue"),refline=0) 
    legend(2.9,0, 
           c("p>0.1", "0.05 < p < 0.1","0.01 < p < 0.05", "p< 0.01","studies"), 
           #p shows the significance/non-significance of effect 
           fill=c("light blue", "blue", "dark blue","light grey","black"))     
     
    #label eggers'regression test 
    text(-5,0.01,cex=0.85,pos=1,"Egger's regression test: ") 
    text(-5,0.1,cex=0.85,pos=1,bquote(paste("p=",.(formatC(regk$pval,digits=2)),", 
z=",.(formatC(regk$zval,digits=2))))) 
     
    title(main="The trim-filled contour-enhanced funnel plot of the MD of TOC in PD vs.NGC.across 
ten studies",cex.main=1) 
     
   
     
     
# L: MD TOC T2DM PD-------- 
    ### MD between prediabetes and T2DM in terms of TOC 
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    #-----(13) MD random effect TOC 
    dfoc13 <- escalc(n1i = nt, n2i = np, m1i = mto, m2i = mtop,  
                     sd1i = sdmto, sd2i = sdmtop, data = dfoc, measure = "MD",  
                     append = TRUE) 
    dfoc13 <- dfoc13[!is.na(dfoc13$yi) & !is.na(dfoc13$vi),] 
    model13 <- rma(yi,vi,data=dfoc13) 
    summary(model13) 
     
    par(mar=c(5,1,0.5,1)) 
    forest(model13, 
           ilab=dfoc13$ss,ilab.xpos = -14, 
           order=order(dfoc13$ye,dfoc13$au), 
           slab = paste(dfoc13$au, as.character(dfoc13$ye), sep = ", "), 
           font=1,cex=1,cex.axis = 1, cex.lab = 0.75, 
           showweights = TRUE) 
     
    # add text with Q-value, dfs,p-value, and I2 statistics for subgroups 
    text(-21,-1,pos=4,cex=0.75,bquote(paste("(Q=",.(formatC(model13$QE,digits=2,format="f")),",df 
=",.(model13$k - 
model13$p),",p=",.(formatC(model13$QEp,digits=2,format="f")),";",I^2,"=",.(formatC(model13$I2,d
igits=1,format="f")),"%)"))) 
    #generate names for items 
    text(-17,8.5,'Sample Size',pos=4,cex=0.8,font=4) 
    text(-29,8.5,'Author(s) and Year',pos=4,cex=0.8,font=4) 
    text(10,8.5,'Mean Difference[95% CI]',pos=4,cex=0.8,font=4) 
    text(4,8.5,'Weights',pos=4,cex=0.8,font=4) 
     
     
## heterogeneity tests(Radial plot, Baujat plot)------- 
    #Radial plot ## galbraith 
    radial(model13, level=0.95,xlab="Inverse of standard error",zlab="Standardised effect size (z-
score) ") 
     
    #Baujat plot 
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    baujat(model13,xlab="Contribution to overall heterogeneity",ylab="Influence on overall result") 
     
     
## publication bias analysis-------- 
    #random version of Egger's test, for class 'rma' 
    regl <-regtest(model13, model="rma", ret.fit=FALSE) 
     
    #funnel plots contour-enhanced funnel plot centreed at 0 (see Peters et al., 2008) 
    par(mar=c(5,5,2,2),mfrow=c(1, 1)) 
    trfl <- trimfill(model13) 
    funnel(trfl,comb.rma=TRUE,level=c(90, 95, 99), shade=c("light blue", "blue", "dark 
blue"),refline=0) 
    legend(2,0, 
           c("p>0.1", "0.05 < p < 0.1","0.01 < p < 0.05", "p< 0.01","studies"), 
           #p shows the significance/non-significance of effect 
           fill=c("light blue", "blue", "dark blue","light grey","black"))     
     
    #label eggers'regression test 
    text(-3,0.01,cex=0.85,pos=1,"Egger's regression test: ") 
    text(-3,0.1,cex=0.85,pos=1,bquote(paste("p=",.(formatC(regl$pval,digits=2)),", 
z=",.(formatC(regl$zval,digits=2))))) 
     
    title(main="The trim-filled contour-enhanced funnel plot of the MD of TOC in T2DM vs. PD 
across seven studies",cex.main=1) 
     
     
     
     
#Characteristics calculation----- 
      #count the numbers of population 
      # remove the studies with duplicate populations: Bador, Choudhury, Dobnig, Manavalan, Rui, 
Sanchez,Villafan 
        dfoc.popl <- dfoc[-cbind(8,9,24,25,31,32,60,61,76,77,96,97,101,102,115),] 
        sum(dfoc.popl$ss)# count the numbers of unique particpants 
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        # count the cases of T2DM and HC or PD------- 
        #remove the duplicate studies 
        dfoc.case <- dfoc[-cbind(7,23,30,59,75,95,100,115),] 
         
        dfoc.case.nt <- dfoc.case[!is.na(dfoc.case$nt),] 
        sum(dfoc.case.nt$nt) # the numbers of T2DM,14933 
         
        dfoc.case.nc <- dfoc.case[!is.na(dfoc.case$nc),] 
        sum(dfoc.case.nc$nc)  # the numbers of healthy controls, 22823 
         
        dfoc.case.np <- dfoc.case[!is.na(dfoc.case$np),] 
        sum(dfoc.case.np$np) #the numbers of prediabetes 2712 
         
        sum(dfoc.case.nt$nt,dfoc.case.nc$nc,dfoc.case.np$np) #total numbers of T2DM, hc, and pd, 
40758 
         
        dfoc.case.no <- dfoc.case[!is.na(dfoc.case$no),] 
        sum(dfoc.case.no$no) #the numbers of other groups,1947 
         
         
        # count the ethnicities of particicpants-------- 
        summary(dfoc.unique$eth) 
         
        dfoc.case.asian <- dfoc.case[dfoc.case$eth=='Asian',] 
        sum(dfoc.case.asian$ss) #count the numbers of Asian, 23500 
         
        dfoc.case.cauca <- dfoc.case[dfoc.case$eth=='Caucasian',] 
        sum(dfoc.case.cauca$ss) #count the numbers of Caucasian, 18111 
         
        dfoc.case.hil <- dfoc.case[dfoc.case$eth=='Hispanic.Latino',] 
        sum(dfoc.case.hil$ss) #count the numbers of hispanic latino, 630 
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        dfoc.case.la <- dfoc.case[dfoc.case$eth=='Latino',] 
        sum(dfoc.case.la$ss) #count the numbers of Latino,531 
         
        dfoc.case.mix <- dfoc.case[dfoc.case$eth=='mix',] 
        sum(dfoc.case.mix$ss) #count the numbers of mix, 653 
         
        sum(23500,18111,630,531,653) 
         
         
        # remove items for same studies, and maintain unique studies------ 
          #Remove Bador, Chen L,Choudhury, Dobnig, Furuyso,  
            #Jung, Kanazawa2009,Kanazawa2011,Kindblom,Lerchbaum,Ma,Manavalan, 
             #Ogawa,Oren,Rui,Sanchez, Villafan 
          dfoc.unique <- dfoc[-
cbind(8,9,22,24,25,31,32,34,52,55,57,60,61,64,71,76,77,84,86,96,97,101,102,115),] 
        # summarize the continents and country of population-------- 
          summary(dfoc.unique$cont) 
          summary(dfoc.unique$cot) 
           
        # summarize the study types of each studies------- 
          summary(dfoc.unique$st) 
           
        #summarize the assyas of TOC/ucOC------ 
          factor(dfoc.unique$asto) 
          summary(dfoc.unique$asto) 
           
          factor(dfoc.unique$asuc) 
          summary(dfoc.unique$asuc) 
        #summarize the study base(source of population)------ 
          summary(dfoc.unique$stba) 
        # select the studies with T2DM%==0 AND T2DM%==100 AND both----- 
          dfoc.unique[dfoc.unique$pt==0.0,1] 
          dfoc.unique[dfoc.unique$pt==100,1] 
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          dfoc.unique[!dfoc.unique$pt==0 & !dfoc.unique$pt==100 ,1] 
    
        #the numbers of the study which provide the mean age of T2DM------ 
        dfoc.unique[!is.na(dfoc.unique$ma2),1] 
         
        #the numbers of the study which provide the mean age of NGC------ 
        dfoc.unique[!is.na(dfoc.unique$mac),1] 
         
        #summarize the studies with renal information--------- 
        dfoc.unique[dfoc.unique$renal=="y",4] #studies suspected of imparied renal funcrtion 
        dfoc.unique[dfoc.unique$renal=="n",4] #studies without imaparied renal fuction 
        dfoc.unique[!is.na(dfoc.unique$renal),4] #studies reported information about renal fucntion 
        sum(dfoc.unique[!is.na(dfoc.unique$renal),4])+149+101 # numbers of subjects in studies 
reported renal function 
        sum(dfoc.unique[is.na(dfoc.unique$renal),4])+946+2285+279+1222+490+110+10 #the numbers 
of subjetcs with NA for renal function 
         
        #summarize the studies with atd-------- 
        omit.atd <- dfoc.unique[!is.na(dfoc.unique$atd),] 
        omit.atd[omit.atd$atd=="Y",4] #studies using atd 
        omit.atd[omit.atd$atd=="N",4]#studies without using atd 
        dfoc.unique[is.na(dfoc.unique$renal),4] # studies withour information of atd 
        sum(omit.atd[omit.atd$atd=="Y",4])+149+1222+490 # subjects using atd 
        sum(omit.atd[omit.atd$atd=="N",4])+2285+279+101 # subjects free from atd 
        sum(dfoc.unique[is.na(dfoc.unique$atd),4])+946+110+10 # subjects without information 
         
        #summarize the studies with bmd------ 
        omit.bmd <- dfoc.unique[!is.na(dfoc.unique$bmd),] 
        omit.bmd[omit.bmd$bmd=="Y",4] #studies using bmd 
        omit.bmd[omit.bmd$bmd=="N",4]#studies without using bmd 
        dfoc.unique[is.na(dfoc.unique$bmd),4] # studies without information about bmd 
        sum(omit.bmd[omit.bmd$bmd=="Y",4]) #subjects using bmd 
        sum(omit.bmd[omit.bmd$bmd=="N",4])+ 
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          946+2285+279+149+101+1222+490+110+10 #subjects free from bmd 
        sum(dfoc.unique[is.na(dfoc.unique$bmd),4]) #subjects without information 
         
         
######========== 
